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Abstract 
 
This research focuses on the design and the development of three positioning 
devices with the ability to accurately move a High Intensity Focused Ultrasound 
(HIFU) transducer guided by a Magnetic Resonance Imaging (MRI) scanner in 
order to create discrete and overlapping lesions in biological tissue such as a 
brain, thyroid, kidney, liver and pancreas. 
The positioning devices were designed and fabricated using construction 
materials selected for compatibility with high magnetic fields and fast switching 
magnetic field gradients encountered inside MRI scanners.  The positioning 
devices incorporate only MRI compatible materials such as piezoelectric 
ultrasonic motors, plastic sheets, brass screws, plastic pulleys, brass racks and 
pinions and timing belts. 
The MRI compatibility of the system was successfully demonstrated in a clinical 
high field MRI scanner. The robots have the ability to accurately move the 
transducer thus creating discrete and overlapping lesions in biological tissue 
and this was also tested successfully.  
The main goals during the design and implementation of all three positioning 
devices were similar and these were to implement a positioning device which is 
simple, cost effective, portable, and can be used in virtually any clinical MRI 
scanner either sited on the scanner's table or mounted on the top of the gantry 
of the MRI.  
Additionally the developed positioning devices incorporate a flexible coupling 
system and thus they can be used in all the anatomies accessible by HIFU like 
liver, kidney, breast, brain, pancreas and thyroids of for experiments in small 
and large animals.   
The three different positioning devices were developed either as an 
improvement of one another, as in case of the first and third positioning devices, 
or to be used for different application, as in case of the second and third 
versions of positioning devices.       
 
The applications of each version of positioning device are described below. 
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a. The first positioning device can be used for brain tumours.  
b. The second version can be applied for experiments on large animals like 
pig, sheep and dog and small animals like rabbit and rat.  However, with a 
slight modification of the base of this positioning device and with the 
collaboration an MRI vendor can be attached on the top of the gantry of the 
MRI scanner.  Therefore, more space will be left for the target body and as a 
result this positioning device will be suitable for abdominal tumours (kidney, 
liver, and pancreas), brain and thyroid. 
c. The third device which is an upgrade of the first positioning device can be 
also used for treating brain tumours and additionally under certain conditions 
it would be suitable for treating abdominal tumours, and thyroid. 
 
The positioning devices were evaluated for their MRI compatibility, reliability, 
accuracy and functionality, with several experiments on phantom gel, pork 
kidney, porcine muscle and rabbit liver. 
 
Furthermore, other experiments were conducted to evaluate the effects of the 
HIFU / MRI system.  The effectiveness of MRI to monitor therapeutic protocols 
of HIFU in freshly excised pig liver and in rabbit liver in vivo were investigated.  
The detection of large lesions using MRI was evaluated as well as the 
possibility to create both thermal and cavitational lesions. MRI sequences were 
best contrast between liver and lesion is obtained were also studied. The range 
of repetition time (TR) and range of echo time (TE) which maximizes the 
contrast to noise ratio (CNR) were investigated. Additionally, MRI was utilized to 
monitor lesions created at temperature below the boiling point and lesions 
created at temperature above the boiling point using HIFU in freshly excised 
kidney, liver and in vivo rabbit kidney.   
 
Results from 1942 since today have proved that HIFU is a very promising 
technology and recent studies convince many experts that HIFU is the future in 
medicine.  Furthermore MRI guidance of a positioning device that guides HIFU 
transducer for non-invasive interventions offers accuracy and reliability and it 
appears to be very encouraging approach for treating tumours.  The evaluation 
of the proposed positioning devices is very optimistic for MRI guided HIFU 
applications.  
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Abbreviations and symbols used 
 
 Abbreviation Expansion 
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1 Introduction 
High intensity focused ultrasound (HIFU) is a promising technology for a variety 
of therapeutic applications.  This concept initiated in 1942 by Lynn Zwemer [1].   
HIFU has long been known as a minimal invasive or non-invasive procedure 
that destroys tissue through ablation.  However, it is only in recent years that 
clinical applications are becoming feasible, with the development of high power 
ultrasound transducers compatible with the MRI scanner which is used to 
monitor these non-invasive HIFU applications.  New technologies, combined 
with more sophisticated treatment methods and monitoring methods allow non-
invasive procedures in many areas such as the brain, eye, breast, kidney, liver, 
pancreas, thyroid, uterine fibroids and pancreas.  Meanwhile, new 
investigations are underway for treading cardiac arithmia, strokes, palliative 
pain treatment of bone metastases and brain disorders such as Parkinson’s 
disease, essential tremor, and neuropathic pain.  These optimistic investigations 
have encouraged physicians and provided them new valuable tools for medical 
research.  
After the introduction of the concept of HIFU in 1942 by Lynn Zwemer the first 
complete system for the use of HIFU was developed by Fry Mosberg [2] in 
1954.  However, at that time Magnetic Resonance Imaging (MRI) did not exist and 
therefore the previous systems were not guided effectively, and therefore had 
not survived in the clinical setting.    
Jolesz and Jakab [3] in 1991 demonstrated that the MRI scanner can be used 
to guide the HIFU transducer and about a year later Hynynen et al. [4], [5] 
produce necrosis in a canine muscle using a HIFU transducer and monitored by 
an MRI.  After these first studies of producing lesions on tissues using a HIFU 
transducer guided by an MRI, this concept was carried on in the following years 
[6], [7] and they have proven that the contrast between necrotic tissue and 
normal tissue was clearly observable.  Therefore, MRI became the only 
modality of guiding HIFU to create lesions. 
Through the years it has been proven that HIFU can be used to accurately heat 
the targeted biological tissues and therefore proven suitable for applications for 
destroying cancerous tissues with non-invasive or minimal invasive procedures 
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guided either by ultrasound or by MRI to provide, to the operator performing the 
procedure, images of a region within the subject being heated [2].   
Furthermore, HIFU was explored in almost every tissue that is accessible by 
ultrasound.  The propagation of HIFU can successfully generate discrete and 
large lesions with reproducible results.  The following literature represents some 
examples of some applications explored: prostate [8], liver [9], brain [2], [10]-
[11], eye [12], kidney [13]-[14], pancreas [15], [16], breast [17] and thyroid [18]-
[22].   
In the recent commercial systems (for example, [8], [23] and [24]) HIFU is either 
guided by ultrasound or MRI.  Although, ultrasonic imaging is the simplest and 
most inexpensive method to guide HIFU, it is not as good as MRI as MRI offers 
superior contrast than ultrasound.  Also, the thermometry capability provided by 
the MRI is unique and is used for the localization and the effect of the HIFU 
beam at any time.  However, the disadvantages of MRI are mainly its cost and 
the fact that MRI imaging is not real time and this makes it difficult to point an 
organ which is moving due to breathing.  
Several examples of MRI compatible positioning devices (robot) have been 
developed for other applications.  Systems have been developed to perform 
breast interventions [25]-[28], to perform brain biopsies [29], to perform prostate 
procedures [30], [32], and one to perform general purpose procedures with the 
“doubledonut” scanner [33].  Although these studies have demonstrated the 
technical feasibility of MR compatible manipulators, these devices are highly 
specialized for a certain anatomy or MR scanner design.  
The proposed positioning devices are prototypes magnetic resonance imaging 
(MRI) compatible positioning devices used to move an MRI-guided high 
intensity focused ultrasound (HIFU) transducer for the treatment of tumours by 
producing lesions on the targeted areas.  The future application of these 
systems is to treat brain tumours (positioning devices versions 1 and 3) 
abdominal tumours (liver, kidney and pancreas with versions 2 and 3) and 
thyroid tumours (positioning devices version 2 and 3).  Also, the positioning 
devices can be used to perform experiments in large animals like pig, sheep 
and dog and small animals like rabbit and rat.  
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1.1 Aims and objectives 
The aims and objectives of the thesis are listed below: 
i. Design and implement a positioning device which will guide the HIFU 
transducer to effectively destroy the targeted tumour and avoiding 
lesions to healthy tissues 
ii. The positioning device must be MRI compatible since it will be used 
inside the gantry of an MRI scanner 
iii. The positioning device must be small in size and light in weight and 
therefore, portable 
iv. Design and develop a universal positioning device which will be capable 
to operate in the gantry any MRI scanner.   
v. The positioning device should be flexible and should be easily modified 
for many different applications 
vi. Design and develop a user friendly interface software application to be 
used to guide the positioning. Furthermore, the software application will 
provide the user with several other functions like,  
 digital thermometer to capture the temperature variations at the 
HIFU transducer focal point, 
 store patient treatment history,  
 set the ultrasound treatment protocol, settings of the HIFU 
treatment, i.e. the parameters of the given therapy like intensity, 
frequency, starting and ending times,  
 maintain patient database with data of the patients treated which 
can be used for statistical purposes, 
 display of MRI images The MRI images of each treatment will be 
stored and the user has the ability to load any image stored, 
 display video or pictures captured from the MR compatible camera 
An MRI compatible camera is connected on the system. The 
camera was interfaced by means of a video capture card.  With 
the aid of the MRI compatible camera, the researcher can monitor 
the welfare of the animal or human. 
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1.2 Chapters Outline 
This section gives an overview of each chapter in this report. 
 
Chapter 2: Abdominal and thyroid tumours 
Kidney, liver and pancreatic tumours are the abdominal tumours 
considered in this report.  Thyroid tumours are also considered 
and therefore this chapter covers the most common tumours of 
these organs as well as the symptoms, diagnostic methods and 
treatments used.  Treating these tumours using HIFU is not 
explained in this chapter since this method is described in details 
in chapter 3. 
 
Chapter 3:  High Intensity Focused Ultrasound (HIFU) technology and 
therapeutic applications 
This chapter gives an overview of the physics and technology of 
HIFU and HIFU transducers.  Also, describes how HIFU can be 
used for treating tumours and how Magnetic Resonance Imaging 
(MRI) can be utilized for the guidance of HIFU transducers.  
Furthermore, MRI compatibility and safety issues as well as 
therapeutic HIFU applications and historical events of therapeutic 
HIFU are also described. 
 
Chapter 4: Applications of HIFU in medicine 
The current state for treating abdominal and thyroid tumours 
using HIFU technology experimentally and commercially is 
described in this chapter. 
Also, in this chapter HIFU technology for treating abdominal and 
thyroid tumours is compared with the current treatment methods 
for treating these tumours and advantages and limitations are 
summarized.  This chapter also gives an overview of MRI guided 
HIFU (MRgHIFU) systems and MRI compatible positioning 
devices and exhibits the existing MRgHIFU positioning devices. 
 
Chapter 5: Development of HIFU system with MRI guidance 
This chapter describes the parts and the setup of a HIFU system. 
MRI compatible materials like piezoelectric motors, piezoelectric 
ultrasonic transducer MRI compatible camera and cavitation 
detector are also discussed here.  
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Chapter 6: Development of the positioning device version 1 
The description, the application, the parts and materials used, 
the designs, the development of the different components as well 
as the integration of the first version of the proposed positioning 
device are given in this chapter. 
 
Chapter 7: Development of the positioning device version 2 
This chapter gives an overview of the applications, the materials, 
the designs of the different components used and the 
development and integration of the second version of the 
proposed MRI compatible positioning device.  
 
Chapter 8: Development of the positioning device version 3 
This third version of the proposed positioning device, as 
mentioned earlier, is an advancement of the first version.  In this 
chapter the applications, the materials used, the design of the 
different parts, the development and the integration of the third 
positioning device are explained in details. 
 
Chapter 9: Software development  
This chapter explains the development of the software that will 
be used to control the HIFU system. The digital thermometer, 
transducer movement, treatment history, ultrasound treatment 
protocol, and patient database, are the main functions of the 
software and these are presented in this chapter. 
 
Chapter 10: Evaluation of the MRI compatible positioning devices 
This chapter describes how the MRI compatible devices are 
tested and evaluated.  All the experiments made to evaluate 
HIFU ablation and the MRI compatibility of the HIFU system are 
analysed. 
 
 
Chapter 11: Conclusion and future enhancements 
Conclusions and future enhancements are described in this last 
chapter.  
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2 Abdominal and thyroid tumours 
This research primarily focuses on the design and development of three 
positioning devices which will be used in an MRI to guide the HIFU transducer 
to treat the brain, the thyroid and abdominal tumours.  More specific, the 
abdominal tumours are tumours appearing on organs such as the liver, kidney 
and pancreas.  These organs are the abdominal organs where HIFU has been 
tested by previous researchers, liver [9], [34]-[47], kidney [13], [14], [34], [46]-
[49] and pancreas [15], [16].  Thyroid tumours were also studied and tested by 
previous researchers [18]-[22].  Abdominal or thyroid tumour is an abnormal 
growth of mass in the abdominal region of the body and this is a result of an 
abnormal growth of the cells in this area.  The positioning device will guide the 
HIFU transducer to ablate the tumour area with and this process will be 
monitored by an MRI scanner.   
In this chapter the basic anatomy and physiology of these abdominal organs, 
and the thyroid will be described.  Also, in brief there will be description of the 
tumours manifested in these organs together with a synopsis of the current 
main treatment regimes.  
2.1 Liver tumours 
The liver is located in the upper right-hand portion of the abdominal cavity, 
beneath the diaphragm, and on top of the stomach, right kidney, and intestines 
[50].  The anatomy of the liver is shown in figure 2.1. 
The liver regulates most chemical levels in the blood and excretes a product 
called bile, which helps carry away waste products from the liver. All the blood 
leaving the stomach and intestines passes through the liver. The liver 
processes this blood and breaks down the nutrients and drugs into forms that 
are easier to use for the rest of the body.  
Important to note is that the liver can lose three-quarters of its cells before it 
stops functioning. In addition, the liver is the only organ in the body that can 
regenerate. 
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Figure 2.1: The Biliary system.  The figure above shows the liver location in 
the abdominal cavity [50]. 
Liver tumours are divided to two categories, the non-cancerous and the 
cancerous (malignant). In this section the different types of tumours are 
discussed. 
 
2.1.1 Non-cancerous liver tumours 
The symptoms of these tumours usually are not noticeable and they are only 
detected incidentally when an ultrasound scan, or computer tomography or CT 
scan or Magnetic Resonance imaging (MRI) is performed on the patient.  
Hepatocellular adenoma which appears usually in women at young age and the 
hemangioma which is a mass of abnormal blood vessels.  There are no 
treatment for these, apart for some cases of infants with large liver 
hemangiomas who might require surgery to prevent clotting and heart failure 
[50]-[54]. 
2.1.2  Cancerous liver tumours 
Cancerous (malignant) liver tumours are also subdivided to primary liver cancer 
and secondary liver cancer.  Primary liver cancer is one that starts in the liver 
where secondary liver cancer is one that spreads into the liver from cancer of 
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another part of the body (metastatic liver cancer). Most cancerous liver tumours 
are secondary [53]-[59]. 
a. Primary liver cancers 
Hepatoma is a type of primary liver cancer and is also called hepatocellular 
carcinoma. Hepatoma is the most common form of primary liver cancer.  Some 
of the causes of this primary liver cancer are chronic infection hepatitis B and C, 
alcoholism and chronic liver cirrhosis.  
b. Diagnostic methods for liver hepatoma 
Diagnosis of hepatoma is done through the medical history of the patient and a 
physical examination. 
The following are some diagnostic procedures for liver hepatoma [50]-[54]: 
 Liver function tests, a series of special blood tests that can determine if 
the liver is functioning properly.  
 Abdominal ultrasound (also called sonography), a diagnostic imaging 
technique which uses high-frequency sound waves to create an image of 
the internal organs. Ultrasounds are used to view internal organs of the 
abdomen such as the liver, spleen, and kidneys and to assess blood flow 
through various vessels.  
 Computed Tomography scan (CT or CAT scan), a diagnostic imaging 
procedure using a combination of x-rays and computer technology to 
produce cross-sectional images (often called slices), both horizontally 
and vertically, of the body. A CT scan shows detailed images of any part 
of the body, including the bones, muscles, fat, and organs. CT scans are 
more detailed than general x-rays.  
 Hepatic arteriography, x-rays taken after a substance in injected into 
the hepatic artery.  
 Liver biopsy, a procedure in which tissue samples from the liver are 
removed (with a needle or during surgery) from the body for examination 
under a microscope.  
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c. Treatment methods for liver hepatoma 
For the treatment of liver hepatoma several approaches are used some of 
which are listed below [50]-[54]: 
 Surgical resection can only be used in some cases to remove 
cancerous tissue from the liver. However, the tumour must be small and 
confined.  
 Radiation therapy that uses high-energy rays to kill or shrink cancer 
cells.  
 Chemotherapy that uses anticancer drugs to kill cancer cells.  
 Liver transplantation  
 Thermal ablation methods using HIFU are also used and these are 
discussed in detail later in this report. 
d. Other Types of primary liver cancers 
Other types of primary liver cancers which are less common are the following: 
 Cholangiocarcinoma, a cancer that originates in the lining of the bile 
channels in the liver or in the bile ducts.  
 Hepatoblastoma, a cancer in infants and children, sometimes causing 
the release of hormones that result in early puberty.  
 Angiosarcoma, a rare cancer that originates in the blood vessels of the 
liver.  
According to the National Cancer Institute primary liver cancer passes through 
the following stages:  
 localized resectable. Cancer is in one place and can be removed 
completely with surgery.  
 localized unresectable. Cancer is in one place, but cannot be totally 
removed. 
 Advanced. Cancer has spread through the liver and other parts of the 
body. 
 Recurrent. Cancer has come back after it was treated. 
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e. Secondary Liver cancers (metastatic liver cancers) 
As explained earlier in section 2.1.2 secondary liver cancer is one that has 
spread from other areas in the body to the liver. These metastatic cancers 
infecting the liver usually start from the lung, breast, colon, pancreas, and 
stomach. Blood cancers including Leukemia are also spread to the liver 
sometimes. 
f. Diagnostic methods for metastatic liver cancer 
Diagnosis of metastatic liver cancer is done through the medical history of the 
patient and a physical examination. 
The diagnostic procedures used for metastatic liver cancer are very similar as 
the one described above for liver hepaptoma. 
g. Treatment methods for metastatic liver 
For the treatment of metastatic liver cancer several approaches are used some 
of which are listed below: 
 Surgical resection as mentioned previously for primary liver cancers 
can only be used in some cases to remove cancerous tissue from the 
liver. However, the tumour must be small and confined.  
 Radiation therapy which uses high-energy rays to kill or shrink cancer 
cells.  
 Chemotherapy that uses anticancer drugs to kill cancer cells.  
 Thermal ablation methods using HIFU are also used and these are 
discussed in detail later in this report. 
Hepatocellular carcinoma (HCC), a primary liver cancer described above in 
primary liver cancers section is considered to be one of the most common 
malignancies worldwide, and metastatic liver cancers are the most common 
cause of death in cancer patients [46]. 
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2.1.3 Liver cancer statistics 
The statistical information shown in appendix 12.3 was taken from the National 
Cancer Institute (NCI) [51] and from the World Health Organization-International 
Agency for research on Cancer [55]. 
 
2.2 Kidney tumours 
Renal is the Latin word for kidneys and therefore the word renal is common 
when referring to kidneys.  The kidneys are two dark-red, bean-shaped organs 
one on each side of the backbone, above the waist. There is a cavity attached 
to the indented side of the kidney, called the renal pelvis which extends into the 
ureter [50]-[54].  Each kidney is enclosed in a transparent membrane called the 
renal capsule which helps to protect them against infections and 
trauma.  Nephrons are about one million of microscopic structures inside each 
kidney responsible for filtering the blood removing waste products and making 
urine.  The urine passes from each kidney into the bladder through a long tube 
called a ureter. The bladder stores the urine until it is passed from the body. 
Blood is delivered to the kidneys through the renal artery and over 180 litres of 
blood pass through the kidneys every day. When this blood enters the kidneys it 
is filtered and returned to the heart via the renal vein. Figure 2.2 shows the 
anatomy of the kidney.  
 
Figure 2.2: The Anatomy of the Kidney [50] 
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Kidneys are located towards the back of the abdominal cavity, just above the 
waist.  One kidney is normally located just below the liver, on the right side of 
the abdomen and the other is just below the spleen on the left side. Figure 2.3 
shows the kidneys’ location in the abdominal cavity.  
The kidney is full of blood vessels since every function of the kidney involves 
blood; therefore, it requires a lot of blood vessels to facilitate these functions. 
Together, the two kidneys contain about 160 km of blood vessels.  
 
Figure 2.3: The Front View of Urinary Tract. The figure above shows the 
kidneys’ location in the abdominal cavity [50].  
The size of an adult human kidney is about 10 to 13 cm long and about 5 to 7.5 
cm wide and weighs approximately 150 grams. Kidneys weigh about 0.5% of 
total body weight.  
Kidney cancers are also called renal cancers.  Kidney cancers are also divided 
to different types. These types of cancers, their symptoms and the method used 
for the treatment of these tumours are explained below.   
2.2.1 Non-cancerous kidney tumours 
Benign kidney tumours are noncancerous.  The symptoms of these tumours are 
not noticeable and usually are detected incidentally.  These tumours are not 
threatening the life of the patients’ [53].  
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Renal adenomas are the most common form of benign, solid kidney tumour, 
and are typically small, low-grade growths. Their cause is unknown. Because 
they usually are asymptomatic, their incidence is unknown, although one study 
found them present in 7% to 22% of autopsy cadavers. In rare cases, when 
they have grown large enough to affect kidney function or adjacent vessels, 
symptoms similar to those of renal cell carcinoma (RCC) may occur. 
Renal Oncocytoma is a benign, usually asymptomatic tumour that can grow 
quite large. They can develop throughout the body and are not unique to the 
kidneys. Their cause is unknown, and they appear with greater frequency in 
men than in women. Typically, they are discovered incidentally by ultrasound, 
IVP, CT, or MRI scan for an unrelated health problem.  
Under a microscope, many oncocytomas resemble early-stage RCCs. Many 
physicians regard them as precancerous growths to be surgically removed 
unless the patient's age or overall health condition dictates otherwise. 
Angiomyolipoma also known as renal hamartoma, angiomyolipomas are rare 
benign tumours usually caused by an inherited genetic mutation. They can 
occur on an isolated, individual basis, but most often are associated with a rare 
genetic disease called tuberous sclerosis, which can cause tumours in the skin, 
kidneys, brain, and other organ systems. About 80% of persons diagnosed with 
tuberous sclerosis also have angiomyolipoma.  
In patients without tuberous sclerosis, these tumours most often occur in 
middle-aged women. Most cases are discovered when the patient undergoes a 
CT scan for an unrelated abdominal problem, suffers gastrointestinal 
discomfort, or suffers a sudden hemorrhage caused by the rupture of a large 
tumour.  
Management of the condition depends on the size of the tumours and the 
severity of the symptoms they produce. Asymptomatic patients and those with 
small tumours usually are not treated; instead, they are observed periodically 
with an eye toward surgery if the tumours grow or produce symptoms. Because 
of the potential for spontaneous rupture and life-threatening hemorrhage, 
patients with large tumours usually are considered candidates for some form of 
surgical treatment, ranging from partial nephrectomy to arterial embolization. 
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Fibromas are tumours of the fibrous tissue on, in, or surrounding the kidney. 
They are rare and are more common in women. Their cause is unknown and 
most do not cause symptoms. Usually they grow on the periphery of the kidney 
and can become large before becoming clinically obvious. While generally 
benign, these tumours have no special characteristics to differentiate them from 
malignant tumours of the kidney. Because of this uncertainty of diagnosis, 
partial or radical nephrectomy is the standard treatment. 
Lipomas are rare renal tumours that originate in the fat cells within the renal 
capsule or surrounding tissue. They typically occur in middle-aged women, can 
grow very large, and produce pain and hematuria. Like many benign tumours, 
they may become cancerous and usually are treated with total nephrectomy. 
 
2.2.2 Cancerous kidney tumours 
Several types of cancer can start in the kidney.  When kidney cancer spreads 
outside the kidney, cancer cells are often found in nearby lymph nodes. Kidney 
cancer also may spread to the lungs, bones, liver or even from one kidney to 
the other [51], [57]-[59].  
a. Types of cancerous kidney tumours 
Kidney cancerous tumours include renal cell cancer, the most common type of 
kidney cancer in adults and the transitional cell carcinoma which affect the renal 
pelvis.  Wilms tumour is another kidney cancer which is the most common type 
of childhood kidney cancer. It also includes renal sarcoma a rare type of kidney 
cancer that starts in the kidney’s blood vessels.  These kidney cancer types are 
described below [51], [57]-[59].  
Renal cell cancer (RCC) is the most common type of kidney cancer in adults 
and it is also called renal adenocarcinoma or hypernephroma. More than 8 in 
every 10 kidney cancers diagnosed in the UK are RCC.  In renal cell cancer the 
cancerous cells start in the lining of very small tubes in the kidney that help filter 
the blood and remove waste products through urine. 
Below there is a list of several subtypes of renal cell cancer (RCC): 
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 Clear cell renal cell carcinoma: This is the most common form of RCC. 
About 7 out of 10 people with RCC have this kind of cancer. When seen 
under a microscope, the cells that make up clear cell RCC look very pale 
or clear. 
 Papillary renal cell carcinoma: This is the second most common 
subtype – about 1 out of 10 people with RCC have this kind. These 
cancers make little finger-like projections (called papillae) in some, if not 
most, of the tumor. Some doctors call these cancers chromophilic 
because the cells take up certain dyes used to prepare the tissue to be 
looked at under the microscope. The dyes make them look pink. 
 Chromophobe renal cell carcinoma: This subtype accounts for a few 
cases of RCCs. The cells of these cancers are also pale, like the clear 
cells, but are much larger and differ in other ways. 
 Collecting duct renal cell carcinoma: This subtype is very rare. The 
major feature is that the cancer cells can form irregular tubes. 
 Unclassified renal cell carcinoma: In rare cases, renal cell cancers are 
called as “unclassified” because they don’t fit into any of the other groups 
or because more than one type of cell is present. 
Transitional cell carcinoma are tumours that begin in the renal pelvis, the 
point where the kidney joins the tube that carries urine form the kidney to the 
bladder (ureter), and not in the kidney itself. About 7 or 8 out of every 100 (7 to 
8 %) kidney cancers diagnosed in the UK are transitional cell carcinomas, also 
known as urothelial carcinomas.  
The symptoms of transitional cell carcinoma are quite similar to those of RCC, 
and include haematuria and back or flank pain. 
At early stage these cancers have a 90% cure rate. Treatment usually involves 
surgical removal of the kidney, ureter, and portion of the bladder connecting to 
the ureter. Depending on the stage of the cancer, chemotherapy and radiation 
may be used as adjuvant treatments. 
Wilms' Tumour is a type of kidney cancer that usually develops in children 
under the age of 5. About 5% of all kidney cancers are Wilms tumours also 
called nephroblastomas. Wilms' tumour can arise anywhere within the kidney's 
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tissues. If left untreated, it can spread to the veins, lymph nodes, adrenal 
glands, large or small bowel, and liver. Wilms' tumour is one of the most curable 
of all childhood cancers. Today the 5-year survival rate approaches 90%. 
Renal sarcoma: Renal sarcomas are a rare type of kidney cancer that starts in 
the kidney’s connective tissue or blood vessels. Less than 1% of all kidney 
tumours are of this type. In most cases, it is impossible to differentiate renal 
sarcoma from RCC externally, so the diagnosis usually is made after 
examination of a CT scan or MRI procedure. 
Such tumours will grow and spread to adjacent organs, bones, and lymph 
nodes if left untreated. The only potentially curative form of treatment is surgery, 
usually radical or partial nephrectomy, sometimes with radiation or 
chemotherapy. 
b. Diagnostic methods for Kidney cancer (renal cell cancer) 
Diagnostic procedures for kidney cancer may include the following [50]-[54]: 
 blood and urine laboratory tests 
 intravenous pyelogram (IVP) - a series of x-rays of the kidney, ureters, 
and bladder with the injection of a contrast dye into the vein - to detect 
tumours, abnormalities, kidney stones, or any obstructions, and to 
assess renal blood flow. 
 renal angiography (Also called arteriography.) - a series of x-rays of the 
renal blood vessels with the injection of a contrast dye into a catheter, 
which is placed into the blood vessels of the kidney, to detect any signs 
of blockage or abnormalities affecting the blood supply to the kidneys. 
 other imaging tests (to show the difference between diseased and 
healthy tissues), including the following:  
o computed tomography scan (Also called a CT or CAT scan.) - a 
non-invasive procedure that takes cross-sectional images of the 
brain or other internal organs; to detect any abnormalities that 
may not show up on an ordinary x-ray. 
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o magnetic resonance imaging (MRI) - a non-invasive procedure 
that produces two-dimensional view of an internal organ or 
structure, especially the brain and spinal cord. 
o ultrasound (Also called sonography.) - a diagnostic imaging 
technique which uses high-frequency sound waves and a 
computer to create images of blood vessels, tissues, and organs. 
Ultrasounds are used to view internal organs as they function, and 
to assess blood flow through various vessels. 
Biopsy is the only sure way to diagnose cancer. 
c. Treatment methods for kidney cancer 
Specific treatment for kidney cancer will be determined by your physician based 
on [50]-[54]: 
 your age, overall health, and medical history 
 extent of the disease 
 your tolerance for specific medications, procedures, or therapies 
 expectations for the course of the disease 
 your opinion or preference 
Treatment may include: 
 Surgery: Surgery to remove the kidney is called a nephrectomy and it is 
the most common treatment for kidney cancer. The following are different 
types of nephrectomy procedures:  
o radical nephrectomy, the whole kidney is removed along with the 
adrenal gland, tissue around the kidney, and, sometimes, lymph 
nodes in the area. 
o simple nephrectomy, only the kidney is removed. 
o partial nephrectomy, only the part of the kidney that contains the 
tumour is removed. 
The remaining kidney is generally able to perform the work of both 
kidneys. 
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 Radiation therapy (also called radiotherapy): Radiation therapy uses 
high-energy x-rays to kill cancer cells, and is also sometimes used to 
relieve pain when kidney cancer has spread to the bone. 
 Biological therapy (also called immunotherapy): Biological therapy is 
a treatment that uses the body's own immune system to fight cancer. 
 Chemotherapy: Chemotherapy is the use of drugs to kill cancer cells. 
 Hormone therapy: Hormone therapy is used in a small number of 
patients with advanced kidney cancer to try to control the growth of 
cancer cells. 
 Arterial embolization: Arterial embolization is a method where small 
pieces of a special gelatine sponge, or other material, are injected 
through a catheter to clog the main renal blood vessel.  This procedure 
shrinks the tumour by blocking the oxygen and other substances it needs 
to grow. It may also be used before an operation to make surgery easier, 
or to provide relief from pain when removal of the tumour is not possible. 
 New chemotherapy drugs and targeted therapies are also under 
development being used to treat kidney cancer.  
 A vaccine for treatment is under study.  
2.2.3 Kidney cancer statistics 
The statistical information shown in appendix 12.3 was taken from the National 
Cancer Institute (NCI) [51] and from the World Health Organization-International 
Agency for research on Cancer [55]. 
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2.3 Pancreatic tumours 
The pancreas is located in the abdomen.  It is surrounded by the stomach, 
intestines, and other organs.  The pancreas is about 6 inches long and is 
shaped like a long, flattened pear wide at one end and narrow at the other.  The 
wide part of the pancreas is called the head, the narrow end is the tail, and the 
middle section is called the body of the pancreas [54]. Figure 2.3 shows the 
pancreas. 
 
Figure 2.4: The Anatomy of the Pancreas [50]. 
Pancreas has two main functions, it makes pancreatic juices, and it produces 
several hormones, including insulin.  Pancreatic juices contain proteins called 
enzymes that help digest food.  The pancreas releases these juices, as they are 
needed, into a system of ducts. The main pancreatic duct joins the common bile 
duct from the liver and gallbladder.  The common bile duct carries bile, a fluid 
that helps digest fat.  Together these ducts form a short tube that empties into 
the duodenum, the first section of the small intestine [50].  
Pancreatic cancer has been called a "silent" disease because the symptoms do 
not appear at an early stage.  The cancer may grow for some time before it 
causes noticeable symptoms. When symptoms do appear, they may be so 
vague that they are ignored at first. For these reasons, pancreatic cancer is 
hard to find early.  In many cases, the cancer spreads outside the pancreas by 
the time it is found [54].  Also, advanced pancreatic cancer patients will only 
survive for about four months.   
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The treatment for these patients as for many other cancer patients is mainly 
chemotherapy and radiotherapy. These therapies can relieve the pain to some 
degree but their efficacy is poor and they also bring side effects.  
The pancreas, its operation, pancreatic tumours their symptoms and the 
common treatments are discussed in this section.  
 
2.3.1 Pancreatic Cancers 
Cancer of the pancreas is also called pancreatic cancer or carcinoma of the 
pancreas.  Most pancreatic cancers begin in the ducts that carry pancreatic 
juices. A rare type of pancreatic cancer begins in the cells that produce insulin 
and other hormones.  These cells are called islet cells, or the islets of 
Langerhans.  Cancers that begin in these cells are called islet cell cancers [53], 
[54], [56]-[58].  
As pancreatic cancer grows, the tumour may invade organs that surround the 
pancreas, such as the stomach or small intestine.  Pancreatic cancer cells also 
may break away from the tumour and spread to other parts of the body. When 
pancreatic cancer cells spread, they often form new tumours in lymph nodes 
and the liver, and sometimes in the lungs or bones.  The new tumours have the 
same kind of abnormal cells and the same name as the primary (original) 
tumour in the pancreas. For example, if pancreatic cancer spreads to the liver, 
the cancer cells in the liver are pancreatic cancer cells.  The disease is 
metastatic pancreatic cancer; it is not liver cancer.  
a. Diagnostic methods for pancreatic cancers 
Diagnosis of pancreatic cancers is through physical examination, patient’s 
medical history in addition to checking general signs of health, blood, urine, and 
stool tests [50].  
The doctor usually orders procedures that produce images of the pancreas and 
the area around it.  Images can help the doctor diagnose cancer of the 
pancreas.  They also can help the doctor determine the stage, or extent, of the 
disease by showing whether the cancer affects nearby organs.  Images that 
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show the location and extent of the cancer help the doctor decide how to treat it. 
Procedures to produce images of the pancreas and nearby organs may include:  
 An upper gastrointestinal (GI) series, sometimes called a barium 
swallow. A series of x-rays of the upper digestive system is taken after 
the patient drinks a barium solution. The barium shows an outline of the 
digestive organs on the x-rays.  
 Computed Tomography scan (CT or CAT) scanning, the use of an x-
ray machine linked with a computer. The x-ray machine is shaped like a 
doughnut with a large hole. The patient lies on a bed that passes through 
the hole, and the machine moves along the patient's body, taking many 
x-rays. The computer puts the x-rays together to produce detailed 
pictures.  
 Magnetic Resonance Imaging (MRI), the use of a powerful magnet 
linked to a computer. The MRI machine is very large, with space for the 
patient to lie in a tunnel inside the magnet. The machine measures the 
body's response to the magnetic field, and the computer uses this 
information to make detailed pictures of areas inside the body.  
 Ultrasound (also called sonography or ultrasonography), the use of 
high-frequency sound waves that cannot be heard by humans. An 
instrument sends sound waves into the patient's abdomen. The echoes 
that the sound waves produce as they bounce off internal organs create 
a picture called a sonogram. Healthy tissues and tumours produce 
different echoes.  
 Endoscopic retrograde cholangiopancreatography (ERCP), a 
method for taking x-rays of the common bile duct and pancreatic ducts. 
The doctor passes a long, flexible tube (endoscope) down the throat, 
through the stomach, and into the small intestine. The doctor then injects 
dye into the ducts and takes x-rays.  
 Percutaneous Transhepatic Cholangiography (PTC), in which a thin 
needle is put into the liver through the skin on the right side of the 
abdomen. Dye is injected into the bile ducts in the liver so that blockages 
in the ducts can be seen on x-rays.  
 Angiography, x-rays of blood vessels taken after the injection of dye 
that makes the blood vessels show up on the x-rays. 
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 Pancreas biopsy, a procedure in which a sample of pancreatic tissue is 
removed (with a needle or during surgery) for examination under a 
microscope. 
 Positron Emission Tomography (PET), a type of nuclear medicine 
procedure. This means that a tiny amount of a radioactive substance, 
called a radionuclide (radiopharmaceutical or radioactive tracer), is used 
during the procedure to assist in the examination of the tissue under 
study. 
Images of the pancreas and nearby organs provide important clues as to 
whether a person has cancer. However, doing a biopsy is the only sure way for 
the doctor to learn whether pancreatic cancer is present.   
b. Pancreatic cancer treatment methods 
Pancreatic cancers are not treated easily unless they have been identified at an 
early stage, before spreading to other organs.  However, treatment can improve 
the quality of a person's life by controlling the symptoms and complications of 
this disease [15].  
The choice of treatment of these tumours depends on the type of cancer, the 
location and size of the tumours, the extent (stage) of the disease, the person's 
age and general health, and other factors. 
Cancer that begins in the pancreatic ducts may be treated with surgery, 
radiation therapy, or chemotherapy. Doctors sometimes use combinations of 
these treatments. Researchers are also studying biological therapy (also called 
immunotherapy or biotherapy, is a type of treatment that uses the body's 
immune system to fight cancer or help to lessen the side effects that maybe 
caused from other cancer treatments like chemotherapy) to see whether it can 
help when pancreatic cancer has spread to other parts of the body or has 
recurred.  
 Surgery may also be done to remove all or part of the pancreas and 
other nearby tissue.  A total pancreatectomy is surgery to remove the 
entire pancreas as well as the duodenum, common bile duct, gallbladder, 
spleen, and nearby lymph nodes. Sometimes, the cancer cannot be 
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completely removed. However, surgery can help to relieve symptoms 
that occur if the duodenum or bile duct is blocked. To relieve such 
symptoms, the surgeon creates a bypass around the blockage.  
Other therapies for pancreatic cancer include, radiation therapy (also called 
radiotherapy), chemotherapy, biological therapy (also called immunotherapy).  
It is hard to limit the effects of treatment so that only cancer cells are removed 
or destroyed. Because treatment also damages healthy cells and tissues, it 
often causes unpleasant side effects.  The side effects of cancer treatment vary. 
They depend mainly on the type and extent of the treatment. Also, each person 
reacts differently.  
2.3.2 Pancreatic cancer statistics 
The statistical information shown in appendix 12.3 was taken from the National 
Cancer Institute (NCI) [51]and from the World Health Organization-International 
Agency for research on Cancer [55]. 
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2.4 Thyroid tumours 
Thyroid is located in the neck, just above the collarbone, around the windpipe 
below the Adam's apple and is a soft, butterfly-shaped gland.  Thyroid anatomy 
is shown in figure 2.5.  The thyroid gland has two main types of cells: thyroid 
follicular cells and C cells (also called parafollicular cells).  The follicular cells 
produce thyroid hormone used to regulate metabolism i.e. it controls the 
process of converting the food we eat to energy C cells make calcitonin, a 
hormone that helps regulate how the body uses calcium. Other, less common 
cells in the thyroid gland include immune system cells (lymphocytes) and 
supportive (stromal) cells [56]-[60]. 
Thyroxine, known as T4 and triiodothyronine, known as T3 are the two essential 
hormones produced by the thyroid.  These two hormones are similar and are 
called thyroid hormones.  T4 hormone acts as a reserve for T3 since most T3 
circulating in the blood stream is a transformation of T4.  Thyroid hormone 
regulates the metabolic rate of almost all the cells of the body, and influences 
the health of the heart, brain and bones. It is also needed for normal 
development of the brain in children and for normal reproductive functioning. 
 
Figure 2.5: The anatomy of thyroid. The figure above shows the thyroid 
location [50].  
Millions of people worldwide most of them women suffer from thyroid disease 
which causes the body uses energy more slowly and called hypothyroidism or 
quickly than it should and called hyperthyroidism.  Hypothyroidism is the most 
common and it can make you gain weight, feel fatigued and have difficulty 
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dealing with cold temperatures.  Hyperthyroidism has a result of producing too 
much thyroid hormone and this can make you lose weight, speed up your heart 
rate and make you very sensitive to heat.   
Hypothyroidism and hyperthyroidism although important, are not to be 
considered here in this study but instead the thyroid cancer and the treatment 
methods available today, are concerned and analysed below. 
 
2.4.1 Thyroid benign and malignant tumours  
Thyroid cancer is a disease that you get when abnormal cells, often appear as 
bumps in the neck, begin to grow in your thyroid gland and these are called 
nodules.  Thyroid cancer is an uncommon type of cancer and in most cases, 
thyroid nodules are not cancerous. Those that are cancerous have the potential 
to spread throughout the body [50].  Thyroid cancer is usually found at early 
stages and therefore it can be treated very well.  Care must be taken after the 
treatment of a thyroid tumour since it is possible to come back some time after 
the treatment.  
Thyroid cancer occurs in all age groups, although its incidence increases with 
age, especially after 30 years of age.  More aggressive forms of thyroid cancer 
are found in older patients.  Thyroid cancer occurs three times more frequently 
in women than in men [61].  Different cancers develop from each kind of cell.  
The differences are important because they affect how serious the cancer is 
and what type of treatment is needed. 
Many types of tumours can develop in the thyroid gland. Most of them are 
benign (non-cancerous) but others are malignant (cancerous), which means 
they can spread into nearby tissues and to other parts of the body [59].   
a. Benign thyroid enlargement and nodules 
Changes in the thyroid gland’s size and shape can often be felt or even seen by 
patients or by their doctor.  
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Some goiters (abnormally large thyroid gland) are diffuse, meaning that the 
whole gland is large. Other goiters are nodular, meaning that the gland is large 
and has one or more bumps in it. There are many reasons the thyroid gland 
might be larger than usual, and most of the time it is not cancer. Both diffuse 
and nodular goitres are usually caused by an imbalance in certain hormones. 
For example, not getting enough iodine in the diet can cause changes in 
hormone levels and lead to a goitre [59]. 
Lumps or bumps in the thyroid gland are called thyroid nodules. Most thyroid 
nodules are benign, but about 1 in 20 is cancerous.  Sometimes these nodules 
make too much thyroid hormone and cause hyperthyroidism. 
People can develop thyroid nodules at any age, but they occur most commonly 
in older adults.  Fewer than 1 in 10 adults have thyroid nodules that can be felt 
by a doctor. But when the thyroid is looked at with an ultrasound test, up to half 
of all people are found to have nodules that are too small to feel [59].  
Solid nodules have little fluid or colloid, and these nodules are likely to be 
cancerous than are fluid-filled nodules.  Still, most solid nodules are not cancer. 
Some solid nodules, such as hyperplastic nodules and adenomas, have too 
many cells, but the cells are not cancer cells.  Moreover, benign thyroid nodules 
can sometimes left untreated as long as they're not growing or causing 
symptoms [59].  
b. Malignant (cancerous) thyroid tumours 
The two most common types of thyroid cancer are papillary carcinoma and 
follicular carcinoma.  Hurthle cell carcinoma is a subtype of follicular carcinoma.  
Other types of thyroid cancer, such as medullary thyroid carcinoma, anaplastic 
carcinoma, and thyroid lymphoma, occur less often [59]. 
Differentiated thyroid cancers develop from thyroid follicular cells. In these 
cancers, the cells look a lot like normal thyroid tissue when looked at under a 
microscope [59]. 
Papillary carcinoma: About 8 of 10 thyroid cancers are papillary carcinomas 
(also called papillary cancers or papillary adenocarcinomas). Papillary 
carcinomas typically grow very slowly.  Usually they develop in only one lobe of 
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the thyroid gland, but sometimes they occur in both lobes.   Even though they 
grow slowly, papillary carcinomas often spread to the lymph nodes in the neck. 
But most of the time, these cancers can be successfully treated and are rarely 
fatal [59]. 
Follicular carcinoma: Follicular carcinoma is the next most common type of 
thyroid cancer. It is also sometimes called follicular cancer or follicular 
adenocarcinoma.  Follicular cancer is much less common than papillary thyroid 
cancer, making up about 1 out of 10 thyroid cancers. Unlike papillary 
carcinoma, follicular carcinomas usually don't spread to lymph nodes, but some 
can spread to other parts of the body, such as the lungs or bones. The 
prognosis for follicular carcinoma is probably not quite as good as that of 
papillary carcinoma, although it is still very good in most cases [59].  
Hurthle cell carcinoma, also known as oxyphil cell carcinoma, is actually a kind 
of follicular carcinoma. It accounts for about 3% of thyroid cancers.  The 
prognosis may not be as good as that of typical follicular carcinoma because 
this type is harder to find and treat. This is because it is less likely to absorb 
radioactive iodine, which is used both for treatment and to look for the spread of 
differentiated thyroid cancer [59].  
c. Other types of thyroid cancers  
Medullary thyroid carcinoma: Medullary thyroid carcinoma (MTC) accounts 
for about 4% of thyroid cancers. It develops from the C cells of the thyroid 
gland. Sometimes this cancer can spread to lymph nodes, the lungs, or liver 
even before a thyroid nodule is discovered.  
Anaplastic carcinoma: Anaplastic carcinoma (also called undifferentiated 
carcinoma) is a rare form of thyroid cancer, making up about 2% of all thyroid 
cancers. It is thought to sometimes develop from an existing papillary or 
follicular cancer.  
Thyroid lymphoma: Lymphoma is very uncommon in the thyroid gland. 
Lymphomas are cancers that develop from lymphocytes, the main cell type of 
the immune system.  
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Thyroid sarcoma: These rare cancers start in the supporting cells of the 
thyroid. They are often aggressive and hard to treat.  
Parathyroid cancer: Behind, but attached to, the thyroid gland are 4 tiny 
glands called the parathyroids. The parathyroids glands help regulate the 
body's calcium levels. Cancers of the parathyroid glands are very rare.  
 
d. Diagnostic methods for thyroid cancers 
The doctor will ask about your symptoms and medical history, and perform a 
physical exam. This may include a careful examination of your neck to look for 
lumps or abnormalities. 
Tests: 
 Fine needle aspiration, removal of fluid and cells from a thyroid nodule 
with the use of a very thin needle  
o This test can be done in the doctor's office and may or may not 
require a local anaesthetic. 
 Blood test 
 Thyroid scan, x-rays taken after radioactive iodine is injected into the 
blood  
o The iodine is absorbed by the thyroid gland. This causes it to light 
up and be more visible on x-ray. 
 Ultrasound, a test that uses sound waves to examine thyroid nodules 
 Surgical biopsy, removal of a sample of thyroid tissue to test for cancer 
cells  
e. Thyroid cancer treatment methods 
Once thyroid cancer is found, staging tests (possibly including CT scans and 
PET scans) are done to find out if the cancer has spread.  Treatment depends 
on the stage of the cancer.  The treatment methods for thyroid cancer are 
surgery, radioactive iodine therapy, external radiation therapy, chemotherapy 
and laser thermal ablation (LTA).  LTA method is under study and suggested 
that light may be delivered interstitially by implanting a laser fibre directly into 
body tissues [63].  In this study US-guided needle inserted into thyroid lesions 
- 29 - 
and an optical fibre positioned in the target area.  Hence a laser irradiation is 
performed on the area being treated.   
f. Thyroid cancer statistics 
The statistical information shown in appendix 12.3 was taken from the National 
Cancer Institute (NCI) [51] and from the World Health Organization-International 
Agency for research on Cancer [55]. 
 
2.5 Brain tumours 
The brain is a large and complex human organ located in the skull which 
protects the brain from injury. Brain is the organ that controls all the processes 
of the human body. All of our thoughts, emotions, senses, skills and memories 
are controlled by the brain by receiving and interpreting information [64], [65]. 
The anatomy of the brain is very complex and is separated in four specialized 
areas that work together.  Figure 2.6 sows the different specialized areas of the 
brain and these areas are listed below: 
 the cortex is the outermost layer of brain cells. Thinking and voluntary 
movements begin in the cortex. 
 the brain stem is between the spinal cord and the rest of the brain. Basic 
functions like breathing and sleep are controlled here. 
 the basal ganglia are a cluster of structures in the centre of the brain. 
The basal ganglia coordinate messages between multiple other brain 
areas. 
 the cerebellum is at the base and the back of the brain. The cerebellum 
is responsible for coordination and balance. 
The brain is also divided into several lobes. These lobes are shown in figure 2.7 
and listed below: 
 The frontal lobe is located in front of the central sulcus associated 
reasoning, planning, parts of speech and movement (motor cortex), 
emotions, and problem-solving. 
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 The parietal lobe is located behind the central sulcus and manages 
sensation, perception of stimuli such as touch, pressure, temperature 
and pain handwriting, and body position.  
 The temporal lobe Located below the lateral fissure concerned with 
perception and recognition of auditory stimuli (hearing) and memory are 
involved with memory and hearing. 
 The occipital lobe is located at the back of the brain behind the parietal 
lobe and temporal lobe contain the brain's visual processing system. 
 
Figure 2.6: The brain is composed of three parts, the cortex the brain stem 
the basal ganglia the cerebellum [50]. 
 
Figure 2.7: The brain is divided into several lobes, the frontal, the parietal, 
the temporal and occipital [50].  
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2.5.1 Benign and malignant and metastatic brain tumours  
A brain tumour is an abnormal growth of tissue in the brain. The tumour can 
either originate in the brain itself, or come from another part of the body and 
travel to the brain [64], [65].  
a. Benign brain tumour  
A benign tumour does not contain cancer cells and usually, once removed, 
does not recur. Most benign brain tumours have clear borders, meaning they do 
not invade surrounding tissue. These tumours can, however, cause symptoms 
similar to cancerous tumours because of their size and location in the brain. 
b. Malignant (cancerous) thyroid tumours 
Malignant brain tumours contain cancer cells. Malignant brain tumours are 
usually fast growing and invade surrounding tissue. Malignant brain tumours 
very rarely spread to other areas of the body, but may recur after treatment. 
Sometimes, brain tumours that are not cancer are called malignant because of 
their size and location, and the damage they can do to vital functions of the 
brain. 
c. Metastatic brain tumours 
Metastatic brain tumours are tumours that begin to grow in another part of the 
body and then spread to the brain through the bloodstream. Common types of 
cancer that can travel to the brain include lung cancer, breast cancer, 
melanoma (a type of skin cancer), and colon cancer. All of these cancers are 
considered malignant once they have spread to the brain. 
d. Types of brain tumours 
There are many different types of brain tumours. They are usually categorized 
by the type of cell where the tumour begins, or they are categorized by the area 
of the brain where they occur.  
Gliomas are the most common type of primary brain tumour. There are several 
type of gliomas and these begin from glial cells, which are the supportive tissue 
of the brain. Several types of brain tumours are given below:  
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 Astrocytomas are glial cell tumours that are derived from connective 
tissue cells called astrocytes. These cells can be found anywhere in the 
brain or spinal cord. Astrocytomas are the most common type of 
childhood brain tumour, and the most common type of primary brain 
tumour in adults. Astrocytomas are generally subdivided into high-grade, 
medium-grade or low-grade tumours. High-grade astrocytomas are the 
most malignant of all brain tumours. 
 Brain stem gliomas are tumours found in the brain stem. Most brain 
stem tumours cannot be surgically removed because of the remote 
location and delicate and complex function this area controls. Brain stem 
gliomas occur almost exclusively in children.  
 Glioblastoma multiforme (GBM) is the most common glioma. It 
represents nearly one fourth of all primary brain tumours. This cancer 
starts in the glial cells, which are cells that help nerve cells work. 
 Ependymomas are also glial cell tumours. They usually develop in the 
lining of the ventricles or in the spinal cord. This type of tumours mostly 
occurs in children younger than 10 years of age. Ependymomas can be 
slow growing, compared to other brain tumours, but may recur after 
treatment is completed. Recurrence of ependymomas results in a more 
invasive tumour with more resistance to treatment. Two percent of brain 
tumours are ependymomas. 
 Hemangioblastomas are tumours usually located in the cerebellum and 
spinal cord. They can cause significant problems, for example angiomas 
in the brain or spinal cord may press on nerve or brain tissue. The 
tumours can occur as the result of von Hippel-Lindau disease. 
 Optic nerve gliomas are found in or around the nerves that send 
messages from the eyes to the brain. They are frequently found in 
persons who have neurofibromatosis, a condition a child is born with that 
makes him/her more likely to develop tumours in the brain. These are 
typically difficult to treat because of the surrounding sensitive brain 
structures. 
 Oligodendrogliomas is a type of tumour also arises from the supporting 
cells of the brain. They are found commonly in the cerebral hemispheres 
(cerebrum). This tumour is more common in persons in their 40s and 
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50s. These tumours have a better prognosis than most other gliomas, 
but they can become more malignant with time. 
 Uveal melanoma is cancer (melanoma) of the eye. Common surgical 
treatment for uveal melanomas is enucleation (removal of the eye), and 
other therapeutic options include radium plaque therapy and proton 
beam therapy.  
e. Diagnostic methods for brain cancers 
In addition to a complete medical history and physical examination, diagnostic 
procedures for brain tumours may include the following: 
 Neurological examination 
 Computed tomography scan  
 Magnetic resonance imaging (MRI) 
 X-ray 
 Bone scan 
 Arteriogram (also called an angiogram) 
 Myelogram 
 Spinal tap (also called a lumbar puncture) 
 Positron emission tomography (PET) 
 Magnetic resonance spectroscopy (MRS) 
 Surgical biopsy 
 
f. Brain cancer treatment methods 
 Surgery is usually the first step in the treatment of brain tumors 
 Chemotherapy 
 Radiation therapy 
 Steroids are used to treat and prevent swelling, especially in the brain. 
 Anti-seizure medication treats and prevents seizures associated with 
intracranial pressure. 
 Placement of a ventriculoperitoneal shunt (also called a VP shunt), 
which is a tube that is placed into the fluid filled spaces of the brain 
called ventricles. The other end of the tube is placed into the abdomen 
to help drain excess fluid that can build up in the brain and cause an 
increase in pressure in the brain. 
 Bone marrow transplantation 
 Supportive care minimizes the side effects of the tumor or treatment. 
 Rehabilitation may be necessary to regain lost motor skills and muscle 
strength; speech, physical, and occupational therapists may be 
involved in the healthcare team. 
 Antibiotics treat and prevent infections. 
 Continuous follow-up care helps manage disease, detect recurrence of 
the tumour, and to manage late effects of treatment. 
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g. Brain cancer statistics 
The statistical information shown in appendix 12.3 was taken from the National 
Cancer Institute (NCI) [51] and from the World Health Organization-International 
Agency for research on Cancer [55]. 
2.6 Conclusion 
 
In this chapter the abdominal organs liver, kidney, and pancreas as well as 
thyroid were described and the different types of cancers on these organs were 
considered.  Furthermore, the current treatments for these tumours were stated.  
However, through research HIFU has proven to be very optimistic method for 
treating many cancers like brain tumours [2], [10]-[11], breast interventions 
[17],[24]-[26], brain biopsies [29], prostate procedures [8], [30]-[32], including 
those discussed in this chapter liver [9], [34]-[47], kidney [13], [14], [34], [46]-
[49], pancreas [15], [16], and thyroid [18]-[22].   
Before these studies are discussed. It will be very useful for the reader to 
receive an overall description of HIFU, and this will be the subject of the next 
chapter.  
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3 High intensity focused ultrasound (HIFU) 
technology  
 
The concept of using ultrasound to treat cancer was not possible in 1930s-
1940s but this conception started to change gradually in 1950s – 1960s and 
today it seems to be a very promising method for treating tumours and is the 
only non-invasive intervention [63].  Many researchers on the field strongly 
believe that HIFU will be the modality of the future when it comes to treating 
tumours although it has been proven that HIFU could also be used for other 
applications.  HIFU applications for treating abdominal and thyroid tumours are 
concerned in this report and these applications are non-invasive and therefore a 
guidance system is a necessity.  For the guidance of the HIFU transducers two 
methodologies are suitable, the MRI scanner and ultrasound.  These two 
methodologies are discussed and compared in this chapter as well as why MRI 
was selected for these applications.  Furthermore, the development of the 
positioning device was initiated by the need to precisely move the HIFU 
transducer inside the gantry of an MRI scanner to treat tumours up to 12 cm 
deep by selectively heating them and therefore causing necrosis with HIFU.  
Therefore, in this chapter the basic theory of ultrasound, and HIFU 
technologies, including MRI compatible ultrasound transducers are presented.  
 
3.1 Ultrasound theory and ultrasound transducers 
Sound is a physical phenomenon that produces vibrations or sound waves 
which propagate through matter and these sound waves transfer energy from 
one point to another.  Important to consider here is that sound waves cannot 
travel through vacuum.  The frequency is a basic characteristic of sound which 
specifies the number of vibrations per second.  Humans can only hear sounds 
of frequencies between 20Hz and 2KHz, any sound of a higher frequency of the 
upper boundary is said to be ultrasound and cannot be heard by humans [69]-
[71].  
Prior to World War II, sound/sonar, was used to detect submerged objects in 
water and this initiate the study to apply the concept to medical diagnosis.  After 
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World War II, researchers in Japan began to explore the medical diagnostic 
capabilities of ultrasound.  In 1950s researchers managed to use ultrasound to 
detect gallstones, breast masses, and tumours.  Japan was also the first 
country to apply Doppler ultrasound, an application of ultrasound that detects 
internal moving objects such as blood coursing through the heart for 
cardiovascular investigation.  Later, ultrasound was applied to detect potential 
cancers and to visualize tumours in living subjects and in excised tissue.  
The concept of producing ultrasounds relies on the conversion of electrical 
pulses to mechanical vibrations and the conversion of returned mechanical 
vibrations back into electrical energy is the basis for ultrasonic testing.  
Ultrasound transducer is the device used for converting the electrical pulses to 
mechanical energy (sound) and the returned sound (echo) back to electrical 
signals.  
The heart of the transducer that converts the electrical energy to acoustic 
energy, and vice versa is the active element which basically is a piece of 
polarized material (i.e. some parts of the molecule are positively charged, while 
other parts of the molecule are negatively charged) with electrodes attached to 
two of its opposite faces. When an electric field is applied across the material, 
the polarized molecules will align themselves with the electric field, resulting in 
induced dipoles within the molecular or crystal structure of the material. This 
alignment of molecules will cause the material to change dimensions. This 
phenomenon is known as electrostriction. In addition, a permanently-polarized 
material such as quartz (SiO2) or barium titanate (BaTiO3) will produce an 
electric field when the material changes dimensions as a result of an imposed 
mechanical force. This phenomenon is known as the piezoelectric effect.  
The active element of most acoustic transducers used today is a piezoelectric 
ceramic, which can be cut in various ways to produce different wave modes.  A 
large piezoelectric ceramic element can be seen in the image of a cut away of a 
typical transducer in figure 3.1. Preceding the advent of piezoelectric ceramics 
in the early 1950's, piezoelectric crystals made from quartz crystals and 
magnetostrictive materials were primarily used. The active element is still 
sometimes referred to as the crystal by old timers in the non-destructive testing 
(NDT) field.  When piezoelectric ceramics were introduced, they soon became 
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the dominant material for transducers due to their good piezoelectric properties 
and their ease of manufacture into a variety of shapes and sizes. They also 
operate at low voltage and are usable up to about 300oC. The first piezoceramic 
in general use was barium titanate, and that was followed during the 1960's by 
lead zirconate titanate compositions, which are now the most commonly 
employed ceramic for making transducers.  New materials such as piezo-
polymers and composites are also being used in some applications.  
The thickness of the active element is determined by the desired frequency of 
the transducer.  A thin wafer element vibrates with a wavelength that is twice its 
thickness. Therefore, piezoelectric crystals are cut to a thickness that is 1/2 the 
desired radiated wavelength.  The higher the frequency of the transducer, the 
thinner the active element. The primary reason that high frequency contact 
transducers are not produced is because the element is very thin and too 
fragile.  
 
Figure 3.1: A cut away of a typical piezoelectric ceramic transducer. 
The ultrasound technology was adopted by medical science initially for the 
diagnostic capabilities and for diagnostic ultrasound the frequencies used are in 
the range of 2 MHz to 20 MHz. 
 
3.2 HIFU transducers, physics and technology of 
HIFU 
High Intensity Focused Ultrasound (HIFU) transducer is like an ordinary 
ultrasound transducer with its area cut from a sphere and in this way the 
ultrasound pulses focus in the centre of the sphere from which the transducer is 
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made of.  Due to the spherical geometry of the construction of the HIFU 
transducers, they can be used to precisely ablate the targeted area producing 
inducing necrosis at any depth from zero to focal length of the selected 
transducer and this can be done without harming the surrounding healthy 
tissues. Figure 3.2 shows a diagram of a HIFU transducer as a part of a sphere, 
with radius of 100mm targeting a tumour seated deeply into a healthy tissue. 
Figure 3.3 shows a photo of a typical HIFU transducer. 
HIFU makes use of the bioeffects that occur with the insonation of human tissue 
with HIFU waves. The basic effects are the change of sonographic energy into 
heat and cavitation. Heat energy is caused by the friction that results from 
vibrating tissues interacting over time.  
 
Exposing a tissue to HIFU energy for long time will cause cavitation [72], [73].  
Cavitation is developed from gas bubbles generated within tissues when the 
HIFU energy hits the target for a long time.  A bubble is formed from gas 
extracted from a tissue due to the pressure of the expansion or rarefaction. If 
the ultrasound beam continues to hit this bubble then the probability of 
cavitation is rising.  The inertial cavitation is the cavitation that occurs when the 
bubble collapses after a rapid growth during the rarefaction phase.  Transient 
cavitation is the bursting of these bubbles within the tissue planes and this 
causes significant cellular damage [74]. 
 
Furthermore, when targeting a tumour with HIFU there is a returned echo.  This 
returned echo is not important absorption.  However, it might be of a great 
importance when detecting cavitation.  HIFU differs from diagnostic sonography 
exposure by the intent to maximize these biological effects to cause destruction 
of tumour cells and tissue planes.  
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Figure 3.2: A diagram of a spherical HIFU Transducer with focal length of 
100mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: A photo of a typical HIFU Transducer.  
 
 
The destruction of the targeted area is achieved by the HIFU Transducer. The 
HIFU transducer incorporates a piezoelectric element, which converts electrical 
signals into mechanical vibrations (transmit mode) [75].  These mechanical 
vibrations are concentrated at the focal point of the transducer and heat energy 
is developed by the friction of vibrating tissues interacting over time.  Tissue 
temperature increases in the focal area resulting in a finite necrotic area. The 
area dimension is related to the firing duration and the necrotic area starts at 
- 40 - 
the transducer focus and progresses toward the transducer during the firing 
sequence as shown in figure 3.4. 
 
 
Figure 3.4: How the ablation causes finite necrosis of tissue at the targeted 
area. 
 
Innovations in HIFU transducer construction in the recent years provide as 
better designs of transducers, acoustic materials.  These advancements of 
HIFU transducers construction have improved the beam control, treatment 
times, and the ability to control beam distortion. In our days scientists have a 
choice of HIFU systems to administer for different applications. The choice is 
between treating tumours with a single transducer that focuses the beam at the 
centre of the sphere from which the transducer surface was cut from or a 
phased-array transducer that is electronically steered.  
The single-transducer approach uses frequencies between 0.5 and 10 MHz, 
with the average around 1.5 MHz.  With focusing intensity varies per procedure 
between 10,000 and 100,000 W/cm2, over a time period of 1 to 30 seconds. 
Depending on the application of HIFU and the area of the body, many of the 
studies reviewed have built transducers and delivery systems that are unique to 
their research. A comparison between systems becomes difficult due to the 
variability of many of these experimental configurations. 
HIFU delivery does have the commonality of maximizing biological effects, 
which are governed by certain physical properties to provide direct treatment.  
The fundamental concepts on which sonographic procedures are based include 
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the transmission frequency and the spatial peak temporal average (SPTA) 
intensity.  The transducer itself has a specific range of output capability.  An 
increase in frequency and/or output will have a direct effect on the temperature 
of the local tissue.  As expected, heating increases as intensity and frequency 
are increased.  It is equally important to note that, because of the attenuation, 
tissue located at a greater depth from the surface will heat to a lesser degree.  
This occurs because of the tissue’s ability to absorb energy and the tendency 
for this energy to diffuse to a lower strength as it travels farther away from the 
source.  The intensity of the beam is also governed by the density of the tissue 
that it is traveling through.  As it is known, bone absorbs more energy than soft 
tissues, which is critical when determining the dosage required for therapeutic 
effects.  These differences are accounted for in the mathematical index 
calculations for the soft tissue thermal index (TIS) and bone thermal index (TIB).  
These indices are the foundation for the as low as reasonably achievable 
(ALARA) principle, used in diagnostic sonographic practice.  A conclusion 
drawn from research is that if temperature elevation exceeding 2°C, in 
diagnostic ultrasound, will cause damage on the tissue.  This threshold is 
achieved at an energy level of 100 mW/cm2 [76]. 
In addition to thermal effects in tissue caused by the sonographic process, it is 
vital to recognize the related pressure effects.  A sound wave creates pressure 
changes as it propagates through a medium; in this case, the medium is tissue.  
Depending on the intensity and frequency at which the transducer is operating, 
the amplitude of the sound wave is directly related to increasing pressure 
against the tissue.  Because the tissues are largely composed of fluids, 
cavitation can occur as the sound wave propagates.  As the amplitude/pressure 
of the sound wave increases, transient cavitation can occur and cause rather 
significant destruction of cells and, ultimately, the tissue.  As with the thermal 
aspect of sonography, thermal index (TI), there is a mechanic index (MI) used 
to measure the threshold at which the pressure becomes destructive, which is 
still under research. 
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3.3 Utilization of MRI for the guidance of the 
therapeutic ultrasound. 
The available techniques for imaging are the following [77]: 
i. Ultrasound 
ii. Computer Tomography (CT) 
iii. Optical tomography 
iv. Positron emission tomography (PET) 
v. Single-photon emission computed tomography (SPECT) 
vi. Magnetic Resonance Imaging (MRI) 
Ultrasonic imaging is small in size, simple and inexpensive method and can 
also create a real-time moving image of what you are looking at.  An ultrasound 
transducer sends sound waves (1 to 10 MHz) into the body and receives the 
reflected sounds and this way creates a real-time moving image.  Because 
sound waves are highly scattered at bone and air interfaces, many parts of the 
body are inaccessible, and effective imaging depth is limited in most organs to 
approximately 10 cm.   
Computed tomography (CT) is an imaging technique for producing 2D and 3D 
cross-sectional images of soft tissue or bone from flat X-ray images.  However 
CT exposes the patients to far more radiation than traditional X-ray in order to 
produce the 3D images. 
Optical tomography is still under development and it seems to be a powerful 
technique for detecting tissue abnormalities and it works best on soft tissues 
such as breast and brain tumours.  Most optical methods use relatively simple 
instrumentation to image-reflected excitation light, or fluorescence emission 
light, from a surface.  Tissue reflectance imaging has high resolution and is fast, 
but because of multiple light scattering, sensitivity is limited by the 1/e optical 
penetration, and contrast is derived primarily from superficial structures, 
typically up to approximately 3 mm in depth.   
Positron emission tomography (PET) is a technology in which radioactive 
isotopes are injected into the patient’s bloodstream and it is mainly used to 
evaluate the extend of tumour metastasis, evaluation of the response to 
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treatment tumour and is considered to be the only imaging test that can 
distinguish a benign tumour from a malignant tumour. 
SPECT is a powerful tool for quantifying the distribution of a radioactive 
compound (i.e., radiotracer) in humans.  SPECT is similar to PET in its use of 
radioactive tracer material and detection of gamma rays.  In contrast with PET, 
however, the tracer used in SPECT emits gamma radiation that is measured 
directly, whereas PET tracer emits positrons that annihilate with electrons up to 
a few millimetres away, causing two gamma photons to be emitted in opposite 
directions.  
MRI uses magnetic fields to align protons inside our bodies and scans the rates 
at which protons change their orientation and creates static cross-sectional 
images of the body which can be combined to create 3D view.   
Given the available techniques for imaging CT, PET and SPECT were excluded 
due to the harm that can cause to patients due to the radiation the patients are 
exposed to (CT), and the injected radioactive isotopes (PET and SPECT).  
Optical tomography is still under development and is currently used for brain 
and breast tumours, therefore is also excluded for abdominal organs or thyroid. 
Comparing ultrasound with MRI both technologies are considered to cause no 
harm to the health of the patients and therefore tumour treatment can be 
repeated any number of times.  
Furthermore, according to Yoav Medan, Chief Systems Architect of InSightec 
and Visiting Associate Professor, Biomedical Engineering at the Technion 
Institute of Technology, in an interview [78], with the current technology MR 
guided HIFU (MRgHIFU) operations on moving organs like liver and pancreas 
are performed while the patient is anesthetized something which should be 
avoided.  Therefore MRI should undergo through major improvements in order 
to track moving organs in real time like ultrasound technology.  Also MRI is a 
huge machine and very expensive compared to ultrasound.   
Although MRI implies three main drawbacks compared to ultrasound 
technology, the limitation on the materials that can be used for the positioning 
devices, the significant higher cost [79] and the difficulty of tracking moving 
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organs, yet is the only available technology that fulfils the requirements of MR 
guided FUS (MRgFUS).  MRI will provide the anatomy of soft tissues, the 
location of the FUS beam using the thermal imaging capabilities of the MRI 
scanner and the feedback of the effect of the FUS on the targeted organ which 
gives the physician a full control over its therapeutic outcome.  Therefore MRI is 
the only modality available today for MRgFUS.  
Moreover MRI guidance of robotic systems will fulfil the expectations of more 
precise interventions with minimal invasive procedures and reduced recovery 
time and additionally MRI provides us with high contrast images of soft tissues 
and without any ionizing radiation or injection of radioactive liquids.   
As a result, in the last fifteen years MRgFUS and intraoperative MRI are 
penetrating the market as tools for various interventions and biopsy procedures 
on various organs [80]. 
 
 
3.4 Therapeutic ultrasound and HIFU 
In our days many professionals in healthcare rely on ultrasound as a diagnostic 
tool but our concern in this research is not the diagnostic property of ultrasound 
but its therapeutic capabilities. 
 
HIFU has the property to deliver heat to targeted tissues and therefore it is used 
extensively for medical applications.  Nowadays HIFU is utilized to selectively 
heat biological tissues mainly for oncological applications with minimal 
invasiveness guided either by ultrasound or by MRI to provide, to the operator 
performing the procedure, images of a region within the subject being heated 
[3], [4], [5].  The main advantage of using HIFU to treat tumours compared to 
other recent treatment technologies, is that HIFU technology is non-invasive 
since the HIFU transducers can be applied to achieve necrosis of the targeted 
area, the tumour, without affecting the surrounding healthy tissue.  This enables 
patients to walk home right after the operation and rehabilitation time is much 
shorter as they do not have to spend time in the intensive care unit (ICU) as 
usually patients do after a traditional operation.  Therefore, this means that the 
cost of the operation will be much lower.  Also, HIFU treatment technology has 
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none or minimal side effects and therefore it can be repeated any number of 
times if necessary. 
Furthermore, HIFU has been proposed as a possible therapy treatment for 
several types of tumours that are complicated to treat using other methods.  
However, due to the nature of HIFU which doesn't pass through either solid 
bone or air it can be applied only for treatment of tumours of solid organs in 
some areas of the body.  Also, HIFU is not suitable for people with cancer that 
has spread to more than one place in their body.  Therefore, HIFU is not a 
candidate treatment technology for all cancers. 
HIFU is considered investigational as a therapeutic option; the ability to provide 
non-invasive treatment for tumours is advantageous, and clinical trials that have 
been performed worldwide are very promising [75], [81].  
In the future, HIFU could be the non-invasive therapeutic choice to treat 
tumours.  This advanced technology would destroy the tumour centrally and any 
migrating cells without compromising the host organ and intervening tissues 
between the transducer and the mass [75]. 
 
3.4.1  How HIFU can be used to treat tumours 
The concept of a HIFU system is to maintain a temperature between 50-100oC 
for few seconds to create tissue necrosis.  This can be achieved with focal peak 
intensity between 1.000 and 10.000 W/cm2 at frequency of 1-5 MHz and 
duration between 1-10 seconds.   
Furthermore this ultrasonic energy can be applied from outside of the subject’s 
body as shown in figure 3.2 [81].  The applied energy can be focused to a small 
spot (few millimetres, between 1 and 3mm) within the body so as to heat the 
biological tissue to a temperature sufficient to create a desired therapeutic 
effect.  Therefore, to create tissue necrosis on larger areas, the HIFU 
transducer should be moved and with overlapping lesions larger areas will also 
be covered.  This is shown in vitro experiments using clear synthetic gel [83].  
This technique can be used to selectively destroy unwanted tissue within an 
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organ. The transducer must be immersed in a fluid container so that acoustical 
coupling is achieved between the transducer and the subject's body.  
 
3.4.2 MRI compatible HIFU Transducers and safety issues  
The idea of Fry brothers [2] half a century ago is now leading the way towards 
non-invasive operations.  The main problem of this concept was the ability of 
the physicians to observe where the HIFU beam is at any time as well as the 
feedback or the effect of the HIFU application.   Fortunately this problem was 
resolved by Jolesz, Jakab in 1991 [3] and as explained in section 3.3  MRI with 
the thermometry capability is the only modality that provides the physician the 
location of the HIFU beam at any time and the required feedback on the effect 
of the HIFU beam.  Therefore, the HIFU transducers suitable for HIFU 
applications must be MRI compatible and safe. Lack of compatibility of the 
transducer with its MRI environment causes distortion of the images used for 
the guidance of the procedure.  Moreover, careful selection of materials for the 
HIFU transducers operating inside the gantry of an MRI is of vital importance 
[84]. 
Moreover, in the recent years HIFU technologies are moving from research to 
commercial applications, therefore, the safety of patients during HIFU 
treatments is also important and need to be considered.  The main safety 
issues to be considered when using HIFU to treat tumours are the following 
[85]:  
 control of the acoustic power, 
 control of the duty cycle (excitation time intervals), 
 control of the acoustic beam to hit the targeted area, 
 and the coupling of the transducer with the patient, 
Excessive acoustic power may result in lesions larger than expected destroying 
healthy tissues or cavitation which causes significant cellular damage and 
possible burns at interface.  Also, higher acoustic power may cause overheat 
resulting to damage of the transducer.  On the other hand if the acoustic power 
is low, necrosis will not be achieved on the targeted area and this will result to 
inappropriate treatment of the targeted tumour.   
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Failure to control the duty cycle might also cause cavitation or inappropriate 
treatment of the targeted area. 
Furthermore, controlling the HIFU beam to hit the targeted area (localization) is 
also very important for HIFU treatment. Defective transducers due to excessive 
heating may modify the focal point causing the beam to hit healthy tissues.  This 
can be avoided with the use of MRI thermometry which gives us the exact 
location of the beam at any time. 
Finally, poor coupling of the transducer with the patient will damage the 
transducer and would be impossible to have an effective treatment of the 
targeted area. 
 
3.5 History of therapeutic HIFU 
The development of ultrasound transducers started with the work of P. Langevin 
who used the piezoelectric properties of quartz crystal for the development of 
active sound devices for detecting submarines in 1915. 
The first investigations of HIFU for non-invasive ablation were reported by Lynn 
et al. [1] in the early 1940s and later in the 1950s by the Fry brothers, Francis 
and William [2], at the University of Illinois and Carl Townsend, Howard White 
and George Gardner at the Interscience Research Institute of Champaign, 
pioneered the first medical application of ultrasonic waves.   
This concept was related to the treatment of neurologic disorders such as 
Parkinson’s disease.  Using a set of ultrasound transducers, they were able to 
focus the energy deep inside the cerebral cortex.  In particular, High Intensity 
ultrasound and ultrasound visualization was accomplished stereotaxically with a 
Cincinnati precision milling machine to perform accurate ablation of brain 
tumours.  Until recently, clinical trials of HIFU for ablation were few (although 
significant work in hyperthermia was performed with ultrasonic heating), 
perhaps due to the complexity of the treatments and due to the lack of 
necessary imaging technology devices required for targeting the beam 
noninvasively. With recent advances in medical imaging and ultrasound 
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technology, interest in HIFU ablation of tumours has increased.  Irradiation of 
experimental tumours using HIFU followed in the late 1970s and early 1980s. 
In the 1980s, Lizzi, with a more advanced technology, set up a device for the 
treatment of glaucoma and intra-ocular tumours. This approach has been 
rapidly replaced by laser technology [12]. 
At the end of the 1980s, the INSERM - French National Institute for Medical 
Research of Lyon Hospitals and EDAP Technomed, engaged in a research 
program on the interaction of High Intensity Focused Ultrasound (HIFU) on 
tissues. The main purpose of this work was to develop applications to treat 
malignant tumours and the result of this joined venture was the prototype 
Ablatherm, the first High Intensity Focused Ultrasound device for the treatment 
of localized prostate cancer [86].  
The first commercial HIFU machine, called the Sonablate 200, was developed 
by the American Company Focus Surgery, Inc. (Milipitas, CA) and launched in 
Europe in 1994 after receiving CE (Conformité Européene, meaning "European 
Conformity) approval, bringing a first medical validation of the technology for 
benign prostatic hyperplasia (BPH). Comprehensive studies by practitioners at 
more than one site using the device demonstrated clinical efficacy for the 
destruction of prostatic tissue without blood loss or long term side effects [79].  
Although, the Ablatherm first patient was treated in 1993 with the first Ablatherm 
HIFU system, the CE mark was only received in 2000.  Later studies on 
localized prostate cancer by Murat and colleagues at the Edouard Herriot 
Hospital in Lyon in 2006 showed that after treatment with the Ablatherm, 
progression-free survival rates were very high for low and intermediate risk 
patients with recurrent prostate cancer (70% and 50% respectively) [86]. HIFU 
treatment of prostate cancer is currently an approved therapy in Europe, 
Canada, South Korea, Australia, and elsewhere.  Prostate cancer trials for the 
new Sonablate 500 in the U.S.A. are currently held for prostate cancer patients 
and those who have experienced radiation failure. 
Magnetic Resonance Guided Focused Ultrasound MRgFUS was first developed 
by Harvey Cline and Ronald Watkins at GE Corporate R&D lab in Niskayuna 
NY and Kullervo Hynynen at the University of Arizona, Tucson AZ. starting in 
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1991. The technology was later transferred to InsighTec in Haifa Israel in 2000. 
The InsighTec ExAblate 2000 was the first MR Guided focused ultrasound 
system to obtain FDA market approval and sold commercially in the United 
States [79], [86].  
Haifu Model JC and JC200 by ChongQing Haifu Ltd [88], [89] are complete 
ultrasound guided tumour treatment systems, and they are only CE approved 
for benign and malignant tumours.  HIFU-2001(By Sumo Corporation Ltd) is an 
enhanced technology treatment system which doesn’t require anaesthesia and 
is used extensively in Asia countries.  
Table 3.1 summarizes the main historical events in the development of 
therapeutic HIFU and table 3.2 lists the active companies in the area of image 
guided ultrasound robotic systems and their medical applications.  
 
 
Table 3.1: The main historical events in the development of medical ultrasonic 
are listed in the above table [90]. 
 
 
Num. Year Event 
1 1912 Sonar 
2 1914 First sonar (sound navigation and ranging) apparatus  
3 1916 Sonar to locate submarines in World War I  
4 1920 Piezoelectric Transducers 
5 1927 Bioeffects 
6 1933 Cancer Therapy (Intensity) 
7 1937 Flow Direction 
8 1939 Physiotherapy 
9 1942 HIFU for non-invasive ablation 
10 1945 World War II -‘reflectoscope’ for non-destructive testing. This was 
used in the testing of aircraft wings. 
11 1949 Erlangen Resolution 
12 1954 Clinical treatments of neurological disorders 
13 1989 EDAP TMS and INSERM jointly develop HIFU technology 
14 1991 Magnetic Resonance Guided Focused Ultrasound MRgFUS 
15 1994 First commercial HIFU machine, called the Sonablate 200 
16 1995 First MRI compatible robot for the guidance of HIFU Transducer 
17 2000 EDAP TMS - Ablatherm HIFU receives the CE mark and industrial 
production starts 
18 2004 First MR Guided focused ultrasound system  ExAblate 2000 to 
obtain FDA market approval in the United States, by InsighTec  
19 2009 Sonalleve MR-HIFU by Philips Healthcare Philips  received the CE 
mark for clinical use 
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Num Company 
country of origin  
and Foundation year 
Model Application 
1  INSERM – French 
Institute of Medical 
Research 
 EDAP TMS 
 Lyon - France 
 founded in 1979 
 Ablatherm  
 CE mark in 2000 
 Ultrasound image guided 
 Treatment of localized 
prostate cancer 
 
2  Focus Surgery, Inc. 
subsidiary of US HIFU  
 Indianapolis, Indiana, 
US 
 Founded in 1996 
 Sonablate 200 
 CE approval in 1994 
 Ultrasound image guided 
 Benign prostatic 
hyperplasia 
 
 Sonablate 500 
 CE Mark in Europe 
 MHW approval in Japan  
 Ultrasound image guided 
 Prostate cancer 
3  InsighTec 
 Tirat Carmel, Israel 
 Founded in 1999 
 ExAblate 2000 
 CE mark in 2002 
 1st HIFU System obtained 
FDA market in 2004 
 MR image  guided 
 Prostate cancer 
 Breast cancer 
 Adenomyosis 
 Pain palliation of bone 
metastases.   
4  Philips Healthcare,  
 Netherland 
 Founded in 1895 
 Sonalleve  
 CE mark in 2009 
 MR image guided 
 Uterine fibroids  
 Non-invasive palliative 
pain treatment of bone 
metastases 
5  ChongQing Haifu Ltd  
 Chongqing, China  
 Founded in 1999 
 Haifu Model JC 
 CE mark in 2005, China: 
SFDA, Korea: KFDA, 
Russian Federation 
approval 
 Ultrasound image guided 
 Primary and metastatic 
liver cancer 
 Breast   
 Kidney  
 Pancreas 
 Primary and metastatic 
malignant bone tumours  
 Soft tissue sarcomas 
 Uterine fibroids 
 Breast fibroadenomas 
 Pain relief of patients with 
advanced-stage 
malignant tumours. 
 Haifu Model JC200 
 CE mark in 2005 
 Ultrasound image guided 
 Uterine fibroids  
 Uterine adenomyosis 
 
6  Supersonic Imagine 
 Aix-en-Provence, 
France 
 Founded in 2005 
 Brain therapy system 
 MR image guided 
 Neurological diseases 
 Brain therapy 
7 
 
 Medsonic 
 Lemesos, Cyprus 
 Founded in 2005 
 Medsonic HIFU Robotic 
System 
 MR image guided 
 Brain 
 Stroke 
 Liver 
 Kidney 
 Pancreas 
8  Image Guided 
Therapy 
 Pessac-Bordeaux, 
France  
 Founded in 2001 
 TargetedFUS  
 MR image guided 
 Uterine Fibroma 
 Breast 
9  Theraclion The sound 
Therapy 
 France 
 Founded in 2004 
 TH-One 
 CE mark in 2005 
 Ultrasound image guided 
 Breast fibroadenoma,  
 Thyroid nodules  
 Primary and secondary 
hyperparathyroidism 
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Num Company 
country of origin  
and Foundation year 
Model Application 
10  Profound Medical Inc. 
(PMI)  
 Toronto, Canada,  
 Founded in 2008 
 high-energy ultrasound 
beam with a number of 
very small transducers (not 
focused) 
 Ultrasound image guided 
 Treatment of prostate 
cancer 
11  National Institute of 
Advanced Industrial 
Science and 
Technology 
 Tsukuba and Tokyo, 
Japan 
 Founded in 2001 
 
 AIST  
 MR compatible surgical 
assist robot  
 2000 
 MR image guided 
 Prostate biopsy 
12  Innomotion 
 Herxheim, Germany 
 Founded in 2004 
 Innomotion MR compatible 
Robotic Arm 
 CE mark in 2005 
 MR image guided 
 Spinal diseases 
 Biopsy 
 Insertion of cannula and 
probes 
 Drainage 
 Drug delivery 
 Energetic tumour 
destruction 
 Aortic valve replacement 
 
13  China Medical 
Technologies, Inc, 
operated through 
subsidiary Beijing 
Yuande Bio-Medical 
Engineering Co., Ltd 
 Beijing, China 
 Founded in 1999 
 
 FEB-BY 
 Ultrasound Image guided 
 Liver,  
 Breast, 
 Kidney  
 Tumours in the pelvic 
cavity  
14  Shanghai A&S 
 Shanghai, China 
 Founded in 2001 
 HIFUNIT9000 
 CE mark in 2005, China 
SFDA in 2002 and Korea 
KFDA in 2007 
 Ultrasound Image guided 
 Treatment of abdominal 
and pelvic benign or 
malignant tumours 
 HIFUNIT9000P 
 Ultrasound Image guided 
 Treatment of abdominal 
and pelvic benign or 
malignant tumours 
Table 3.2: Active companies in image guided ultrasound robotic systems [79], 
[86]. 
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4 Applications of HIFU in medicine 
 
As explained in previous chapters due to the nature of HIFU (ultrasound doesn’t 
pass through bones or air) it can be applied only for treatment of tumours of 
solid organs in some areas of the body.  For this reason HIFU is not a candidate 
for lungs for example.   
Moreover, recent studies show that the contrast between necrotic tissue and 
normal tissue in MRI images is very good [7], [91]-[93] and therefore MRgFUS 
is becoming one of the best candidates when using HIFU treatment.  
Nowadays apart from the treatment of tumours in abdominal organs considered 
in this report, liver, kidney, and pancreas researchers are studying application of 
HIFU to treat brain tumours [11], [83], [94], [95], cardiac arrhythmia [96], [97], 
strokes [98]-[100], breast interventions [17], [24]-[26], brain biopsies [29], and 
prostate procedures [30]-[32].   
Moreover, in a study in 2008 sixteen patients were treated with HIFU and the 
results show that symptoms like pain were significantly alleviated and the 
quality of life of the patients in terms of eating, sleeping and mental status was 
markedly improved in most of the patients. They also claim that no serious 
complications were observed [15], [56].   
However, this chapter focuses only on the utilization of HIFU technology to treat 
tumours of the abdominal area and thyroid.  Furthermore, pros and cons of the 
HIFU technology as well as magnetic resonance image guided robots used to 
guide the ultrasonic transducers are also discussed in this chapter. 
 
4.1 Current state of the art of HIFU for treating 
abdominal tumours and thyroid tumours  
The current methods used for treating abdominal and thyroid tumours are 
described in chapter 2.   
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The traditional methods for treating tumours found in liver, kidney, pancreas and 
thyroid are described in chapter 2.  Over the last two decades, non-invasive and 
minimally invasive procedures have been developed to provide means for the 
ablation of solid tumours in the liver, kidney, pancreas and thyroid.   On-going 
research on these therapies have developed more efficient methods for treating 
tumours, laser [101]-[104] cryotherapy-cryosurgery [105]-[107], radiofrequency 
[108]-[112], ethanol injection [113], [114], and microwave [115]-[117] and 
comparison of these methods [118]-[121], have open the doors towards the 
non-invasive surgeries.  However, HIFU remains the only modality to be 
completely extracorporeal [47]. 
Apart from the image guided ultrasound robotic systems models appeared in 
table 3.2, Siemens Medical Solutions and Chongqing Haifu Technology Co., Ltd 
have signed a contract to jointly develop an MRI guided High Intensity Focused 
Ultrasound (HIFU) therapy system.  This collaboration aims to combine Haifu’s 
therapy technology with Siemens’ expertise in high field Magnetic Resonance 
Imaging (MRI) to develop a new MRgHIFU system which will focus on women’s 
health treatments like benign uterine fibroids and cancer as well as malignant 
and benign tumours of liver, kidney, pancreas and bone.  
Another partnership which aims to develop a HIFU system to treat prostate 
cancer is the US HIFU and Riverside Research Institute (RRI).  This partnership 
claims to develop a system that will combine the advanced tissue-type imaging 
with ultrasound energy from the Sonablate 500 medical device in order to more 
reliably detect and evaluate cancerous tissue and make treating only the 
cancerous prostatic tissue instead of the entire gland possible.  
The third partnership that aims to penetrate the market of MRI Guided HIFU is 
the cooperation of Siemens, German Cancer Research Center (D.K.F.Z.) and 
Heidelberg University. This partnership aims to develop an MRgFUS system for 
the treatment of localized tumours, whether in the prostate, the breast, or in any 
ultrasound accessible organ. 
Furthermore, the treatment of abdominal and thyroid tumours using HIFU 
systems were also studied and tested by previous researchers during the last 
two decades like liver  [9], [34]-[47], kidney [13], [14], [34], [46]-[49], pancreas 
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[15], [16] and thyroid [18]-[22].  However, as shown in table 3.2 only seven out 
of seventeen commercial image guided ultrasound robotic systems are using 
MRI for the image guidance, but it seems that in the near future more and more 
companies will invest on MRgFUS systems and few of them are currently under 
development.  Moreover, from these seventeen models displayed in table 3.2 
apart from the robotic systems under development of Medsonic Ltd. (presented 
in this report) only four models are applied on liver tumours, (Haifu Model JC, 
FEB-BY, HIFUNIT9000 and HIFUNIT9000P), the same four for kidney tumours, 
one for pancreatic tumours (Haifu Model JC), and one for thyroid tumours (TH-
One).  Finally from the seventeen commercial image guided ultrasound robotic 
systems presented in table 3.2 none of these is using MR for the image 
guidance for treating tumours located in liver, kidney, pancreas and thyroid. 
As mentioned previously this research concerns with HIFU technology and in 
particular on the positioning devices that can be utilized to guide the HIFU 
transducers inside the gantry of an MRI scanner to treat liver, kidney, pancreas 
and thyroid tumours. 
 
4.1.1 Disadvantages of the current methods for treating 
abdominal tumours 
All of the current treatments have several disadvantages. These disadvantages 
are listed below: 
 With the current treatments it is hard to limit the effects of treatment so 
that only cancer cells are removed or destroyed.  In surgical resection for 
example, the surrounding healthy tissue is also removed to prevent 
cancer spreading.  Chemotherapy also kills healthy cells. 
 Because treatment also damages healthy cells and tissues, it often 
causes unpleasant side effects. The side effects of cancer treatment may 
vary.  They depend mainly on the type and extent of the treatment. Also, 
each person reacts differently.  Chemotherapy for some persons causes 
tragic side effects.   
 Most of these methods have several side effects. 
 Patients suffer from pain after surgical resection.  
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 Patient after surgery they entered the intensive care unit and after the 
intensive unit care they need some time for recovery at home.  Thus 
implies higher cost. 
 The psychological effects on the patients caused by the side effects, the 
pain and the recovery time of traditional treatment methods is also a 
major limitation of these therapies.   
 Treatments cannot be repeated if necessary. 
 
 
4.2 Advantages of HIFU 
High Intensity Focused Ultrasound is often considered a promising technology 
within the non-invasive or minimally invasive therapy segments of medical 
technology. HIFU’s capacity to generate in-depth precise tissue necrosis using 
an external applicator, with no effect on the surrounding structures, is unique. 
The history of using therapeutic ultrasound dates back to early in the 20th 
century. Technology has continually improved and additional clinical 
applications, both diagnostic and therapeutic, have become an integral part of 
medicine today. 
Furthermore, an important difference between HIFU and many other forms of 
focused energy, such as radiation therapy or radio surgery, is that the passage 
of ultrasound energy through intervening tissue has no apparent cumulative 
effect on that tissue [122].  Also, treatment with HIFU is minimally invasive; in-
depth as well it generates precise tissue necrosis. There is no effect on the 
surrounding areas. Another advantage of HIFU is the repetition of the treatment.  
HIFU can also be administered to older patients as well. "When patients in their 
70s are diagnosed with prostate cancer, this is the only technique we 
recommend. It is also recommended for young patients who suffer from high 
blood pressure, diabetes and cardiac diseases," shares Dr Desai [122]. 
Explaining the advantages, Dr Ramana Murthy adds, "The use of HIFU is quite 
effective showing no sign of cancer in biopsies taken following the procedure. 
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The levels of Prostate-Specific Antigen (PSA), drop dramatically after the 
treatment. "He adds that in general cases, no hormones are required. Also, 
people who have been treated with HIFU so far have had very few side effects 
[122]. 
Experts consider HIFU as a promising technology and recent studies prove that 
HIFU is the future in medicine. The healthy tissue through which the ultrasound 
passes is not affected and therefore HIFU is not invasive therapy. 
 
The benefits of HIFU treatment are listed below: 
 With HIFU the tumour is targeted and ablated precisely and therefore 
healthy tissues are not destroyed. Furthermore, the pain is minimized 
since only the cancerous cells are ablated. 
 HIFU treatment causes far less damaging side-effects than conventional 
treatments.  
 HIFU can avoid chemotherapy.  
 HIFU does not involve radiotherapy.  
 With HIFU technology surgery is not required since it is non-invasive.  
Therefore, the pain and the recovery time are minimized.  
 Patient after HIFU treatment they don’t entered the intensive care unit. 
Therefore, this will lower the cost to the patient.  
 The recovery time after HIFU treatment is minimized and patients can go 
to work the day after the treatment.  Therefore, the cost is lower and also 
the psychological effects on the patient are minimized. 
 Not limited by tumour size  
 HIFU treatment may result in a strengthening of the patient's immunity to 
cancer [123]-[125].  
 HIFU treatment can be repeated, if necessary, any number of times with 
no any effects on the patient. 
 
Therefore HIFU technology with so many advantages it seems to be very 
promising in future medicine and especial in treating tumours. 
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4.3 Limitations and drawbacks of HIFU 
HIFU may cause some pain for three to four days post-surgery. In some cases, 
HIFU also causes sore skin in the area treated.  
Generally, HIFU is used for treating small tumours on solid organs it cannot be 
used in case the tumours are more widespread. This means that HIFU is not 
suitable for people with cancer that has spread to more than one place in their 
body.  
HIFU cannot propagate through either solid bone can absorb or reflect an 
ultrasound beam or air." This also means that it is not suitable to treat every 
type of cancer. 
Although it has been showed that pancreatic and liver tumours can be treated 
with today’s technology, in such cases the patient needs to be anesthetised.  
Anesthetising the customer is not desirable, however this cannot be avoided 
with the current state of MRI.  As mentioned earlier, MRI cannot track organs in 
real time like ultrasound and therefore, moving organs are hard to be treated.  
To solve this problem either MRI will have to go through major improvement so 
imaging will be in real time and this will enable physicians to point an organ 
which is moving or though research we will be able to control breathing and 
moving organs [126], [127].  
   
4.4 Magnetic Resonance guided High Intensity 
Focused Ultrasounds (MRgHIFU) systems 
 
HIFU, as explained in the previous chapters is a promising technology with 
many advantages when compared with other available methodologies for 
treating tumours.  The fact that the number of scientist devoted in this area is 
rising exponentially in the recent years proves that HIFU is considered to be the 
future solution for treating tumours.  However since HIFU is a non-invasive 
technique the main gap that  Fry brothers faced is the targeted organ anatomy 
and the feedback on the effect of the applied HIFU beam.  Without these, it is 
like a physician trying to perform a surgery blindfolded.  The solution to the real 
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time guidance and the necessary feedback is provided by the MRI scanner and 
its thermometry capability.  
Moreover, as explained in chapter 3 in order to treat large areas by creating 
tissue necrosis, the HIFU transducer should be maneuverer to create 
overlapping lesions of a diameter 1 to 3mm, leaving no untreated tissues.  The 
positioning device of the HIFU transducer is responsible for this motion and 
should be placed inside the MRI scanner and monitored using a software 
interface from a distance.  Therefore a positioning device which will guide the 
HIFU transducer to cover large regions of tumours is necessary in order to 
assure that the movement of the HIFU transducer is more precise creating the 
overlapping necrosis of the tumour.  Furthermore, as the positioning device is 
placed inside the MRI scanner and this can cause interference with the RF field 
and therefore can cause some corruption of the images.  Thus, care must be 
taken when selecting materials for its construction as all the components must 
be MRI compatible and small enough as to fit in the gantry of a typical MR 
scanner with diameter of 55 cm and length between 150 cm and 200 cm.  MRI 
compatible robotic system refers to a system that is not hazardous in any way 
and neither generates any interference to the MRI scanner nor affected by the 
strong electromagnetic field of the MRI scanner [128], [129].  
The development of a positioning device compatible with MRI is revolutionary 
since such applications will be guided by the three dimensional (3D) technology 
provided by the MRI.  During the last decade the concept and the development 
of MRI compatible robots is moving with an accelerated pace and the number of 
the involved groups and funding is increasing [128].  The MRI guidance of a 
robot provides reliability and accuracy necessary for non-invasive or minimally 
invasive interventions [79].   
The robots proposed in this study will be used to accurately move the HIFU 
transducer inside the gantry of an MRI scanner to create necrosis on the tissue 
where a tumour is identified.  
The next section explains the choice of MRI guidance and gives an overview of 
image guided robots and HIFU systems with MRI guidance.  Furthermore 
existing MRI compatible positioning devices are reviewed. 
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4.5 Image guided robots and HIFU systems with MRI 
guidance 
The concept of using MRI to guide a real time non-invasive surgery with HIFU, 
as described earlier, proved to be feasible since the early nineties with clearly 
visible lesions produced by HIFU beams on a canine muscle in vivo inside the 
gantry of an MRI. Studies followed this concept [6], [7] showed that the contrast 
between necrotic tissue and normal tissue is superior when compared with 
ultrasound technology and this proves that MRI is an excellent tool for HIFU 
systems guidance.  As a result the use of MRI to guide HIFU systems increased 
rapidly in recent years. 
The advantages of using MRI compatible positioning device for different 
medical applications are the following: 
i. non or minimal invasive methods, 
ii. use of 3D view provided by the MRI scanner during the intervention, 
iii. the use or a robot assures high precision and repeatability, 
iv. and the main advantage of MRI over ultrasound imaging is the better 
anatomical information and is the only modality to show thermal lesions 
and temperature maps which will provide feedback to a physician for 
controlling the non-invasive procedure. 
 
4.6 Existing imaging positioning devices 
The concept of image guided robots using CT was introduced by Minerva 
system [130] for placing a needle precisely during stereotactic brain biopsy in 
1993.  The concept transferred to the gantry of the MRI scanner with the first 
MRI compatible robot developed by Masamune et al. [29] in 1995.  This robot 
was made of polymers and MRI compatible material.  However, the robot would 
not maneuverer during scan time.  
As described in the previous section the combination of focused ultrasound with 
MRI imaging for the guidance of non-invasive procedures, was proposed in the 
early nineties by Jolesz and Jakab [3] and after that Harvey Cline and Ronald 
Watkins at the GE Corporate R&D lab and Kullervo Hynynen at the University of 
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Arizona joined Jolesz to develop the first focused ultrasound prototype [131].  
The early MRgFUS developed by General Electric in the years 1993-1994 
[132]-[133] used hydraulic principles to move the transducer.  Several studies 
were done with these systems [134].  These MRgFUS systems place the 
transducer directly beneath the targeted tumour.  Additionally, the hydraulic 
positioning systems have serious repeatability and reliability problems, and 
have never reached the clinics.  The motors used in the hydraulic positioning 
systems interfere with the MRI scanner, and therefore are placed far from the 
MRI scanner, thus requiring the use of long motor drive shafts, which result to a 
large and complicated positioning system. 
Another patent of MRgFUS by General Electric in 1995 [135] uses threaded 
shafts and screw drives through universal joints.  This patent also requires the 
ultrasonic transducer to be placed directly beneath the object to be treated.  The 
motors of this positioning system are made out of magnetic material and 
therefore they are placed at a distance from the MRI scanner.  
This group of Hynynen, Jolesz and GE Healthcare in collaboration with Brigham 
and Women’s Hospital and Elbit Medical Imaging continue successfully together 
until 1999.  At that time their proprietary transferred to the newly formed 
company InSightec which had started as InSight Therapeutics and was based 
in Tirat Carmel, near Haifa Israel.  The robotic system of patent [136] uses 
piezoelectric motors to move the transducer inside an MRI scanner. InSightec is 
considered to be the leader in the market of MRgFUS and system ExAblate 
2000 was the first commercial MRgFUS for the treatment of uterine fibroids 
received the Food and Drug Administration (FDA) approval in 2004.  InSightec 
claims that more than 8.000 patients have been treated with the ExAblate 
system worldwide since 2011 [86].  Furthermore, according to InSightec the 
ExAblate system can also be used to treat prostate cancer, breast cancer, 
adenomyosis, and for pain palliation of bone metastases.  The ExAblate 2000 
MRgFUS system is embedded on the patient’s table which is compatible with 
the bore of both 1.5 Tesla and 3 Tesla MRI Systems. 
In 1999 Chinzei et al. [84] delivered a study on the criteria to design MR 
compatible mechatronic devices and in the year 2000 a five degrees of freedom 
(DoF) MR compatible surgical assist robot [137] was developed by Chinzei et 
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al.  This robot is placed outside the bore of the General Electric signa SP 
double-doughnuts intraoperative MRI, is actuated by ultrasonic motors and 
used for prostate biopsy.  
Chongqing Haifu (HIFU) Technology Co., Ltd. founded in 1999 [88], [89] in 
Chongqing China have developed two models of HIFU therapeutic systems.  
The Haifu Model JC, which offers a non-invasive treatment of solid tumours 
including primary and metastatic liver cancer, breast cancer, primary and 
metastatic malignant bone tumours, soft tissue sarcomas, and benign tumours 
such as uterine fibroids and breast fibroadenomas and the Haifu Model JC200 
Focused Ultrasound Tumour Therapeutic System which offers non-invasive 
treatment of uterine fibroids to reserve the patients’ uterus and ablate the 
fibroids extracoporeally.   
Another commercial robotic device for precise needle insertion during MR-
guided therapy of spinal diseases [138], [139] was developed by Hempel et al. 
in 2003.  This MR-guided robotic system was commercialized by the start-up 
company Innomedic. This MR guided robotic system was made to perform 
biopsy, insertion of cannula and probes, drainage, drug delivery and energetic 
tumour destruction [140], [141].  In 2008 Mazilu et al. use this MR guided 
robotic system of Innomotion for aortic valve replacement (AVR) [96].  The 
Innomotion MR guided robotic arm which has 6 DoF is moving along an arch 
which is mounted on the MRI patient table. An arm sitting on the arch takes 
advantage of the clearance between the patient and the bore.  Further 
evaluation and different applications of the Innomotion robotic system are 
performed until today [80], [142]-[144]. 
Sonalleve MR-HIFU is also a commercial MRgFUS by Philips Healthcare 
Philips Healthcare, Netherland [145]. This MR guided robotic system is 5 DoF 
positioning system and is integrated with the HIFU transducer on the patient’s 
table. According to the Focused Ultrasound Surgery Foundation the Sonalleve 
MR-HIFU system, received the CE mark for clinical use in December 2009, and 
offers a non-invasive alternative to the traditional surgical treatments for uterine 
fibroids in women. The Sonalleve MR-HIFU system has also received CE 
marking for non-invasive palliative pain treatment of bone metastases in 2011.   
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Another company that innovates in therapeutic products using High Intensity 
Focused Ultrasound and ultrasonic image guidance for the treatment of solid 
cancers and benign tumours is China Medical Technologies, Inc.  FEB-BY is a 
non-invasive HIFU tumour therapy system and it was approved for sale by the 
Chinese State Food and Drug Administration (SFDA) in 1999 for the treatment 
of a wide variety of cancerous and benign solid tumours including: liver, breast, 
and kidney tumours and tumours in the pelvic cavity.   According to China 
Medical Technologies, Inc. this HIFU tumour therapy system has been used in 
over 40,000 cases in China. 
Theraclion is a French company, founded in 2004. Theraclion develops, 
manufactures and markets the TH-One, used in the non-invasive and 
ambulatory treatment of breast fibroadenoma, as well thyroid nodules and 
primary and secondary hyperparathyroidism [18], [22].  TH-One combines HIFU 
technology guided by real-time ultrasound imaging.  It’s an online step-by-step 
procedure through a touch screen monitor with a mobile unit and a robotic arm.   
Profound Medical Inc. (PMI) - Prostate Focus Ultrasound is based in Toronto, 
Canada, and founded in 2008 [86].  PMI has developed an MRI-compatible 
ultrasound energy wand to deliver controlled thermal therapy to the regions of 
the prostate gland via a trans-urethral approach.  This PMI system is not using 
the HIFU technology but is using high-energy ultrasound beam with a number of 
very small transducers (not focused) aligned on a probe introduced through the 
urethra.  
Image Guided Therapy (IGT) founded 2001 based in Pessac, Bordeaux, 
France.  Their HIFU system, the TargetedFUS, is a totally non-invasive MR 
guided thermal ablation device based on Focused Ultrasound (MRgFUS).  The 
TagetedFUS model can be fitted with two different tabletop positioning systems 
optimized for different anatomies.   
Focus Surgery is subsidiary of US HIFU, a US company in Indianapolis, Indiana 
who commercialized the Sonablate 500 system for non-invasive treatment of 
prostate cancer.  Sonablate 500 system combines proprietary multi-focal length 
transducer technology in a custom transrectal imaging and therapy probe 
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[146].  The Sonablate 500 system is not using MRI for image guidance but it 
uses ultrasound imaging for treatment planning and monitoring.  
The MR guided HIFU robotic system proposed by Damianou et al. [81] has 
three DoF and is small and portable and it can be seated on the table of any 
MRI scanner.  This positioning device is to be used to treat brain tumours. 
The patent [147] describes a manual positioning system, which can be used 
only in an open MRI system.  Despite the fact that open MRI offers several 
advantages, it is not widely used because of its poor image quality.  Moreover, 
the manual system is user dependent, whereas the system we propose is not 
user- dependent. 
Another positioning system developed by Tsekos et al.  [148], also utilizes 
piezoelectric motors in order to guide a biopsy needle. However, this system 
cannot be used in combination with a HIFU system, because there are no 
means to provide acoustical coupling between the transducer holder and the 
targeted tissue. 
MR compatible robotic systems are very attractive for non-invasive surgeries 
where the physician will get continuous feedback from the MRI in order to have 
full control over the procedure. In the past fifteen years MRgHIFU robotic 
devices have been developed for a variety of applications like breast 
intervention [17], [24]-[26], [27], [149]-[150], prostate procedures [30]-[32], 
interventional spinal procedure [138], neurosurgery [29], [151], interventional 
liver therapy [152], cardiac intervention [96] and for experimental work on small 
animals [153]. 
Although these MRgHIFU robotic systems have demonstrated the technical 
feasibility of MR compatible manipulators, these devices are highly specialized 
for a certain anatomy or MR scanner design. Some of these robots are very 
complicated, expensive, not portable due to their complicated structure or size, 
and not compatible with all MRI scanners.  Moreover, most of these robotic 
systems are not flexible to perform a variety of applications. 
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5 Development of HIFU system with MRI 
guidance 
 
The importance of the MRI compatible positioning device which will guide the 
HIFU transducer was explained earlier.  In this chapter three positioning devices 
are proposed for use in different MRI scanners for different applications and 
with several improvements from version to version.  All three were designed 
and developed to be small, light, portable, cost effective, flexible and universal.  
 
5.1 Design Criteria and requirements 
The required devices for the implementation of the proposed HIFU-MRI system 
are summarized in table 5.1 and described in the following sections. 
 
Commercially Available Components 
Num Required Devices Devices Used 
1 RF amplifier 250 W, AR, Souderton, PA, USA 
2 Signal generator HP 33120A Hewlett Packard, now Agilent technologies, 
Englewood, CO, USA 
3 High intensity focused 
ultrasound transducer 
Etalon, Lebanon, IN, USA, 4 MHz, focal length of 10 cm 
and diameter of 3 cm. 
4 Piezoelectric Ultrasonic 
Motors (PUM) 
Shinsei USR60E3N  
5 Dedicated driver for 
Shinsei PUM  
Piezo Systems/Shinsei D6060E 
6 Data acquisition Card National instruments 6251 DAQ 
7 MRI compatible camera MRC Systems GmbH, Heidelberg, Germany 
9 MRI compatible cavitation 
detector 
Onda Corporation, Sunnyvale, CA 
10 Thermocouple-to-analogue 
converter 
Omega M2813-1205 
11 Personal computer Sony Vaio PCG-6W2M 
12 MRI scanner Signa 1.5 T, by General Electric, Fairfield, CT, USA 
Componets used for Positioning Device Version 1 
1 Brass rods 0.95 cm diameter brass rod 
2 Timing belt  the material of the band is Neoprepene 
 width of 9 mm,   
 pitch 5.8 mm 
 length 60 cm (120 teeth)  
3 Pulleys The pulley has a width of 9.5 mm, and a pitch 5.8 mm 
and is made of Polycarbonate. 
4 Plastic parts of the 
positioning device 
 polyethelyne  
 supplied by United States Plastic Company (USP)   
5 Brass Screws - 
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Componets used for Positioning Devices Version 2 and 3 
1 Plastic parts of the 
positioning device 
 Acrylonitrile Butadiene Styrene (ABS) 
 Design using CAD software, Microstation V8, 
Bentley Systems, Inc.  
 Produced by 3D printer, Stratasys, FDM400, 7665 
Commerce Way Eden Prairie, MN 55344 U.S.A. 
2 Brass racks and pinions  supplied by Sterling instrument NY USA 
3 Brass screws - 
  Design and Implemented Components 
1 Positioning Device Design and implemented with MRI compatible materials 
and it will be used to guide the HIFU transducer inside 
the gantry of the MRI. 
2 Coupling System This is the container filled with the degassed water 
within which the transducer will operate and is attached 
on the positioning device. Is the media used for the 
focused ultrasound beam to travel through to the 
targeted area. 
3 Software  the application software to be developed for the user 
interface of the system. This software application will 
be used to control and guide the therapy. 
 software used for the development of the user 
interface application is MATLAB (The Math works 
Inc., Natick, MA, USA) 
 
Table 5.1:  Design criteria and requirements for the development of the HIFU-
MRI system. 
 
 
5.2 HIFU/ MRI system 
The block diagram of the HIFU/MRI system used for the development of the 
MRI compatible positioning device is shown in figure 5.1.  Figure 5.2 shows the 
actual components and devices used for the proposed positioning device.  The 
HIFU/MRI system devices are summarized in the table 5.1 above. 
 
5.2.1 HIFU system 
The HIFU system consists of a signal generator (HP 33120A Hewlett Packard, 
now Agilent technologies, Englewood, CO, USA), an RF amplifier (250 W, AR, 
Souderton, PA, USA), and a spherically shaped bowl transducer (Etalon, 
Lebanon, IN, USA) made from piezoelectric ceramic which is non-magnetic. 
The transducer operates at 4 MHz, has focal length of 10 cm and diameter of 3 
cm.  The transducer is rigidly mounted on the MR compatible positioning 
device.  
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Figure 5.1: Block diagram of high intensity focused ultrasound (HIFU) system with the MRI guidance.  This diagram shows the 
arrangement of the devices used in the HIFU system. 
- 67 - 
 
 
Figure 5.2: Setup of the actual devices used for the HIFU system with the MRI guidance (The positioning device shown is the third 
version).    
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5.2.2 Positioning device (Robot)  
 
As explained previously the positioning device will operate inside the MRI 
scanner and therefore all the materials to be used for the construction of the 
robot should be MRI compatible (non-magnetic).  This section here describes 
the devices and the materials used for the positioning device.  
 
a. Piezoelectric Ultrasonic Motors (PUM) and their drivers 
 
Piezoelectric ultrasonic motors (PUM) are used in various MRI compatible 
robotic systems [25], [29], [81], [137].  These motors are driven by the ultrasonic 
vibration of a piezoelectric transducer when high-frequency voltage is applied. 
Therefore PUMs do not interfere with the magnetic fields of the MRI scanner.  
However, according to Chinzei et al. [84], some commercially available PUM 
are prone to cause image artifacts and significant signal-to-noise ratio (SNR) 
loss [80]. 
 
The actuators of the robot apart from being non-magnetic in order to be used in 
the MRI must also be accurately controlled.   The accuracy, by which the 
actuators are control to guide the HIFU transducer is of great importance and 
should be considered very carefully.  The reason for this is due to the fact that 
actuators should precisely move the robot to cover the targeted area only 
avoiding lesions to healthy tissues.  Furthermore, actuators must be small to 
save space inside the gantry of the MRI and must also be light to contribute to 
the portability of the robot. 
 
Piezoelectric ultrasonic motors (PUM) have several advantages for space-
based robot applications.  These motors are MRI compatible, small, light in 
weight, bidirectional with high torque output, accurately driven and mechanically 
simple.  Therefore PUM are well-suited to these requirements.  PUM can 
achieve high precision as a result of low speed, lack of gears and 
transmissions, and freedom from backlash [154]. They are quite simple 
mechanically, consisting of a single moving part that provides the same 
functionality as motor, transmission, and brake in a conventional motor-driven 
system. 
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A typical piezoelectric ultrasonic motor consists of a toothed piezoelectric disk 
(stator) in contact with a metal disk (rotor) as shown in figure 5.3.  Time-varying 
electric fields applied to the piezoelectric stator induce a travelling wave which 
is mechanically rectified, causing the rotor to rotate.  This mechanism produces 
relatively high torque at low rotor angular velocities, obviating the need for 
gearing. The friction between rotor and stator provides a passive holding torque 
typically larger than the rotating torque, eliminating the need for mechanical 
brakes or active holding torque. These motors can be built such that they 
neither produce nor are affected by magnetic fields, making them useful in 
highly magnetic environments and applications in which magnetic fields are 
harmful. 
 
 
Figure 5.3: Diagram of the mechanism of the ultrasonic motor. The diagram 
above was taken from the manual of Shinsei motors.  
 
Figure 5.4 shows the traveling wave formation and the direction of the rotor.  
The photo of figure 5.5 is a cross-section of a Shinsei PUM motor and shows 
the structure inside the motor. 
 
 
Figure 5.4: Traveling Wave Formation 
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Figure 5.5: Inside structure of ultrasonic motor (USR60-S4) 
 
The production of drive signals for the PUM requires special circuitry that 
produces a pair of phased sinusoidal signals of variable frequency.  The motor 
was supplied with a standard commercial driver (Piezo Systems/Shinsei 
D6060E) that permits open-loop speed control via an analogue input signal and 
direction control via a pair of discrete input signals. Figure 5.6 shows a photo of 
piezoelectric ultrasonic motor by Shinsei USR60E3N and Figure 5.7 a photo of 
dedicated driver for Shinsei USR60 series, Shinsei D6060E. 
b. Robot drivers 
The box hosting the motor drivers is placed outside the MRI room since 
magnetic materials are involved.  The diagram of figure 5.8 shows the basic 
connection diagram of the dedicated driver for Shinsei USR60 series, Shinsei 
D6060E and the diagram of figure 5.9 shows the wiring diagram of the driving 
electronics and computer-controlled interface. 
 
Figure 5.6: A photo of piezoelectric ultrasonic motor by Shinsei USR60E3N. 
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Figure 5.7: A photo of dedicated driver for Shinsei USR60 series, Shinsei 
D6060E. 
A DC supply (24 V, 6 A) is used to drive the Shinsei drivers. Wires from the 
Shinsei drivers are connected to a PCI 6602 interface card (National 
instruments, Austin, Texas, USA) via a connecting block. The PCI 6602 
interface card includes timing and digital I/O modules. The interface is 
connected in a PC (Dell Inc. Round Rock, Texas, USA).  
 
 
Figure 5.8: Basic connection diagram of the dedicated driver for Shinsei USR60 
series, Shinsei D6060E 
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Figure 5.9: Wiring diagram of the motor drivers for 3 degrees of freedom 
positioning device. 
The motors are driven when the ground and clockwise terminals of the Shinsei 
drivers are connected (clockwise rotation) or when the ground and anti-
clockwise terminals of the Shinsei drivers are connected (anti-clockwise 
rotation). This is achieved by initiating a command from the software which 
places 2 digital output terminals of the PCI card (for example ground and 
clockwise) in the same potential. Movement of a certain axis can be achieved 
also manually by means of an ON-OFF-ON switch.  
 
c. Temperature measurement at the focal point of the HIFU 
 
The development of the digital thermometer was one of the first tasks of this 
research since this thermometer is of vital importance for all the experiments.  
The importance of the digital thermometer arises from the fact that necrosis of 
biological tissues is achieved through the induction of thermal dose only in the 
targeted area which is situated at any depth between 0cm and 10cm.  Therefore 
this digital thermometer can be used during the experimental work to locate the 
focus of the HIFU transducer by emerging its thermocouple into the targeted 
biological tissue and measure the heat produced inside the tissue.  Also it will 
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be used to store in a text file the variation of temperature with respect to time as 
heat is generated with the use of the HIFU transducer.  This text file can then be 
used for the analysis of the thermal dose in to the tissue and these can give 
useful conclusions related to frequency, exposure time and cool off period and 
the intensity used.  
 
d. Data Acquisition Card-National instruments 6251 DAQ 
 
The data acquisition board used for the development of this project is the 
National Instruments 6251 DAQ model which feature 16 analogue input (AI) 
channels, two analogue output (AO) channels, up to 8 lines of digital 
input/output (DIO), Programmable Function Interface (PFI)or Digital I/O. As an 
input, each PFI terminal can be used to supply an external source for AI, AO, 
DI, and DO timing signals or counter/timer inputs. As a PFI output, you can 
route many different internal AI, AO, DI, or DO timing signals to each PFI 
terminal. You also can route the counter/timer outputs to each PFI terminal. As 
a Port 1 or Port 2 digital I/O signal, you can individually configure each signal as 
an input or output. 
 
The digital input/output lines are used to drive the motors of the robot, and one 
of the analogue lines is used to capture the temperature into the computer. Also 
this card will be used for the localization of the robot. 
 
e. Driving the piezoelectric motors with the Data Acquisition 
Board 
The driver (Shinsei D6060 E) provided for the piezoelectric motors (Shinsei 
USR 60-E3N) permits speed control via an analogue input signal and the 
direction is controlled via a pair of discrete input signals.  The analogue input 
signal is provided by the data acquisition card used by National instruments 
6251 DAQ which is connected to the PC and driven by the software to be 
developed.  This arrangement is shown in figures 5.1 and 5.2.  This driver of 
piezoelectric motor also accepts a feedback from the motor and this will be fed 
back to the software through the data acquisition card to verify the localization 
of the motors.   
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5.2.3 Cavitation detector  
From a scientific point of view it will be useful to separate lesions developed 
based on thermal and based on cavitation mechanisms.  In this system we use 
a passive MRI compatible cavitation detector (Onda Corporation, Sunnyvale, 
CA), shown in figure 5.10, which is placed perpendicularly to the beam of the 
HIFU transducer.  Since the HIFU protocol is applied inside the magnet of an 
MRI scanner, the detector must be MRI compatible.  The diameter of the 
detector was 1 cm, its radius of curvature was 10 cm and operated between 1 
and 13 MHz (centre frequency is 7 MHz). The detector was mechanically 
coupled to the HIFU transducer. The voltage from the detector was fed to an 
analogue to digital (A/D). The signal was then displayed in order to visualize 
whether cavitation occurs or not. 
 
 
Figure 5.10: The photograph shows the cavitation detector. 
 
5.2.4 MRI compatible camera 
In order to monitor the condition of the animal or humans (future use), a MRI 
compatible camera (MRC Systems GmbH, Heidelberg, Germany) shown in 
figure 5.11, was mounted on the system. The camera was interfaced by means 
of a video card. With the aid of the MRI compatible camera, the researcher can 
monitor the welfare of the animal. 
5.2.5 Software 
A user-friendly program written in MATLAB (The Mathworks Inc., Natick, MA) 
has been developed in order to control the system. The software serves the 
following main tasks:  
i. Displaying of MR images 
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ii. Transducer movement (the user may move the robotic arm in a specific 
direction or customize the automatic movement of the robotic arm in 
any rectangular formation by specifying the pattern, the step and the 
number of steps) 
iii. Messaging (starting time, treatment time left etc.) 
iv. Patient data (age, weight, etc.) 
v. Display of motor position 
vi. Display of the contents of the MR compatible camera 
vii. Cavitation detection window 
viii. Temperature measurement 
 
 
Figure 5.11: The photograph shows the MRI compatible camera. 
 
5.3 Advantages and limitations of the three versions 
of positioning devices 
This thesis report proposed three versions of positioning devices each of which 
has several benefits and limitations.  In this section the pros and cons of all 
three versions are outlined. The first version of positioning device was designed 
and implemented to overcome some of the limitations of the existing MRI 
guided HIFU positioning devices. The design requirements of the first version 
positioning device are listed below:  
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i. to be used in experimental work to treat brain tumours in small animals in 
vivo or in vitro and hence transfer this concept to treat human brain 
tumours  
ii. to be portable therefore, small in size and light in weight  
iii. to be used in all commercially available MRI Design   
iv. to be flexible in order to be used for a variety of HIFU applications 
v. to be guided and controlled easily and effectively with a user friendly 
interface software. The requirements of the end user application are 
described in section 1.1 
The completion of the first version of positioning device revealed some 
limitations and that’s why the second version was considered. These limitations 
are listed below: 
i. the positioning device is driven with the timing belts and timing belts will 
not provide the robot with the best accuracy and stability.   
ii. the positioning device is applicable mainly for brain tumour and therefore, 
it’s considered flexible multi-tool. 
iii. many parts of the robot are fabricated and assembled manually and thus 
makes the reproduction of the robot very difficult.   
Designing the second version of positioning device all the advantages of the 
first version were retained with some additional features and some advantages. 
These new features and advantages are outlined below: 
i. the timing belts were replaced with racks and pinions and this granted 
better stability and accuracy  
ii. the second version of positioning device was designed with detachable 
HIFU transducer holders and this makes this robot a more flexible tool in 
the hands of the physicians. This robot can be utilized to treat tumours 
on liver, kidney, pancreas and thyroid tumours. This robot can also be 
used to perform experiments in large animals like pig, sheep and dog 
and small animals like rabbit and rat 
iii. related to the above advantage the capability of attaching different HIFU 
transducer holders of different length, height, and pointing direction or 
angle provide the robot the advantage to accept HIFU transducers from 
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different manufacturers or with different focal length and different 
diameter, for different applications 
iv. this robot was designed on CAD software and manufactured from a 3D 
printer and this will give smother edges more accurate design and the 
reproduction of the robot will be possible. 
v. the production material and the new design made this version lighter and 
more compact compared to version one. 
This second version also has some limitations the main of which is the effective 
working space for the targeted objects which is limited if it is to be sited on the 
table of the MRI. An alternative for this positioning device is to be attached on 
the top of the gantry of the MRI providing more effective operational area. 
However, this approach requires the cooperation with the MRI manufacturers.  
The third version of positioning device adopted all the advantages of the second 
version of positioning device and resolves the limitation given above. All 
advances of this version compared to version two are listed below: 
i. the robot can operate on any MRI scanner available without any 
modification of the MRI 
ii. can be utilized treat brain liver, kidney, pancreas and thyroid tumours  as 
well as to perform experiments in large animals like pig, sheep and dog 
and small animals like rabbit and rat.  
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6 Development of the positioning device 
version 1 
 
This first version robot was to design to overcome the limitation of other existing 
similar devices.  Therefore, the focus was to design a robot that is small, light, 
cost effective, universal and flexible positioning device which will be used to 
accurately guide the HIFU transducer inside the gantry of any MRI scanner to 
provide in medicine a non-invasive alternative to the traditional surgical 
treatments to treat tumours by creating overlapping lesions to the targeted area.  
This positioning device was designed and implemented for experimental work 
on small animals in vivo or in vitro and to treat brain tumours.  
Furthermore, the proposed positioning device will be used inside the gantry of 
an MRI scanner and therefore care must be taken when considering any part to 
be attached to the positioning device to be MRI compatible.  For this reason the 
screws, the timing belts and the material for the construction of the robot are all 
selected having this in mind as described in chapter 5.  
This section describes the design and development stages of the positioning 
device version 1. 
 
6.1 Description of the positioning device – 1st version 
The proposed positioning device is a prototype magnetic resonance imaging 
(MRI)-compatible positioning device used to move an MRI-guided high intensity 
focused ultrasound (HIFU) transducer. The positioning device has 3 user-
controlled degrees of freedom that allow access to various targeted lesions.  
However, it can be easily developed for 5 degrees of motion.    
The main component of an ultrasonic system guided by MRI is the positioning 
device. The positioning devices and HIFU transducers cause problems when 
used inside an MRI scanner.  Any interference with the RF field will reduce the 
quality of the image. The imaging will occur if the robotic system and transducer 
or any other therapeutic object does not interfere with the magnetic and RF 
fields needed by the MRI system.  Therefore these devices must be made out 
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of non-magnetic materials and the proposed positioning device incorporates 
only MRI compatible materials such as piezoelectric motors, plastic sheets, 
brass screws, plastic pulleys and timing belts. 
Moreover, since the positioning device is placed on the table of the MRI 
scanner its height and length should less than 55 cm (diameter of the gantry of 
the MRI scanner).  The height of the proposed positioning device 34 cm, its 
length is 45 cm and its width 30 cm.  The weight of the positioning device is only 
6 kg and therefore it can be considered portable.  Furthermore the positioning 
device was not designed based on any specific MRI scanner and can be 
positioned on the bed of any MRI scanner, therefore is also considered 
universal. 
This chapter describes the non-magnetic materials and parts acquired for the 
development of the positioning device, the designs based on the limitations and 
considerations gathered for this application, and photographs of the different 
stages and the final product developed.   
 
6.2 Design and implementation of positioning device 
version 1 
As mentioned previously the selection of the materials and parts for the 
development of this positioning device are restricted to be compatible to operate 
within the gantry of an MRI scanner.  The devices of an integrated HIFU system 
are shown in figure 5.2 and described in chapter 5.  The piezoelectric ultrasonic 
motors and their drivers are described in sections 5.1.3 and the photographs of 
these are shown in figures 5.6 and 5.7.  Apart from the piezoelectric ultrasonic 
motors and their drivers which are described earlier, the following sections 
describe the rest of the selected parts and materials used as well as the 
designs of the three stages of the robot. 
 
- 80 - 
6.2.1 Parts and materials used for the positioning device 
Figure 6.1 shows the angular part which is useful in order to support the rods 
and the pulleys.  It is also used to hold the surface plate of the other axis as 
shown in figure 6.10.  Figure 6.1.A shows the side view of the angular part and 
the top view is shown in figure 6.1.B.   The top view of the angular part of figure 
6.1.B shows the brass screws used for mounting this part on the other plates.  
Figure 6.1.C shows a photograph of the actual part.  This angular part of figure 
6.1 is made of polyethelyne and is 90o. Its thickness is 0.65cm and the two 
sides are 3.8cm long. This part is supplied by the company named United 
States Plastic Company (USP) and comes in length of 120cm.   
 
 
 
 
 
Figure 6.1: Corner part used to support the rods and the pulleys.  This part is 
also used to support the different stages of the robot. 
 
Figure 6.2.A. shows the diagram of the rod used to guide and support the 
surface plate of the stages X, Y and Z and figure 6.2.B. shows a photo of the 
rod.  Each stage/dimension it’s supported by two rods. The rod shown in figure 
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6.2 is of 0.95cm diameter.  The length of the rod is 30cm and this is the length 
used for supporting and guiding the X-stage responsible for the back and 
forward motion. The material used for the rod is brass. 
  
 
 
Figure 6.2: The brass rod used to support and guide the surface plates of the 
stages X, Y and Z. 
 
The rod mounted with a brass screw on the angular part is shown in Figure 6.3. 
  
Figure 6.3: Position of the brass screw which is used to mount the rod on the 
angular part.  
The brass screws used for mounting the parts of the positioning device are 
shown in figure 6.4. 
 
 
 
 
Figure 6.4: The brass screws used to mount the parts of the positioning 
device. 
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Three surface plates were used each of which is used to hold the guidance 
mechanism of each of the three stages (X, Y, Z).  Two angular parts are 
mounted on a surface plate, facing each other and a rod is attached across the 
two plates to serve as a guide for the next stage.  As mentioned previously two 
rods are used to support and guide a stage surface plate as shown in figure 6.5. 
 
 
 
Figure 6.5: Brass rod mounted on two angular parts which are attached on the 
base of the positioning device.  
 
 
The surface plate of figure 6.6.A. is the diagram of the base of the positioning 
device and figure 6.6.B. shows a photo of this plate.  The diagram and the 
photo of the surface plates for X-stage and Y-stage are shown in figures 6.6.C., 
6.6.D and 6.6.E., 6.6.F respectively.  The thickness of all surface plates is 
1.27cm and the material used is polyethelyne.  
The timing belt and the pulley are shown in figure 6.7.A and 6.7.B respectively.  
The belt has a width of 9 mm, a pitch 5.8 mm and length 60 cm (120 teeth) and 
the material of the band is Neoprepene.  The pulley has a width of 9.5 mm, and 
a pitch 5.8 mm and is made of Polycarbonate. 
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Figure 6.6: Diagrams and photos of surface plates of the base, X-Stage and Y-
Stage.  
 
The timing belt is attached between two pulleys and is also mounted on a 
surface plate of the stage which it moves.  One of the pulleys is attached on a 
Piezoelectric Ultrasonic Motor shown in figure 6.7.C and 6.7.C, and when the 
motor spins the pulley attached to it rotates and that’s how the motion of the 
surface plate is achieved.   
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Figure 6.7: Pulleys, timing belt, and the piezoelectric ultrasonic motor attached 
on the base with an angular part which is driving the timing belt to 
achieve the motion of a surface plate of the X-axis. 
 
The pulley on the other end of the timing belt is held within two angular parts as 
shown in figure 6.8. 
 
 
 
 
 
 
Figure 6.8: The pulleys on the other end of the timing belt held with two angular 
parts.  
 
The base of the positioning device with the two brass rods used for supporting 
and guiding the X-axis plate is shown in figure 6.9.  The timing belt shown in 
figure 6.9 is driven by the pulley which is attached on the piezoelectric 
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ultrasonic motor.  This timing belt is anchored on the X-axis plate with a brass 
screw and that’s how the X-axis plate moves back and forth.   
 
 
Figure 6.9: Top view of the base with the brass rods that support and guide the 
X-axis plate.  The timing belt is mounted on the X-axis plate (not 
shown here) with a brass screw.  
The photograph of figure 6.10 shows the angular parts attached with brass 
screws at the bottom of the X-axis plate and the brass rod which how the X-axis 
plate moves the angular parts  
 
Figure 6.10: The angular parts attached at the bottom of the X-axis plate are 
sliding along the brass rod which acts as a support and guide.  
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6.2.2 Description of the operation of the positioning device 
Figure 6.11.A shows the rectangular base of the positioning device made out of 
polyethylene.  This plastic base holds the 3 stages that establish motion in the 
X, Y and Z direction. Four polyethylene angles are placed on the base.  Two 
brass rods are attached to the 4 angles (see figure 6.9). A fixed polycarbonate 
pulley is supported on polyethylene angles through a plastic rod.  A 
piezoelectric motor (USR60-S3N, Shinsei Kogyo Corp., Tokyo, Japan) is fixed 
on another polyethylene angle. A neoprene belt is placed around the fixed 
pulley and the pulley which is coupled to the motor. This figure shows also the 
water container that hosts the transducer. The transducer is immersed in the 
water container which is filled with degassed water or saline. The water is 
poured in a mylar bag. The mylar bag is made thin enough to conform to the 
contours of the target. A circular window is opened in the water container in 
order to allow ultrasound energy to be applied through the body. For the 
purpose of brain ablation, the head of the subject is placed inside an open MRI 
coil.   
Figure 6.11.B shows the bottom side of the polyethylene sheet that establishes 
motion in the X-direction. If the motor is energized, the belt which is coupled to 
this sheet will rotate, and eventually linear motion of this sheet is established. 
This sheet is coupled to the brass rods of the base (Figure 6.11.A).  
Figure 6.11.C shows the rectangular sheet (top side) which is used to provide 
motion in the Y-axis. The same principles as in Figure 6.11.A are implemented. 
The only difference is the smaller size of this sheet. Figure 6.11.D shows the 
bottom side of the polyethylene sheet that establishes motion in the Y-direction.  
Figure 6.11.F shows the rectangular sheet made out of polyethylene for moving 
the transducer in the Z axis (same principles are applied as in Figure 6.11.A). 
Figure 6.11.G shows the bottom side of the polyethylene sheet that establishes 
motion in the Z-direction.  
Figure 6.11.H shows the holder of the transducer. A plastic rod is attached on 
the Z –axis sheet. A brass rod is coupled to the plastic rod. The transducer 
holder is attached to the brass rod. The HIFU transducer is coupled to the 
holder.  
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Figure 6.11: Drawings of the various mechanical stages of the positioning 
device. 
 
Figure 6.12 shows the complete positioning system with all the components 
described in Figure 6.11.  The movement of the positioning device is monitored 
by an MRI compatible camera (not shown in the figure) which is placed on a 
non-magnetic holder.  
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Figure 6.12:  Schematic of the robot showing all of its stages. 
Finally the photograph of the positioning device is shown Figure 6.3. 
 
Figure 6.13: Photograph of the complete positioning device.  
 
6.2.3 Coupling mechanism 
The system provides three main mechanisms for achieving coupling to tissues. 
Figure 6.14 illustrates the two mechanisms. In Figure 6.14.A the tissue (in vitro 
or in vivo) is placed outside the container which is filled with degassed water.  
Due to the weight of the water container, the coupling with this method is very 
good.  This method can be described as a top to bottom approach, meaning 
that the transducer is on top of the tissue. In the commercial system described 
by Yehezkeli et al. [136] the approach used is bottom to top, meaning that the 
transducer in below the tissue. In Figure 6.14.B the tissue is placed inside the 
container which is filled with degassed saline. The use of saline is needed for 
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this method in order to preserve the excised tissue, which is placed inside the 
saline bath. This method which provides good coupling since the tissue is 
placed inside the container can be used only for tissues in vitro. In both 
methods the liquid in the container (water or saline) was maintained at 37 oC.  
  
Figure 6.14: Coupling methods, A. In vitro or in vivo (tissue outside the water 
container). B. In vitro (tissue inside the water container).  
 
6.3 Conclusion and Discussion 
The First version positioning device described in this chapter seems to fulfil the 
requirements set prior its design.  The robot proves to move the transducer 
accurately with both methods available for the end user, manual and automatic, 
and thus discrete and large thermal lesions can be formed reliably and 
repeatedly on the targeted tissue.  This has been proven in both in vitro and in 
vivo tissues. The evaluation of the positioning device can be found later in 
chapter 10. 
Furthermore this device is much simpler, smaller and inexpensive than the 
existing systems, while maintaining high standards of repeatability and 
readability.  Also, this positioning device is flexible since it can be easily 
reduced or increased in size.  This can be adjusted easily by modifying the 
length of the rods, the length of polyethylene sheets used as base for each level 
and the length of the belts.  All the other components remain fixed in size. Thus, 
easily any size of positioning device can be designed and manufactured. There 
is limitation though based on the diameter of the MRI scanner.  Moreover, the 
transducer holder can be easily replaced and this will make the robot suitable 
A B 
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for a variety of tissues targets.  Also, this positioning device is lightweight 
(approximately 6 Kg) and therefore it can be transported and placed on the 
table of any MRI scanner.  Thus the positioning device is considered portable 
and universal.  
Furthermore, this system has the potential to be marketed as a cost effective 
solution for performing experiments in large animals (pig, sheep and dog) and 
small animals (rabbit and rat).  
However, this positioning device is driven with the timing belts and timing belts 
will not provide the robot with the best accuracy and stability.  In addition, the 
robot described in this chapter cannot be reproduced precisely.  Many parts of 
the robot are fabricated and assembled manually and thus makes the 
reproduction of the robot difficult.   
These limitations of the first version brought the idea of the next version of the 
positioning device.  For the second version of the robot the timing belts will be 
replaced with racks and pinions and is expected that this will result better 
stability and accuracy.  Moreover, the new robot will be design on CAD software 
and manufactured from a 3D printer and this will give smother edges more 
accurate design and the reproduction of the robot will be possible. 
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7 Development of the positioning Device 
version 2 
The second version of the positioning device is a simple, cost effective, and 
portable, and it has been developed to be used in virtually any clinical MRI 
scanner since it can be placed on the scanner's table.  This system has the 
potential to be marketed as a cost effective solution for performing experiments 
in large animals (pig, sheep and dog) and small animals (rabbit and rat).  
Moreover, with a slight modification of its base as shown in figure 7.11, this 
positioning device can be attached on top of the gantry of an MRI scanner and 
this will maximize the space of the targeted body.  Also, this positioning device 
can be used in a double-donut MRI scanner which offers a 50cm vertical gap 
between the two facing superconductive magnets. The proposed positioning 
device can be accommodated in this gap.  Finally the base of the positioning 
device can be modified to be placed on a side table of an open C-shape MRI 
scanner.  With the modifications described above the positioning device can be 
used to treat abdominal tumours on kidney, liver and pancreas, as well as for 
thyroid tumours. 
The main constrain when designing a positioning device to be used inside the 
gantry of an MRI scanner is the space.  With the new generation of scanners 
(Siemens MAGNETOM Espree 1.5T) with short bore of 125cm and increased 
diameter of 70cm offers better patient access and comfort and makes 
intervention access and interventional robot assistance within the magnet more 
feasible.  Philips MR Ingenia also features a 70 cm gantry in order to decrease 
anxiety of the patient and provides additional space for MR guided robotic 
systems. 
This positioning device also incorporates only MRI compatible materials such as 
piezoelectric ultrasonic motor by Shinsei USR60E3N, Acrylonitrile Butadiene 
Styrene (ABS) plastic, brass screws, and the motion of the X, Y, and Z plates is 
accomplished with brass racks and pinions replacing the pulleys and timing 
belts of the first version. The system is manufactured automatically using a 
rapid prototyping system (FDM400, Stratasys, 7665 Commerce Way, Eden 
Prairie, Minnesota, 55344, USA). 
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The MRI compatibility of the system was successfully demonstrated in a clinical 
high field MRI scanner.  The robot has the ability to accurately move the 
transducer thus creating discrete and overlapping lesions in biological tissue.  
The following sections describe the mechanical parts and the specifications as 
well as the details of how the proposed positioning device was design and 
implemented. 
 
7.1 Parts and specifications of positioning device 
version 2 
The ABS parts of the robot were first designed using Computer-Aided Design 
(CAD) software (Microstation V8, Bentley Systems, Inc.) and exported to 
Computer-Aided Manufacturing (CAM) software (Insight V. 6.4.1, Stratasys Inc.) 
and finally were send to a 3D printer (FDM400, Stratasys, 7665 Commerce 
Way, Eden Prairie, Minnesota, 55344, USA) for production.  Therefore, the 
manufacturing of the positioning device is absolutely reproducible. 
Brass rack, and pinions (Sterling instrument, NY, USA) were used to convert 
the rotational motion of the three piezoelectric ultrasonic motors (USR60-S3N, 
Shinsei Kogyo Corp., Tokyo, Japan) into linear motion for the three degrees of 
freedom. The three racks were attached on the ABS plates with brass screws.  
The positioning device is controlled by a user friendly interface application 
developed in MATLAB (The Math works Inc., Natick, MA, USA). 
The positioning device can be placed on the table of any MRI scanner and 
therefore its height is 32.5 cm (diameter of the gantry of a typical MRI scanner 
is about 55 cm).  The length of the positioning device is 25 cm and its width 25 
cm. The weight of the positioning device is only 2.9 kg and therefore it is 
considered portable. The range of the robot is, X: 135mm, Y: 112mm, Z: 68mm.  
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7.2 Design and development of the 2
nd
 version of the 
positioning device 
The CAD drawing of the base of the positioning device is shown in figure 7.1.A.  
Figure 7.1.B shows the corresponding photograph of the base shown in figure 
7.1.A.  This base was needed in order to hold the robot for conducting 
experiments and for demonstration purposes outside an MRI.  In real life the 
robot can be fixed inside the bore of an MRI scanner, which requires the 
collaboration with MRI vendors. The tracks in which the X-axis plate slights in 
are located on the left and right side of the base as shown in figure 7.1.B. 
The plate, responsible for the movement in the X-axis is shown in figure 7.2.   
Figure 7.2.A shows the 3D CAD drawing and figure 7.2.B shows the 
corresponding photo of the produced part of the 3D printer.  The PUM motor 
attached at the bottom of the plate is the motor which will guide the Y-axis plate.  
The brass rack shown on the top of this plate will be driven by the pinion which 
is attached on the PUM motor of the top cover of the robot as shown in figure 
7.9.  The length of the brass rack is 150mm however; the effective range of the 
X-axis plate is 135mm because of the two brass screws at the two ends of the 
rack necessary to mount the rack on the ABS plate. The X-axis plate of figure 
7.2 will slide in the grooves shown in figure 7.1.  The form of the guides sliding 
in the grooves used for the motion of all axis plates is shown in the photograph 
of figure 7.3.  Figure 7.4.A and 7.4.B shows the CAD drawing and photograph 
of the X-axis plate attached in the guiding slot of the base.  
 
 
Figure 7.1: CAD design and photograph of the base of the positioning device: 
A. CAD drawing, B. actual photo (with zooming in the guide). 
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Figure 7.2:  A. CAD design of the X-axis plate and B. photograph of the X-axis 
plate base of the positioning device.  
 
 
Figure 7.3: A photograph of the groove and the guide used for the motion of all 
axis plates. 
The CAD drawing of the plate responsible for the Y-axis motion of the guided 
HIFU transducer is shown in figure 7.5.A and the corresponding photograph of 
the resulting product is shown in figure 7.5.B.  This Y-axis plate will slight in the 
grooves of the X-axis plate and the brass rack mounted on the top of the Y-axis 
plate will be driven by the brass pinion attached on the PUM motor mounted at 
the bottom of the X-axis plate as shown in figure 7.6.  Although the length of the 
brass rack for the Y-axis plate is 130mm, the effective range for the Y-axis is 
112mm because of the brass screws used to mount the rack on the ABS plate 
as shown in figure 7.5.B.   The Y-axis plate mechanism carries the Z holder 
together with the PUM motor and associated brass pinion which drives the Z-
axis plate, which is also assembled to slide within the guiding slot of the Z-
holder (shown in figure 7.7).  The 3D drawing of the Z holder with the PUM 
motor and the Z-axis plate is shown in figure 7.7.A.  Figure 7.7.B shows the 
corresponding photograph of the Z-axis plate.  The brass rack mounted on the 
back side of the Z-axis plate is 83mm long but the effective range is only 68mm 
since 15mm were used for the brass screws used to support the rack on the 
ABS Z-axis plate. 
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Several designs were made for the y-axis plate in order to deliver enough 
strength to support the Z holder and provide stability for the HIFU transducer.  
Fortunately the positioning device was design for flexibility and changing the 
design of any part will not affect the other parts.  Therefore, redesigning the Y-
axis plate to reach the final form, which is stable, did not affect the other parts of 
the robot.   
 
 
 
Figure 7.4: A. CAD drawing of the X-axis plate mounted on the base and B. 
photograph of the X-axis plate mounted on the base.  
 
 
 
 
Figure 7.5: A. the CAD drawing of the Y-axis plate of the positioning device and 
B. a photograph of the Y-axis plate of the positioning device.  
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Figure 7.6:  A. the 3D drawing of the base and the X and Y-axis plates 
assembled together and B. the corresponding photograph of the 
base, X and Y-axis plates.  The piezoelectric ultrasonic motor 
shown between the X and Y plates drives the Y-axis plate.  
 
On the front side of the Z-axis plate of figure 7.7 there is a slot.  This slot will be 
used to attach a variety of HIFU transducer holders for different applications as 
shown in figure 7.8.  The CAD drawing of the HIFU transducer holder attached 
on the Z-axis plate is shown in figure 7.8.A.  Figure 7.8.B shows the 
corresponding photograph of this part as produced by the 3D printer and 
assembled together. 
 
 
  
Figure 7.7:  A. the 3D drawing of the holder of the Z-axis plate, the Z-axis plate 
with the PUM motor which moves the Z-axis plate and B. a 
photograph of the actual part of 7.7.A as developed and 
assembled.  
The CAD drawing of the top plate of the robot with the PUM motor which drives 
the X-axis plate via the brass rack shown in figure 7.2 is shown in figure 7.9.A.  
The produced part is shown in the photograph of figure 7.9.B.  The brass pinion 
attached on the PUM motor shown in the photograph of figure 7.9.B will drive 
the brass rack mounted on the top of the X-axis plate. 
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Figure 7.10.A shows the isometric view of the CAD drawing of the developed 
positioning device and figure 7.10.B shows a photograph of the developed 
positioning device. The photograph of figure 7.11 shows the positioning device 
placed on the bed inside the MRI scanner for testing.   
The degassed water container that hosts the transducer is shown in the CAD 
drawing of Figure 7.10.A.  This container is also shown in the photograph of 
Figure 7.11 and is made of Polymethyl methacrylate (PMMA), sometimes called 
acrylic glass. The transducer is immersed in the container which is filled with 
degassed water.  The water is poured in a milar bag.  The milar bag is made 
thin enough to conform to the contours of the target.  A circular window is 
opened in the water container in order to allow ultrasound energy to be applied 
through the body.  
 
  
 
Figure 7.8:  A. the CAD drawing of the HIFU transducer holder attached on the 
Z-axis plate and B. a photograph of the HIFU transducer holder 
attached on the Z-axis plate. 
 
 
 
 
 
 
Figure 7.9:  A. the CAD drawing of the top plate of the positioning device and 
B. a photograph of the top plate of the positioning device.  The 
piezoelectric motor shown moves the X-axis plate.  
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As described at the beginning of this chapter the base of the proposed 
positioning device is designed in order to hold the robot for conducting 
experiments and for demonstration purposes outside the MRI.  Figure 7.12.A 
shows how this base can be modified and with the collaboration with the 
vendor(s) of MRI scanners this can be mounted inside the bore of an MRI 
scanner as shown in figure 7.12.B.  This modification will qualify the robot to 
perform lesions on: 
i. abdominal organs like kidney, liver and pancreas and  
ii. also used for treating thyroid tumours.  
 
 
 
Figure 7.10: A. the final 3D drawing and B. the developed positioning device.  
 
 
 
 
 
Figure 7.11:  A photograph of the positioning device inside the gantry of the 
MRI scanner with a phantom gel target inside the tank which is 
filled with degassed water.   
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Figure 7.12: A. the base of the positioning device can be easily modified and B. 
the device as attached on the top of the gantry of the MRI 
scanner.  
7.3 Conclusion and Discussion 
The proposed second version of the positioning device it’s proved to be MRI 
compatible, lightweight, cost effective, reproducible and universal since with 
slight modifications can be used in most MRI scanners available.  Furthermore 
this second version of the positioning device is more stable and accurate and 
approximately half weight when compared with the first version.  
An important improvement of this version is that it was designed to be as 
flexible as possible.  All the parts of the positioning device can be easily 
detached and this provides better portability but even more important is that any 
part of the robot can be redesigned and/or replaced at no time and this will have 
no effect on the rest of the parts of the robot.  During the development phase 
most of the parts although seemed to be operational on the 3D drawing 
(Microstation V8), but in reality when these parts were manufactured and 
assembled together showed that they needed some modification.  Fortunately 
due to the flexible design these modifications on the individual parts caused no 
effect on the rest of the parts of the positioning device.  Also, the slot on the Z-
axis plate of figure 7.6 allows attaching different HIFU transducer holders of 
different length, height, and pointing direction or angle.  Moreover, HIFU 
transducers from different manufacturers or with different focal length and 
different diameter, for different applications can be easily mounted on the 
positioning device. In such modifications the only part that needs to be 
remanufactured will be the HIFU transducer holder. 
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Finally this is the first demonstration of showing that a robot can be attached on 
the top of the gantry thus providing top-to-bottom access to patients.  This robot 
can be used for several organs such as liver, kidneys, pancreas and especially 
thyroid.  Especially for thyroid a similar mechanism has been designed-
developed [18].  This method does not involve an MRI scanner, but employs the 
HIFU principle which is emitting a beam of converging high intensity ultrasound 
from an external applicator attached on a robotic arm.  The process is controlled 
with a diagnostic ultrasound probe, integrated into the applicator and this allows 
designing the protocol and conducting follow up treatment in real time.   
The limitations of this second version of the positioning device are that although 
it is a flexible device suitable for a variety of applications, yet this device cannot 
be applied for all tissues where HIFU can be applied.  The second limitation is 
that at this moment it is not feasible to attach it on the top of the gantry of the 
MR scanner as shown in figure 7.12 since this requires cooperation with the 
manufacturer of the MRI scanner.  Therefore, at present will only be used for 
experiments in vitro tissues and gel phantom or on animals.  Therefore the idea 
of the new third positioning device came to resolve the limitations of the second 
version robot.   
  
- 101 - 
8 Development of the positioning Device 
version 3 
The proposed third version of positioning device is a flexible MR compatible 
positioning device for treating multiple tumours.  This positioning device is 
suitable for in vitro targets like kidney, liver, turkey fillet, porcine muscle etc. as 
well as in vivo targets like small animals as rabbits and rats.  Furthermore, by 
attaching the appropriate HIFU transducer holder the positioning device is 
qualified to treat brain tumours and strokes.  
This positioning device was also designed and constructed using materials 
selected for compatibility with high magnetic fields and fast switching magnetic 
field gradients encountered inside MRI scanners. The positioning device 
incorporates only MRI compatible materials such as piezoelectric ultrasonic 
motors by Shinsei USR60E3N, ABS plastic, brass screws, brass racks and 
pinions. 
As mentioned previously, a main constrain of such positioning devices is the 
limited working space available in the bore of an MRI scanner.  Therefore, 
during the design process great effort was taken to achieve a minimum size 
device and as a result maximize the useful operational space.  Even though 
different designs and many different attempts were made, the useful operational 
space in a conventional 55-60cm bore diameter of MRI is still limited.  An 
alternative approach to extend the operating space of this positioning device is 
to accommodate it in the 50cm vertical gap between the two facing 
superconductive magnets of a double-donut MRI scanner.  The open C-shape 
MRI scanner provides another solution to this constrain and the new generation 
of scanners (Siemens MAGNETOM Espree 1.5T) with short bore of 125cm and 
increased diameter of 70cm will also provide more space for the robot to 
operate within the magnet. 
Another major consideration when designing a positioning device that will guide 
a HIFU transducer inside the gantry of an MRI is the coupling mechanism 
described in chapter 6 and shown in figure 6.14.  Since sound waves cannot 
travel through vacuum, the HIFU transducer has to be immersed in degassed 
saline where sound waves can propagate through and transfer the energy to 
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the transducer’s focal point (the targeted area).  As a result of this property of 
sound waves, it makes it necessary that liquid should surround the HIFU 
transducer inside the bore core of the MRI scanner.  Therefore, the container in 
which the HIFU transducer will operate is unavoidable and this raises two 
important issues to be addressed.  The first issue to be addressed is the 
protection of degassed saline to avoid spills inside the MRI, and the second is 
the space required by the container in a situation where space is limited.    
This third version of the positioning device was designed in such as way so it 
could be placed on the table of any MRI scanner (diameter of the gantry of a 
typical MRI scanner is about 55 cm) and therefore it’s also considered portable 
and universal.  
Furthermore, this robot employs detachable HIFU transducer holders for 
different transducers as well as, for a variety of applications demonstrated in the 
following sections.  This feature of the proposed robot makes it even more 
flexible. 
The following sections describe the parts, specifications and a description of the 
operation of the third positioning device.   
 
8.1 Parts and specifications of positioning device 
version 3 
The ABS parts of this positioning device as for the second version, were 
designed using Computer-Aided Design (CAD) software (Microstation V8, 
Bentley Systems, Inc.) and exported to Computer-Aided Manufacturing (CAM) 
software (Insight V. 6.4.1, Stratasys Inc.) and then produced by the 3D printer 
(Stratasys FDM400 7665 Commerce Way Eden Prairie, MN 55344 U.S.A.).  
Therefore this positioning device is also one hundred per cent reproducible. 
Brass racks and pinions (Sterling instrument NY USA) were used to convert the 
rotational motion of the three piezoelectric motors (USR60-S3N, Shinsei Kogyo 
Corp., Tokyo, Japan)  into linear motion for the three degrees of freedom. The 
three brass racks were attached on the ABS plates with brass screws.  The 
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positioning device is controlled by a user friendly interface application 
developed in MATLAB (The Math works Inc., Natick, MA, USA). 
The dimensions of the third version of the positioning device are as follows, 
height 33.5 cm, length 55 cm and its width 25 cm.  The weight of the positioning 
device is only 3.0 kg.  Therefore, this is a cost effective solution, portable and 
universal since it can be placed on the table bed of any MRI scanner.  
Furthermore this positioning device is flexible since different transducer holders, 
shown in figures 8.16 and 8.17 can be attached on the Z-axis plate for different 
applications.  The effective range of the positioning device is, X: 135mm, Y: 
110mm, Z: 68mm. 
 
8.2 Design and development of the 3
rd
 version of the 
positioning device 
The CAD drawing of the base of this positioning device and the PUM motor that 
drives the X-axis plate is shown in figure 8.1.A and figure 8.1.B shows a 
photograph of the produced by the 3D printer ABS base.  The PUM motor of 
figure 8.1.B is used for the motion on the X-axis plate through the brass pinion 
attached on the motor which is driving the brass rack at the bottom of the X-axis 
plate of figure 8.2.A.  The length of the brass rack responsible for the motion of 
the X-axis plate is 150mm and the effective range for the X-axis is 135mmsince 
15mm were used for the brass screws supporting the rack on the X-axis plate. 
The groove in which the guide of the X-axis plate will slide in a forward-
backward motion is expanded as shown in figure 8.1.B.  This groove and guide 
were used for the motion of all three plates of X, Y, and Z axis.  A close-up 
photograph of this guiding mechanism is show in figure 7.3 of the previous 
chapter.  Figure 8.2.A shows the CAD drawing of the X-axis plate and the 
corresponding photograph of the ABS X-axis plate along with the PUM motor 
with the brass pinion which will drive the Y-axis plate are shown in figure 8.2.B.  
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Figure 8.1:  A. the CAD design of the base of the positioning device with the 
PUM motor attached to it and B. a photograph of the produced 
base of the positioning device with zooming in the groove in which 
the X-axis plate will slide in.  The brass pinion attached to the 
PUM motor will drive the X-axis plate (back – forward motion).  
 
The X-axis plate of figure 8.2 is attached on the grooves of the base of figure 
8.1 and the CAD drawing of this assembly is shown in figure 8.3.A.  The 
photograph of the X-axis sliding in the guiding slots of the base is shown in 
figure 8.3.B. 
 
 
  
 
 
Figure 8.2:  A. the CAD design of the X-axis plate responsible for the back and 
forward motion and B. a photograph of the formed X-axis plate 
with zooming on the male guide which will slide in the 
corresponding groove of the base. The brass pinion shown here, 
will drive the Y-axis plate. 
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Figure 8.3:  A. the CAD drawing of the base with the X-axis plate attached and 
B. a photograph of the base together with the X-axis plate.  The X-
axis plate will slide back and forward within the groove of the base.  
The piezoelectric ultrasonic motor shown here on the top of the X-
axis plate is the motor that drives the Y-axis plate.  
 
Figure 8.4.A shows the CAD drawing of the Y-axis plate and the photograph of 
the ABS Y-axis plate is shown in figure 8.4.B.  This Y-axis plate is attached in 
the guiding slots of the X-axis plate and the CAD drawing of this assembly and 
the photograph of the ABS parts are shown in figures 8.5.A and 8.5.B 
respectively.  The Y-axis plate will be driven by the brass pinion which is 
attached on the PUM motor of the X-axis plate of figure 8.2.B.  The brass rack 
used for the Y-axis plate motion is mounted with brass screws at the bottom of 
the Y-axis plate of figure 8.4.B.  The length of the brass rack is 130mm and the 
effective range of the Y-axis plate is 110 since 20mm were used for the brass 
screws supporting the rack on the ABS Y-axis plate. 
For the Y-axis plate several designs were made in order to achieve the final 
stable design.  The main problem was the accumulated weight of the Z holder, 
Z-axis plate, PUM motor driving the Z-axis plate, brass pinion, transducer holder 
and the HIFU transducer that had to be carried by the support holder mounted 
on the Y-axis plate shown in the photograph of figure 8.5.B.  This accumulated 
weight made the motion of the HIFU transducer unstable and this problem was 
finally resolved after several attempts, by modifying the design of the support 
holder on the Y-axis plate and by adding extra supporting ABS material on the 
base of the support holder.  The CAD drawing of the Z holder supported by the 
Y-axis plate discussed previously is shown in figure 8.6.A and the photograph of 
the corresponding ABS part is shown in figure 8.6.B.  The Z holder is attached 
on the support holder of the Y-axis and the CAD drawing of the assembly is 
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shown in figure 8.7.A and figure 8.7.B shows the photograph of ABS parts 
assembled together.  
 
  
Figure 8.4:  A. the CAD design of the Y-axis plate and B. a photograph of the 
ABS Y-axis plate. 
 
  
Figure 8.5:  A. the 3D drawing of the base and the X and Y-axis plates 
assembled together and B. the corresponding photograph of the 
ABS base, X and Y-axis plates. 
 
  
Figure 8.6: A. the 3D drawing of the holder of the Z-axis plate with the PUM 
motor which moves the Z-axis plate and B. a photograph of 
corresponding ABS Z-axis holder and the PUM motor with the 
brass pinion that drives the Z-axis plate. 
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Figure 8.8.A shows the CAD drawing of the base extension which will 
accommodate the water container used for the coupling mechanism and figure 
8.8.B shows the photograph of the ABS base extension.  This base extension is 
attached on the slot of the robot base and the CAD drawing of this joint is 
shown in figure 8.9.A.  The photograph of the ABS extension base attached on 
the base of the robot is shown in figure 8.9.B.  The extension of the base is also 
designed to be detachable and this contributes to the portability and flexibility of 
the robot.  The robot can be easily disassembled to offer portability and the 
extension of the base can be easily modified to accommodate different coupling 
parts for different targets. 
 
 
 
 
Figure 8.7:  A. the CAD drawing of the Z holder attached on the support holder 
of the Y-axis plate and B. a photograph of corresponding ABS Z-
axis holder attached on the Y-axis plate. 
 
The CAD drawing of the Z-axis plate which will slide in the grooves of the Z-
holder, shown in figure 8.6.A and 8.6.B is shown in figure 8.10.A and the 
corresponding photograph of the ABS Z-axis plate is shown in figure 8.10.B.  
The brass rack attached on the Z-axis plate will be driven by the PUM motor of 
figure 8.6 and is 83mm long and this gives an effective range for the Z-axis 
68mm since 15mm are used for the brass screws supporting the rack on the 
ABS Z-axis plate shown in figure 8.10.B. 
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Figure 8.8: A. the CAD extension of the base that hosts the coupling and B. a 
photograph of the produced ABS extension of the base. 
 
 
 
Figure 8.9:  A. the CAD drawing of the base extension attached on the base of 
the robot and B. a photograph of the ABS base extension joined 
with the base of the robot. 
 
 
  
Figure 8.10: A. the CAD drawing of the Z-axis plate and B. a photograph of the 
ABS Z-axis plate. 
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The Z-axis plate is attached in the sliding grooves of the Z-holder and the CAD 
drawing of this is shown in figure 8.11.A.  The photograph of the corresponding 
ABS construct is shown in figure 8.11.B.  
Figure 8.12.A shows the CAD drawing of the water tank holder which is 
attached on the base extension of figure 8.8 and a photograph of the ABS 
construct of this water tank holder is shown in figure 8.12.B.  The CAD drawing 
of the water container which is fitted inside the water tank holder is shown in 
figure 8.13.A and the acrylic glass container is shown in figure 8.13.B.   
 
 
Figure 8.11: A. the CAD drawing of the Z-axis plate attached on the Z holder 
and B. the corresponding photograph of the ABS Z-axis plate 
positioned on the Z holder. 
 
 
 
 
Figure 8.12: A. the CAD drawing of the water tank holder used for the coupling 
of the HIFU transducer with the targeted tumour and B. the 
corresponding photograph of the ABS water tank holder. 
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Figure 8.13:  A. the CAD drawing of the degassed water container and B. a 
photograph of the acrylic glass container covered with milar bag.  
 
 
Figure 8.14.A shows the CAD drawing of the water tank holder mounted on the 
base extension and the water container fitted inside the water tank holder and 
figure 8.14.B shows a photograph of the construct arrangement of the water 
tank holder and the water container fixed on the base extension. 
  
 
 
 
Figure 8.14:  A. the CAD drawing of the water tank holder fitted on the base 
extension and the water container placed inside the water tank 
holder and B. a photograph of the ABS water tank holder mounted 
on the ABS base extension and the acrylic glass container fitted 
inside the water tank holder.   
The CAD drawing of the detachable vertical and horizontal HIFU transducer 
holders are shown in figure 8.15.A and 8.16.A respectively and the ABS 
constructs of these HIFU transducer holders are shown in the photographs of 
figure 8.15.B and 8.16.B respectively.  The different types of HIFU transducer 
holders could be constructed to accommodate different types and/or sizes of 
B A 
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HIFU transducers and also for different applications.  The HIFU transducer 
holders can be easily attached on the slot of the Z-axis plate shown in figure 
8.10.B.  Figure 8.17.A shows the CAD drawing of the complete robot with the 
vertical HIFU transducer holder attached in the slot of the Z-axis plate and 
figure 8.17.B shows a photograph of the ABS robot with the vertical HIFU 
transducer holder mounted in the slot of the Z-axis plate.  The CAD drawing of 
the horizontal HIFU transducer holder fitted on the slot of the Z-axis plate of the 
positioning device is shown in figure 8.18.A and the corresponding ABS 
construct is shown in figure 8.18.B.  The photograph of figure 8.19 shows how 
the proposed positioning device can be used for brain tumours. 
 
 
 
 
Figure 8.15:  A. the CAD drawing of the vertical HIFU transducer holder and 
B. the photograph of the corresponding ABS vertical HIFU 
transducer holder. 
 
 
 
 
 
 
Figure 8.16:  A. the CAD drawing of the horizontal HIFU transducer holder and 
B. the photograph of the corresponding ABS horizontal HIFU 
transducer holder. 
 
 
B A 
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Figure 8.17: A. the CAD drawing of the complete positioning device with the 
vertical HIFU transducer holder attached in the slot of the Z-axis 
plate and B. the photograph of the ABS vertical HIFU transducer 
holder mounted in the slot of the Z-axis plate. 
 
 
 
 
 
Figure 8.18: A. the CAD drawing of the complete positioning device with the 
horizontal HIFU transducer holder attached in the slot of the Z-axis 
plate and B. the photograph of the ABS horizontal HIFU 
transducer holder mounted in the slot of the Z-axis plate. 
 
 
Figure 8.19: A photograph showing how the robot can be used for brain 
tumours. 
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Figure 8.20 shows the CAD drawing of the robot inside the gantry of a typical 
MRI scanner and figures 8.21.A and 8.21.B shows photographs of the 
positioning device placed on the table of an MRI scanner. 
 
Figure 8.20: The CAD drawing of the robot inside the gantry of a typical MRI 
scanner. 
 
 
  
Figure 8.21: A. a photograph of the robot with the MRI compatible camera 
outside the gantry of an MRI and B. a photograph of the robot 
inside the gantry of an MRI scanner with the HIFU transducer 
immerse in the degassed water saline.   
 
 
The photographs of figures 8.22.A and 8.22.B show the positioning device 
placed on the table inside the gantry of an MRI and were taken from the MRI 
compatible camera which is also placed on the table of the MRI scanner as 
shown in figure 8.21.A.  
B A 
- 114 - 
  
Figure 8.22: Photographs A and B show the robot placed in the gantry of an 
MRI scanner and are taken from the MRI compatible camera 
which is also placed in the gantry of the MRI scanner. 
 
8.3 Conclusion and Discussion 
The third version of the positioning device inherited all of the characteristic 
advantages of the second version since it is also designed on CAD software 
(Microstation V8, Bentley Systems, Inc.) and exported to a CAM software 
(Insight V. 6.4.1, Stratasys Inc.) and then produced by the 3D printer (Stratasys 
FDM400 7665 Commerce Way Eden Prairie, MN 55344 U.S.A.).  Therefore, 
this third version is also MRI compatible, lightweight, cost effective, 
reproducible, and universal.  Moreover this robot is as stable and accurate as 
the second version since the PUM motors, the brass racks and pinions, the 
guiding mechanism, as well as the software routines used for the guidance are 
identical with the second version robot.    
The proposed third version of the positioning device can be used for brain 
tumours as shown in figure 8.19 with the horizontal HIFU transducer holder.  
Furthermore the water container holder shown in figure 8.12.B, is suitable for in 
vitro targets placed inside or underneath the water tank (kidney, liver, turkey 
fillet, porcine muscle etc.) by attaching the appropriate vertical HIFU transducer 
holder and also for in vivo targets  (small animals like rabbit and rats).   
This third version of the positioning device is also designed to be as flexible as 
possible.  As in the case of the 2nd version of the robot all the parts can be 
easily detached and this provides better portability and any part of the robot can 
be redesigned and/or replaced at no time and this will have no effect on the rest 
B A 
- 115 - 
of the parts of the robot.  During the development phase many parts had to be 
redesign for better stability or for more efficient and smooth movement of the 
robot.  However, due to the flexible design these modifications on the individual 
parts cause no effect on the rest of the parts of the positioning device.  
Furthermore, this positioning device can also accept different HIFU transducer 
holders of different length, height, and pointing direction or angle as well as 
HIFU transducers from different manufacturers or with different focal length and 
therefore different diameter, for different applications.   
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9 Software and peripheral devices of a HIFU 
system development  
 
This chapter describes the software that provides the user interface that drives 
the motors of the positioning device.  Furthermore, this software keeps the 
history of the steps of each treatment, stores and retrieves MRI images 
captured during the treatment, and captures images from the MRI compatible 
camera.  The MR compatible camera which is placed on the table of the MRI 
scanner monitors the welfare of the person/animal being treated and displays 
and stores the temperature at the focus of the HIFU transducer which is 
necessary for the experimental work.  This latest feature will not be used in 
clinical trials since it involves the insertion of a thermocouple in to the targeted 
biological tissue and as mentioned earlier our method is non-invasive.  The 
software also controls the signal generator driving the ultrasound transducer. 
For the development of the software several attempts were made to use 
different programming languages such as visual basic and visual C#, but finally 
MATLAB (The Mathworks Inc., Natick, MA) was found to be more suitable for 
this purpose.  Moreover the individual parts of the software were implemented 
separately and they were embedded together, after their completion, to the 
main user interface.  
 
The features of the software developed are listed below: 
 
i. Transducer movement 
The user may move the robotic arm in a specific direction manually, or 
customize the automatic movement of the robotic arm in any formation by 
specifying the pattern, the step and the number of steps. 
 
ii. Treatment History 
A database is used to keep records of treatments and displays the starting time, 
elapsed treatment time, treatment time remaining, etc. 
 
iii. Ultrasound treatment parameters  
Settings of the ultrasound treatment parameters i.e. the intensity, frequency, 
treatment starting and ending times 
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iv. Patient database  
A database was developed to store and retrieve the records of patients.  A 
patient record keeps the first name, last name, date of birth, weight, height and 
gender.  
 
v. Feedback from the encoders  
This will be used to verify that the HIFU transducer is at the right location at any 
moment during the treatment. 
 
vi. Display of MRI images 
The MRI images of each treatment will be stored and the user has the ability to 
load any image stored. 
 
vii. Display video or pictures captured from the MR compatible camera 
An MRI compatible camera is connected on the system. The camera was 
interfaced by means of a video capture card.  With the aid of the MRI 
compatible camera, the researcher can monitor the welfare of the animal or 
human. 
 
viii. Temperature monitor along the beam of the HIFU transducer 
This feature will capture and store in a text file the temperature at the focal point 
of the HIFU transducer at given time intervals.  
 
9.1 Software development and setup of the peripheral 
devices used for capturing temperature, 
photographs and video displayed in the user 
interface. 
For the movement of the PUM motors the main problem was to associate the 
CPU clock with the millimetres of the linear motion.  For all three axis the same 
rack and pinions were used to convert the rotational motion of the piezoelectric 
ultrasonic motors into linear motion.  The only difference for the three axis 
versions is the length of the rack.  The length of the rack will define the range of 
the motion of the specified stage.  Therefore, once the distance of the motion 
was associated with the duration of powering a motor, the same concept was 
applied for all three axis PUM motors. 
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Figure 9.1 shows a photograph of the power supply, the data acquisition board 
(National Instruments 6251 DAQ) and the enclosure designed to host the three 
dedicated drivers of the PUM motors.  The power supply feeds the dedicated 
drivers of the motors with 24V DC.  The robot may move forward, backward, 
left, right, up and down, manually using the three switches fixed on the front 
panel of the enclosure as shown in figure 9.1.  These dedicated drivers are also 
connected to the three PUM motors and to the data acquisition board as shown 
in the photograph of figure 9.2.  Each motor is connected to its dedicated driver 
with two cables.  These cables are provided by the manufacturer of the PUM 
motors and one is used to send the signal to the motor so it can move and the 
other is to return through the encoder of the dedicated driver, a signal that the 
motor has moved to the right direction at the distance specified.    
 
 
Figure 9.1: Photograph of the power supply and the three dedicated drivers 
(X, Y and Z) 
The data acquisition board is connected at the rear panel of the enclosure as 
shown in figure 9.2 and is used to drive the PUM motors by sending the right 
signal from the PC to the dedicated driver.  The data acquisition board will also 
receive a feedback signal from the dedicated driver which is then fitted to the 
PC.  The data acquisition board is connected to the PC through a USB port.  
The photograph of Figure 9.3 shows how the three dedicated drivers are 
mounted insight the enclosure.  
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Figure 9.2: Photograph of the rear panel of the enclosure that holds the 
dedicated drivers.    
 
 
Figure 9.3: Photograph of the three dedicated drivers of the PUM motors 
mounted inside the enclosure    
 
The connections in the data acquisition board are shown in the photograph of 
figure 9.4.  On the left side of the data acquisition board of figure 9.4 the red 
and black wires are connected to the analogue input of the board and they are 
coming from the Omega thermocouple-to-analogue connector.  This analogue 
input is converted to digital signal and entered in the computer to capture in real 
time the temperature at the focal point of the HIFU transducer.  More details on 
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this digital thermometer can be found in section 9.2.  The grey cable on the right 
side of the data acquisition board of figure 9.4 hosts the wires coming from the 
dedicated drivers of the PUM motors mounted in the enclosure shown in the 
photographs of figures 9.2 and 9.3.  These wires are used to transmit the signal 
from the PC to the dedicated drivers to drive the PUM motors and also receive 
the signal from the encoder of the dedicated drivers. 
 
 
Figure 9.4: Photograph of the data acquisition board (DAQ) National 
Instruments 6251   
 
The photograph of figure 9.5 shows the setup arrangement of the MR 
compatible camera (MRC Systems GmbH, Heidelberg, Germany).  The filter 
box comes from the manufacturer and includes power and signal lines as well 
as shielding.  The filter box includes a low pass filter that suppresses 
frequencies higher than 1 MHz with over 100 db.  This filter prevents damage 
and interferences caused by the high frequency signals of the MR scanner. 
 
The camera is connected to the filter box and the output video signal from the 
filter is entered in to the video capture card and hence the output video signal of 
the video capture card enters the PC.   
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Figure 9.5: Photograph of the setup of the MR compatible camera.  
 
 
9.2 Development of the digital thermometer 
 
The digital thermometer will be used for capturing the variations of temperature 
at the focal point of the HIFU transducer at specified time intervals and store 
them in a text file in order to be used later for further analysis.  
 
The first attempt to read the temperature is shown in figure 9.6 where the 
thermocouple was connected directly to the analogue input of the data 
acquisition board.  It appeared that the signal was too weak and noise was 
interfering and therefore the temperature was not entered correctly in to the 
software.   
 
Figure 9.6: The thermocouple is connected directly to the analogue input of 
the data acquisition card. 
 
Figure 9.7 shows the second attempt used to acquire the temperature which 
was better but the signal was too weak and therefore we had some temperature 
fluctuations.  
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Figure 9.7: The thermocouple is connected as shown in the diagram to the 
analogue input of the data acquisition card. 
 
Finally a commercial readymade thermocouple-to-analogue proved to work fine 
for our purposes.  With the Omega M2813-1205 thermocouple-to-analogue 
connector shown in figure 9.8, the process was much more accurate. The 
thermocouple-to-analogue connector gives analogue output 1mv per degree oC 
and this was entered in to the data acquisition card and read by the software. 
 
 
 
Figure 9.8: Omega thermocouple-to-analogue connector. 
 
Figure 9.9 shows the National Instrument acquisition card used to drive the 
Shinsen dedicated drivers for the motors of the positioning device mounted in 
the white box (to the right of the PC) and also to capture the temperature from 
the Omega thermocouple-to-analogue connector.  
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Figure 9.9: Data acquisition set up 
 
Figure 9.10 shows a snap shot of the end user interface of the digital 
thermometer.  The temperature readings will be displayed in textbox 1 and 
stored in a text file the name of which is given by the end user in textbox 3 
along with the time taken shown as Elapsed Time 2.  Button 4, temperature 
readings will start the timer and the temperature values will be stored in the file 
and button 5, stop temperature will stop the process.  The exit, button 6, will 
terminate the application.  Part of the text file that keeps the temperature 
readings along with the time taken is shown in figure 9.11.  
 
 
Figure 9.10: The end-user interface used to capture the temperature 
fluctuations at the focal point of the HIFU transducer at specified 
time intervals. 
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The digital thermometer module was designed, implemented and tested 
extensively in isolation from the other modules of the software and then the final 
version was embedded in the main software as shown in the lower right corner 
of figure 9.12 with labels 30 to 34.  
  
 
 
Figure 9.11: Part of the temperature file stored during an experiment. 
 
 
9.3 The complete end-user interface 
 
Two methods were implemented to move the robot in the space.  The first 
method is manual and this can be done by entering the number of millimetres 
desired for each axis, X, Y and Z shown in figure 9.12 shown as labels 1, 2 and 
3 respectively.  The resolution of all 3 axes of the positioning device is 0.1 mm. 
 
The software apart from driving the positioning device provides the user, the 
physician, with other useful features described at the beginning of this chapter.  
The complete end-user interface is shown in Figure 9.12.  Table 9.1 describes 
all the elements and the features of the user interface of figure 9.12. 
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Figure 9.12: The user interface for the software of the HIFU system. 
 
User Interface functions 
Num Function Description 
1 Textbox for the user to enter the number of millimetres for the manual movement 
of  X-plate  
2 Textbox for the user to enter the number of millimetres for the manual movement 
of  Y-plate 
3 Textbox for the user to enter the number of millimetres for the manual movement 
of  Z-plate 
4 Buttons that will move the X-plate forward and backward a number of millimetres 
specified by the number entered in the textbox 1  
5 Buttons that will move the Y-plate forward and backward a number of millimetres 
specified by the number entered in the textbox 2 
6 Buttons that will move the Z-plate forward and backward a number of millimetres 
specified by the number entered in the textbox 3 
7 The user will use this textbox to enter the number of steps for the motor of the X-
axis plate 
8 The user will use this textbox to enter the number of steps for the motor of the Y-
axis plate 
9 The user will use this textbox to enter the number of steps for the motor of the Z-
axis plate 
10 This textbox will be used by the end user to enter the step of the automatic 
motion of the X-axis plate in millimetres  
11 This textbox will be used by the end user to enter the step of the automatic 
motion of the X-axis plate in millimetres 
12 This textbox will be used by the end user to enter the step of the automatic 
motion of the X-axis plate in millimetres 
13 This button will start the automatic motion with the settings of 7, 8, 9, 10, 11 and 
12. 
14 This button will reset the robot to its origin, 0, 0, 0 
15 The encoder of the dedicated driver will return the position of the X PUM motor 
after its movement 
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16 The encoder of the dedicated driver will return the position of the Y PUM motor 
after its movement 
17 The encoder of the dedicated driver will return the position of the Z PUM motor 
after its movement 
18 This listbox will display all past movements of the three motors 
19 The user will use this textbox to enter the voltage for the signal generator in 
millivolts 
20 The user will use this textbox to enter the frequency in MHz for the signal 
generator 
21 The user will use this textbox to enter the duration of sonification in seconds 
22 The user will use this textbox to enter the delay between sonifications in seconds 
23 This button will turn the on the power of the RF amplifier and set the settings of 
the signal generator as specified by textboxes 19, 20, 21 and 22. 
24 This button will turn the off the power of the RF amplifier 
25 A selected MRI image from the listbox 28 will be displayed in this area 
26 This button will load the selected MRI image to the area 25 
27 The user will enter the full path for the MRI images to be loaded in the listbox 28 
28 The listbox will display a list of all the MRI images found in the directory specified 
in 27  
29 This function will open a window to display a real time video or images captured 
during the treatment of  a patient or an animal from the MRI compatible camera 
placed on the table of the MRI scanner to monitor the welfare of the 
person/animal being treated 
30 The user will enter the name of the text file in which the temperature readings 
and the time of each reading will be stored 
31 This textbox will display the current temperature reading 
32 This button will start the timer and display the current temperature captured from 
the digital thermometer and elapsed time in textboxes 31 and 33 respectively.  
These values will be stored in the file specified in 30 
33 This textbox will display the elapsed time in seconds 
34 This button will stop the timer and the readings from the digital thermometer. 
35 This button will terminate the application 
36 The patient data menu has two options.  The first option will be used to open a 
form to enter the personal data of the patient and save them in the patients file 
and the second option will display the personal data of a selected patient. 
Table 9.1: The table above describes all the elements of the user interface of 
figure 9.12 
 
 
The MatLab R2007b code written for this application can be found in appendix 
12.3 
 
9.4 Conclusion   
The software developed to drive the robot is user friendly and provides the user 
two methods for moving the robot in the gantry of the MRI.  The user may move 
the robotic arm in a specific direction or customize the automatic movement of 
the robotic arm in any rectangular formation by specifying the pattern, the step 
and the number of steps.  Furthermore, the software has additional useful 
features that can be used by the physician during or after the procedure.  These 
features include, displaying of MR images, monitoring the time of the processes 
(starting time, treatment time left etc.), stores patient records, display the 
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position of the motor, display images captured from an MR compatible camera, 
cavitation detection window, and temperature measurement.  
 
The user interface was tested extensively and proved to be reliable, stable and 
accurate.  The software tested thoroughly in a complete HIFU/MRI system and 
the results provided in section 10.2. The software was also used and tested in 
all the experiments executed for the evaluation of this study and the results can 
be found in the evaluation section, chapter 10. Additionally, the software can be 
easily updated and modified to fulfil any future requirements.  
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10 Evaluation of the MRI compatible positioning 
devices 
 
MRI compatible robotic system design is a challenging task due to the strong 
magnetic field of the MRI scanner.  Therefore, there are many obstacles to 
overcome.  These limitations concern the selection of the materials, the HIFU 
transducer, the sensors, the actuators and the wiring of the motors and 
transducer.  The challenge is to assemble a robot which will cause no 
interference to the MRI scanner nor affected by the strong electromagnetic field 
of the MRI scanner.  Moreover, tight geometric limitations, 55-60 cm diameter of 
bore core of a typical MRI cylindrical scanner, builds up to the challenge of 
designing and implementing an MRI compatible robot.  
 
The compatibility of the parts of the proposed HIFU system, the functionality, 
and the accuracy were tested and evaluated.  The experiments and the results 
of these are described here in this chapter.  
 
 
10.1 Measuring the efficiency of the HIFU transducers 
 
The efficiency of any transducer needs to be measured prior to its use.  Figure 
10.1 shows a photograph of the apparatus (UPM-DT100N, Ohmic Instruments 
Co. Easton MD 21601) used to measure the power of the HIFU transducers.   
 
 
Figure 10.1: The photograph shows the ultrasound power meter, a device used 
to measure the ultrasound power of the transducers. 
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To measure the power of a HIFU transducer the cylindrical part is filled with 
degassed saline water.   Hence the spherical area at the bottom of the HIFU 
transducer is immersed in the degassed saline water facing the metal silver 
cone of the photograph of figure 10.1.  Then the transducer is firing on this 
metal cone and the device shows the reading.  Several measurements had to 
be made in order to verify the power of the transducer.  
10.2 In vitro and in vivo experiments to evaluate the 
MRI Guided HIFU system 
The MRI compatible positioning device version 1 is used to move an MRI-
guided high intensity focused ultrasound (HIFU) transducer.  This device 
includes a flexible coupling system, and thus it can be used in all the anatomies 
accessible by HIFU (liver, kidney, breast, brain and pancreas).  However, in this 
research only the superior top to inferior approach is utilized i.e. the HIFU 
transducer is firing the beam from the top of the target.  Moreover, details of this 
positioning device can be found in chapter 6.   
10.2.1 Material and methods 
a. HIFU/ MRI system: 
The HIFU/MRI system is described in chapter 5.  Figure 5.1 shows the block 
diagram of all the components required for a typical HIFU system with the MRI 
guidance and figure 5.2 shows setup the actual components of the HIFU/MRI 
system.  These components of figure 5.2 were used for most the laboratory 
experiments.  However, for different experiments and for the clinical 
experiments in MRI room some parts were substituted. 
b. HIFU system 
The HIFU system consists of a signal generator (HP 33120A Hewlett Packard, 
now Agilent technologies, Englewood, CO, USA), RF amplifier (250 W, AR, 
Souderton, PA, USA), and a spherically shaped bowl transducer (Etalon, 
Lebanon, IN, USA) made from piezoelectric ceramic which is non-magnetic. 
The transducer operates at 4 MHz, has focal length of 10 cm and diameter of 3 
cm.  The transducer is rigidly mounted on the MR compatible positioning device 
version 1 which is described in chapter 6. 
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c. MRI Imaging 
The positioning device and the transducer were tested inside a MRI scanner 
(Signa 1.5 T, by General Electric) at Ygia Polyclinic Private Hospital, Lemesos, 
Cyprus. A spinal or a brain coil was used to acquire the MRI signal. 
d. Coupling mechanism 
The system provides two main mechanisms for achieving coupling to tissues. 
Fig. 6.14 illustrates the two mechanisms.  In Fig. 6.14.A the tissue (in vitro or in 
vivo) is placed outside the container which is filled with degassed water.  Due to 
the weight of the water container, the coupling with this method is excellent. 
This method can be described as a top to bottom approach, meaning that the 
transducer is on top of the tissue.  In the commercial system by [136] the 
approach used is bottom to top, meaning that the transducer in below the 
tissue. In Fig 6.14.B the tissue is placed inside the container which is filled with 
degassed saline.  The use of saline is needed for this method in order to 
preserve the excised tissue, which is placed inside the saline bath.  This 
method which provides perfect coupling since the tissue is placed inside the 
container can be used only for tissues in vitro.  In both methods above the liquid 
in the container (degassed water or saline) was maintained at 37 oC. 
 
10.2.2 In vitro experiments 
Various in vitro experiments were carried out in order to assess the motion of 
the positioning devices.  The tissue under ablation was placed in a degassed 
saline water tank (Figure 6.14B).  The tissue was placed on top of an absorbing 
material in order to shield adjacent tissue from stray radiation from the bottom of 
the plastic water tank.  The transducer was placed on the arm of the positioning 
device and was immersed in the saline tank, thus providing good acoustical 
coupling between tissue and transducer. Any bubbles that may have collected 
under the face of the transducer face were removed in order to eliminate any 
reflections.  In all experiments the tissues used were extracted from freshly 
killed lamb, and the experiment was conducted 1-2 hours after the animal was 
killed.  
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10.2.3 In vivo experiments 
For the in vivo experiments, adult rabbits from Cyprus were used weighing 
approximately 3 kg. The rabbits were anaesthetized using a mixture of 500 mg 
of ketamine (100 mg/mL, Aveco, Ford Dodge, IA), 160 mg of xylazine (20 
mg/mL, Loyd Laboratories, Shenandoah, IA), and 20 mg of acepromazine (10 
mg/mL, Aveco, Ford Dodge, IA) at a dose of 1 mL/kg. The animal experiments 
protocol was approved by the national body in Cyprus responsible for animal 
studies (Ministry of Agriculture, animal services) and all licenses are found in 
the appendix.  The coupling method of Figure 6.14A was used. 
10.2.4 Evaluation of MRI compatibility 
The robot motion should not have any adverse effect on the imaging, and it 
should not be affected by the acquisition of images.  The MR safety of the robot 
requires that it is not moved unintentionally from any activity of the MRI scanner 
such as eddy currents or radio frequency (RF) pulses.  The loss of homogeneity 
of the magnetic field, and the signal to-noise ratio (SNR) of the image has been 
examined when the robot is moving inside the MRI scanner. The presence and 
motion of the robot can distort the image by decreasing the homogeneity of the 
magnetic field.  The images with the presence of the positioning device or not 
were evaluated using a rectangular phantom that contained CuSO4 solution.  A 
reference image is taken without the presence of the material under evaluation. 
Then the material under evaluation is placed in very close proximity to the 
phantom.  Then the two images are subtracted and if the resulted image is dark, 
it means that the material does not affect the MRI image at all. 
10.2.5 Results 
Figure 10.2A shows the MRI image of the phantom without the presence of the 
motor, and Figure 10.2B shows the MRI image of the phantom with the 
presence of the motor. Finally, Figure 10.2C shows the subtraction of the two 
images showing no shift. Similar procedure was applied to evaluate the effect of 
all the system’s materials (plastics, pulleys, belts, piezoelectric materials, and 
brass screws and rods). None of the tested materials resulted in any distortion 
of the MRI images.  
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Figure 10.2: A. an MRI image of phantom without the presence of the motor. B. 
an MRI image of phantom with the presence of the motor. C. an 
MRI image of the subtraction of the two images showing no shift. 
Figure 10.3 shows various discrete lesions (more detailed results can be found 
in [155]) created by moving the transducer using the robot (2000 W/cm2 in-situ 
average spatial intensity for 5 s).  The thermal lesions measured were between 
2.8-3.4 mm (average was 3.0 mm and standard deviation was 0.3 mm). The 
lesions are repeatable for a given acoustic exposure.  Some differences that are 
observed are attributed to the variation of focal depth arising from the kidney 
curvature.  On the flat surface of the kidney the lesion width varied from 3.0 to 
3.2 mm (average was 3.1 mm and standard deviation was 0.04 mm).  This 
figure demonstrates the excellent repeatability of the HIFU system for creating 
well controlled discrete lesions. 
 
Figure 10.3: Lesions created in pig kidney demonstrating the excellent 
repeatability of the positioning device. 
Figure 10.4 shows a lesion created by moving the transducer in a patterned 
movement (square grid of 8x8 with 3 mm step) in both directions. The intended 
target was the round shape in red colour.  The same intensity as in Figure 10.4 
was used for each firing. The dimensions of the large lesion clearly 
demonstrates that the robot can move the transducer as instructed, thus 
creating well controlled ablation.  
A B C 
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Figure 10.4: Large lesion in pig kidney in vitro by moving the transducer in grid 
formation (8 X 8) (top view) 
 
A very important aspect of this system is the ability to monitor thermal lesions 
created by HIFU using MRI. Figure 10.5A shows MR images of lesions in 
kidney using T2-weighted, Fast Spin Echo (FSE) (TE=32 ms, TR=3000 ms, 
NEX=1, FOV=16 cm, slice=5 mm, 256x256, BW=32 KHz, ETL=8). This image 
shows the lesion in a plane parallel to the ultrasonic beam.  This large lesion 
volume was created by moving the transducer using a 4x4 grid pattern with step 
of 3 mm.  Figure 10.5A shows the photograph of the kidney after slicing.  
 
  
Figure 10.5: A. Axial MR images of HIFU ablation using T2-weighted FSE 
(TE=32ms) pulse sequence. B. Photograph after slicing. 
 
Figure 10.6 shows nine MRI images in a plane perpendicular to the beam 
acquired by using T1-weighted, Fast Spoiled Gradient echo (FSPGR) (TR=50 
ms, TE=2.7 ms, FOV=16 cm, matrix=256x256, flip angle=50o, BW=62.5 KHz, 
A B 
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NEX=1).  The transducer was moved in a 3x3 pattern and the in situ average 
spatial intensity used was 100 W/cm2 for 10s.  This intensity was used 
previously in vitro [155] and the temperature measured using a thermocouple 
was around 2-5 oC, which means that there is no tissue damage with this 
ultrasonic exposure.  These images show, that in every of the nine firings, there 
is good penetration, since heating is observed (dark spot of 1-2 mm diameter). 
Therefore, this proves that the ultrasound penetration to this target is excellent 
in all nine locations. Following this diagnostic scan, the intensity was increased 
to 1500 W/cm2 (with 5 s duration) and the nine locations were ablated once 
more.  Figure 10.7 shows the MRI image in a plane perpendicular to the beam 
by using T2-weighted FSE (same parameters as in Figure 10.5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.6:  MR images showing the focal beam during a 3 X 3 scanning 
using low intensity ultrasound using T1 weighted FSPGR. 
 
  
 
   
   
- 135 - 
Note that spatial necrosis is continuous, thus resulting in absolutely no 
untreated spaces. The continuous necrosis coverage was visually confirmed 
after gross examination of the kidney. On the same tissue, a single lesion 
(reference) was created using the same exposure (1500 W/cm2 for 5 s) in order 
to show the size of a discrete lesion for this specific exposure. Note that, by 
using this intensity none of the lesions were created under the mechanism of 
cavitation (confirm by the cavitation detector).  
A good indicator of the contrast between necrotic tissue and normal tissue is the 
contrast-to-noise ratio (CNR). CNR was obtained by dividing the signal intensity 
difference between the necrotic and normal tissue by the standard deviation of 
the noise in the normal tissue.  In Figure 10.7 the CNR was around 30 
indicating the excellent contrast between necrotic and normal tissue. 
Figure 10.8 shows the MRI image using T2-weighted FSE of a large lesion in 
the kidney in a plane perpendicular to the beam. This lesion was created by 
using a 4x5 grid of lesions. The intensity used was 2000 W/cm2 at 5 s and the 
spacing between the lesions was 3 mm. Note that the necrosis coverage is 
incomplete, resulting to some untreated spots (CNR was around 30). The 
diagnostic scan of this result has shown that the penetration at the location of 
the untreated area was poor, since no detectable temperature elevation was 
observed.  
 
 
 
      
 
 
 
 
 
 
 
     
Figure 10.7:  MR images (in plane perpendicular to the transducer beam) of 
large lesions (full coverage of the intended target) using T2-
Weighted FSE with TE = 32ms. The spatial average intensity 
was 1,500 W/cm2 for 5s  
  
 
Reference 
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Figure 10.8:  MR images (in plane perpendicular to the transducer beam) of 
large lesions (partial coverage of the intended target) using T2-
Weighted FSE with TE = 32ms. The spatial average intensity was 
2,000 W/cm2 for 5s   
 
10.2.6 Discussion 
The robot version 1 presented here is utilized in the research setting for 
performing experiments either in vitro tissue or in vivo animals.   
The positioning system employs piezoelectric motors and various materials 
(sheets, rods, angles, pulleys and belts) in order to move the transducer in 3 
dimensions.  The rotational motion of the piezoelectric motors is coupled to a 
timing belt which is supported by a fixed plastic pulley. The belt is coupled to a 
plastic rectangular sheet and thus the rotation of the belt results in a linear 
motion of the involved sheet.  The same principle is applied for every stage. 
Totally 3 linear axes are implemented for the case of brain ablation. The 
piezoelectric motor which is the most important element of the positioning 
device does not affect the quality of imaging of the MRI scanner.  
The positioning device is placed on the table of the MRI scanner and access of 
ultrasound to the brain is achieved either from superior to inferior or laterally. 
Since the positioning device is placed on the table of the MRI scanner, this 
device can be used in all the available MRI scanners (i.e. it is a universal 
positioning device).  The existing systems are placed inside the gantry on the 
table of the MRI scanner, and therefore the dimensions of the system must be 
adjusted depending on the type of MRI scanner.  Also, the existing systems can 
access the patient from bottom up whereas this positioning device can access 
patient from the side or from top to bottom. 
 
Reference Incomplete necrosis 
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Another advantage of this device is that it is much simpler and inexpensive than 
the existing systems, while maintaining high standards of repeatability and 
readability.  Another advantage of this positioning device is that it can be easily 
reduced or increased in size.  This can be adjusted easily by modifying the rod 
length, sheet length and belt length. All the other components remain fixed in 
size.  Thus, easily any size of positioning device can be designed. There is 
limitation though based on the diameter of the MRI scanner.  Moreover, this 
positioning device is lightweight (approximately 6 Kg) and therefore it can be 
transported from one MRI scanner to another (i.e. it is portable and universal).  
The positioning device moves the transducer accurately and thus discrete and 
large thermal lesions can be produced reliably and repeatedly.  This has been 
proven in both in vitro and in vivo tissues. 
The concept of scanning the area to be treated, by applying low intensity 
ultrasound (diagnostic scan) was shown to be feasible.  It is up to the HIFU 
clinicians whether or not this diagnostic scan is used during clinical work, but 
certainly this tool can be very useful during research investigations. This 
concept was demonstrated for a single shot in in vivo kidney by Hynynen [14], 
but was never demonstrated spatially in two dimensions (grid). This diagnostic 
scan was demonstrated in a plane perpendicular to the beam, but it is possible 
to demonstrate it in a plane parallel to the beam.  When all the points of the grid 
show decrease of temperature (black spot in the T1-weighted FSPGR), then, 
during the application of high intensity ultrasound (therapeutic scan), complete 
necrosis is observed in the targeted area.  If ultrasound goes through an 
interface that includes bubbles, then the diagnostic scan reveals sites with poor 
ultrasound penetration and, therefore, later in the therapeutic scan, some 
spaces are left untreated.   
10.2.7 Conclusion 
A simple, cost effective, portable positioning device has been developed which 
can be used in virtually any clinical MRI scanner since it can be sited on the 
scanner's table.  The propagation of HIFU can use either a lateral or superior-
inferior approach.  Discrete and large lesions were created successfully with 
reproducible results. The quality of MRI imaging is not affected by the presence 
of the HIFU system.  
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10.3 Testing the MRI Compatibility of Robot V2 on 
phantom 
 
The purpose of this experiment was to test the MRI compatibility of positioning 
device version 2 targeting a gel phantom.   
10.3.1 Material and methods 
Equipment used 
HIFU transducer  
 diameter d = 4 cm  
 focal radius R = 10 cm,   
 operating at a frequency of 1 MHz. 
Tissue: gel phantom (Onda Corp., Sunnyvale, CA).  .  
RF amplifier: LA 100-CE, Kalmus, Bothell, WA, USA 
 
The block diagram and the equipment necessary for a HIFU/MRI system is 
shown in figures 5.1 and 5.2 respectively and the system is described in chapter 
5.  Figure 10.9 shows the photograph of the positioning device version 2 placed 
on the bed of the MRI scanner (Signa 1.5 T, by General Electric, Fairfield, CT, 
USA).  The vertical HIFU transducer is attached on the positioning device and 
the HIFU transducer was mounted on this holder. 
The coupling method of figure 6.14B is used.  Therefore, the gel phantom target 
is immersed in the degassed water saline as shown in the photograph of figure 
10.9. 
 
Figure 10.9: Photograph of the positioning device version 2 in the gantry of 
the MRI scanner.  The gel phantom is immersed in the degassed 
water saline.   
 
 The MRI image of figure 10.10 was captured using T2 W FSE and shows the 
HIFU transducer, the phantom gel and the tank filled with degassed water 
saline placed in the gantry of the MRI scanner.   
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Figure 10.10: The MRI image shows the HIFU transducer, the phantom gel and 
the tank filled with degassed water saline using T2 W FSE. 
 
The MRI images of Figure 10.11 captured using FSPGR.  These images show 
the phantom gel and the tank filled with degassed water saline.  The red arrow 
of MRI images 10.11A, 10.11B and 10.11C is pointing at the focal spot at three 
different positions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
     
    
 
 
 
 
 
 
 
 
 
 
Figure 10.11: The MRI image shows the HIFU transducer, the phantom gel and 
the tank filled with degassed water saline using FSPGR.  The red 
arrow indicates the focal spot A. at position 1 B. at position 2 and 
C. at position 3. 
 
 
 
 
A B 
C 
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This focal spot in different positions achieved by moving the HIFU transducer 
attached on the vertical transducer holder of the positioning device. 
 
10.3.2 Conclusion 
The MRI images captured during this experiment show no significant RF artifact 
caused by the positioning device, motors, cables and HIFU transducer.  Both 
FSE and FSPGR not affected significantly by the positioning device.  This 
proves the positioning device is MRI compatible. 
 
 
10.4 Test MRI compatibility of positioning device 
version 3. 
 
The purpose of this experiment was to test the MRI compatibility of positioning 
device version 3.   
10.4.1 Material and methods 
Equipment used 
HIFU transducer  
 diameter d = 4 cm  
 focal radius R = 10 cm,   
 operating at a frequency of 1 MHz. 
Tissue: gel phantom (Onda Corp., Sunnyvale, CA) and thrombi inserted in a 
silicone tube.  
RF amplifier: LA 100-CE, Kalmus, Bothell, WA, USA 
 
For this experiment the equipment used for the HIFU/MRI system were the  
same  as for experiment of section 10.4 with the only exception the positioning 
device version 2 which was replaced with the positioning device version 3.  
Moreover, the vertical HIFU transducer attached on the positioning device and 
the HIFU transducer was mounted on this holder. 
 
For this experiment the coupling method of figure 6.14B was also used as for 
the experiment of section 10.4.  Two targets were used for this experiment.  The 
first target was a gel phantom.  The second, a silicone tube with the inserted 
thrombi fixed between two polyethylene corners mounted on the base of the 
tank.  The tank was then filled with degassed water saline as shown in the 
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photograph of figure 10.12A.  The photograph of figure 10.12A also shows the 
positioning device and the water tank placed on the table of the MRI scanner.  
The photograph of figure 10.12B shows the positioning device and the subject 
target in the gantry of the MRI. 
 
  
Figure 10.12: A Photograph of the positioning device version 3 on the table of 
the MRI scanner, B the positioning device version 3 in the gantry 
of the MRI scanner.  
 
Figure 10.13A shows the MRI image of the HIFU transducer and the phantom 
gel this image captured using T1 W FSE,  and Figure 10.13B shows the MRI 
image of the phantom gel and the tube passes through the gel. The image was 
also captured using T1 W FSE. 
 
The MRI image of Figure 10.14 shows the phantom gel mounted within the 
plastic holders. The image captured using FSPGR in a plane inside the gel. 
 
 
 
 
 
     
     
 
 
 
 
 
 
 
Figure 10.13: A the MRI image shows the HIFU transducer, and the phantom 
gel this image was captured using   T1 W FSE,  B the MRI image 
shows the phantom gel and the tube passes through the gel. The 
image was also captured using T1 W FSE. 
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Figure 10.14: The MRI image shows the phantom gel mounted within the 
plastic holders. The image captured using FSPGR in a plane 
inside the gel. 
 
10.4.2 Conclusion 
 
The MRI images capture during this experiment show no significant RF artifact 
caused by the presence of the positioning device version 3, the PUM motors, 
the cables and the transducer in the gantry of the MRI scanner. FSE and 
FSPGR not affected significantly by the positioning device.  This proves as 
expected, that the positioning device version 3 is also MRI compatible. 
 
10.5 Ablate a porcine muscle tissue using the 
positioning device version 3. 
 
The purpose of this experiment is to create lesions in porcine muscle tissue 
using the positioning device version 3.  The HIFU transducer mounted on the 
vertical transducer holder using the coupling method of figure 6.14A, i.e. the 
porcine muscle was placed at the bottom of the tank filled with degassed water 
saline. 
 
10.5.1 Material and methods 
Equipment used 
Tissue: porcine muscle  
RF amplifier: 250 W, AR, Souderton, PA, USA 
Positioning Device version 3 (without a HIFU transducer attached) 
 
Gel 
Plastic holders 
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Two transducers were used for the exposures A and B: 
Transducer T1: f=2 MHz, R=4 cm, d=4 cm, 100 W, 2 minutes,  
Tissue depth: 2 cm. 
Transducer T2: f=1 MHz, R=4 cm, d=4 cm, 100 W, 1 minute,  
Tissue depth: 3 cm. 
 
The photograph of figure 10.15 shows the robot version 3 with the vertical 
transducer holder attached to it.  The photograph also shows the target, the 
porcine muscle placed under the tank filled with degassed water saline.   
 
 
 
Figure 10.15: Photograph shows the positioning device version 3 with the 
porcine muscle placed under the tank filled with degassed water 
saline.  
 
A milar bag is fixed inside the tank which is pushed downwards tangential on 
the surface of the porcine muscle with the weight of the degassed water saline.  
That’s how the coupling is achieved.  For both exposures the tissue was 
ablated. 
 
The photograph of figure 10.16 shows the lesion achieved with the first 
exposure and the photographs of figures 10.17A and 10.17B show the lesion 
from the top and the cross section respectively. 
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Figure 10.16: Exposure A, the cross section – depth. 
 
 
        
Figure 10.17: Exposure A. is the top view of the lesion, B. cross section 
showing the depth of the lesion. 
 
 
Conclusion 
 
The photographs of figure 10.16 and 10.17 show that for both exposures well 
penetrated lesions were achieved.  Therefore the coupling method is 
considered successful. 
 
 
10.6 Visualize the coupling method of robot V3 using 
MRI. 
 
The purpose of this experiment is to visualize the coupling method of the 
positioning device version 3 using MRI. 
10.6.1 Material and methods 
Equipment used 
Tissue: Gel phantom (Onda Corp., Sunnyvale, CA).  
Positioning Device version 3 (without a HIFU transducer attached) 
A B 
Lesion 
Lesion Lesion 
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For this experiment the positioning device version 3 is used without the HIFU 
transducer.  The HIFU transducer is not required for this experiment since the 
purpose of this experiment is to visualize the effectiveness of the coupling.  The 
coupling method is described in the previous section (10.6).  The photograph of 
figure 10.18A shows the positioning device on the table of the MRI scanner with 
the tank filled with degassed water saline and the gel phantom at the bottom of 
the tank.  Figure 12.18B show a photograph of the positioning device after the 
table slide in to the gantry of the MRI.  
 
 
 
 
        
 
 
 
 
 
 
 
 
Figure 10.18: A. photograph of the positioning device on the table of the MRI 
with the tank filled with degassed water saline and the gel 
phantom at the bottom of the tank, B. photograph of the 
positioning device inside the gantry of the MRI scanner. 
 
The MRI image of figure 10.19 shows the coupling between the milar bag fitted 
in the tank and filled with degassed water saline and the target used (gel 
phantom). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.19: An MRI image showing the coupling between the milar bag which 
is filled with degassed water saline and the gel phantom. 
 
 
 
 
A B 
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10.6.2 Conclusions 
The MRI image of figure 10.19 is an excellent visualization of coupling.  This 
image proves and verifies the results of the experiment described on section 
10.6, that the coupling method is successful. 
 
 
10.7 MRI Compatible Camera using gel 
 
The purpose of this experiment was to investigate the effect of an MRI 
compatible camera on the quality of MR images and the effect of the MRI 
scanner on the quality of the camera images.  
10.7.1 Material and methods 
Equipment used 
Tissue: MRI Gel.  
MRI compatible camera (12M, MRC Systems GmbH, Heidelberg, Germany) 
Positioning Device version 3 (without a HIFU transducer attached) was used as 
a subject for the MRI compatible camera. 
 
The setup of this experiment is shown in the photograph of figure 8.21A in 
chapter 8 with the table of the MRI scanner out of the gantry and the 
photograph of figure 10.20 show the positioning device version 3 with the MRI 
compatible camera in the gantry of the MRI.  The positioning device in this 
experiment was used as a target of the MRI compatible camera. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.20: Photograph of the experiment setup showing the positioning 
device version 3 and the MRI compatible camera. 
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The photographs of figures 8.22A and B in chapter 8 and the photographs of 
figures 10.21 and 10.22 were captured from the MRI compatible camera.  
Photograph of figure 8.22B shows the positioning device on the table of the MRI 
scanner outside the gantry and the photographs of figures 8.22A and 10.21 
shows the positioning device in the gantry of the MRI.  Furthermore, the 
photograph of figure 10.22 shows the MRI gel in a plastic container.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.21: Photograph of the positioning device version 3 inside the gantry 
of the MRI scanner, taken from the MRI compatible camera. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.22: Photograph of the MRI Gel inside the gantry of the MRI scanner 
taken from the MRI compatible camera.  
 
The MRI image of figure 10.23 A was captured using T1 FSE with the MRI 
compatible camera in the gantry of the MRI and the MRI image of figure 10.23 
B was also captured using T1 FSE but without the presence of the MRI 
compatible camera. 
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Figure 10.23: A. MRI image with T1 FSE with the MRI camera in the gantry of 
the MRI scanner, B. MRI image with T1 FSE without the MRI 
compatible camera. 
  
 
10.7.2 Conclusions 
The photographs captured from the MRI compatible camera show that there is 
no effect of the MRI scanner on the images, although, the photograph of figure 
10.21 it seems to be dull, most probably this is due to the fact that the camera 
was out of focus. 
 
Moreover, there were some RF artifacts on the MRI image due to the presence 
of the MRI camera and some loss of signal. 
 
  
  
A B 
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11 Experiments using HIFU/MRI system 
 
11.1 HIFU ablation of porcine liver guided by MRI  
In this section several experiments using gel phantom and in freshly excised pig 
liver are explained and the results are discussed.  
11.1.1 In vitro experiments 
 
Before creating lesions in a tissue the system is tested in a gel phantom (Onda 
Corp., Sunnyvale, CA).  Figure 11.1A shows a photograph of the lesion created 
in the phantom at a plane perpendicular to the transducer beam axis. Figure 
11.1B shows the corresponding photograph in a parallel plane. Figure 11.1C 
shows the MRI image of the result of Figure 11.1A using T2–W FSE (for MRI 
parameters see Table 11.1, row 2), and Figure 11.1D shows the same result 
using T1-W FSE.   
 
 
Figure 11.1: A. show a photograph of large lesion created in the phantom at a 
plane perpendicular to the transducer beam axis. B. shows the 
corresponding photograph in a parallel plane. C. shows the MRI 
image of the result of A using T2–W FSE (for MRI parameters see 
Table 11.1, row 2), and D. shows the same result using T1-W 
FSE. 
A B 
C D 
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Note that with T2-W, the contrast is poor because the T2 value of gel and lesion 
is similar, whereas the relaxation time T1 of the lesion and gel is sufficiently 
different, and thus, the contrast using T1-W FSE is satisfactory.  
 
11.1.2 Experiments on liver 
 
High intensity focused ultrasound (HIFU) is a thermal modality which is mainly 
utilised to destroy tumours.  HIFU transducers are guided either by ultrasonic 
imaging or magnetic resonance imaging (MRI).  For the clinical application of 
prostate Foster et al. 1994 [156] and Gelet et al. 1998 [157] utilized ultrasonic 
imaging.  For the clinical application of breast [24], [149], [150] MRI was utilised 
for guidance and monitoring.  For the case of uterine leiomyomas, Tempany et 
al. 2003 [158] utilized MRI.  At the moment there is only one HIFU clinical 
system for liver cancer [159].  Liver metastases and primary liver cancer are 
one of the main causes of death [160].  The traditional surgical methods may be 
curative for some cases, but they are not effective for all cases [161]. Therefore 
research efforts in the area of HIFU ablation of liver guided my MRI is essential. 
 
A lot of work has been done in many directions earlier in the area of liver 
ablation using HIFU.  The threshold of intensity that is needed to cause 
irreversible damage in liver was suggested by Frizell 1987 [34] and Frizell 1988 
[35].  The first attempt to monitor the effect of HIFU using MRI was reported by 
Rowland et al. 1997 [162], who demonstrated that monitoring of thermal lesions 
in liver is feasible. 
 
In this experiment the goal was to investigate the effectiveness of MRI to 
monitor therapeutic protocols of HIFU in liver in vitro. Several MRI pulse 
sequences are investigated.  For high quality imaging which can be used at the 
end of a therapeutic protocol or at some instances of the protocol, T1-weighted 
FSE, and T2-weighted FSE are investigated.  For fast imaging, the T1-weighted 
fast spoiled gradient echo (FSPGR) pulse sequence was used. The goal was to 
create large lesions that included both thermal and cavitational lesions. 
Therefore, MRI pulse sequences are investigated in order to discriminate 
between liver and lesion and between thermal and cavitational lesions. 
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a. Materials and methods 
HIFU system guided by MRI with cavitation detection. 
Figure 11.2 shows the block diagram of the system with photos of the actual 
instruments.  The ultrasonic system consists of a signal generator (HP 33120A 
Hewlett Packard, now Agilent technologies), a RF amplifier (LA 100-CE, 
Kalmus, Bothell, WA, USA), and a spherically shaped bowl transducer made 
from piezoelectric ceramic of low magnetic susceptibility (Etalon, Lebanon, IN, 
USA).  The transducer operates at 4 MHz, has focal length of 10 cm and 
diameter of 3 cm. The efficiency of the transducer was 55%.  The transducer 
was rigidly mounted on the MRI compatible positioning system.   The serial port 
of a personal computer (PC) controlled the signal generator, whereas the 2-d 
robotic system (slave robotic system) was controlled by the master robotic 
system, which is controlled by the parallel port. The slave positioning device 
was moved by the master positioning device by means of non-magnetic wires.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.2: MRI guided HIFU system with cavitation detection system using 
the actual photos of the instruments. 
 
The slave positioning device and the transducer were placed inside a MRI 
scanner (Signa 1.5 T, General Electric).  The coil used was the one used 
commercially for spinal imaging.  The signal generator, the RF amplifier, master 
robotic system and the PC were placed outside the MRI scanner. 
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In order to detect cavitation the acoustical method used by [163] was used. This 
method includes a receiver, which is placed perpendicularly to the beam of the 
HIFU transducer.  Since the HIFU protocol is applied inside the magnet of an 
MRI scanner, the receiver was MRI compatible.  The receiver diameter was 10 
mm, its radius of curvature was 10cm and operated with a bandwidth of 10 
MHz.  The receiver was mechanically coupled to the HIFU transducer.  The 
signal from the receiver was fed to an A/D PCI card (CS1250, A/D 12 bit, 50 
MHz, from GAGE, Lachine, Canada).  The A/D card was synchronised to 
receive the signal when the HIFU transducer was activated.  The received 
signal was stored in a PC.  
 
b. Acoustical Field 
The size of the focal region produced by this transducer was obtained by 
mapping the acoustic pressure field with a needle hydrophone (Specialty 
Engineering Associates, San Jose, CA, USA) having an active element 1 mm.  
The transducer under test was driven by a pulse/receiver (Panametrics 5050R, 
Waltham, MA, USA).  The hydrophone was connected to the receiver input of 
the pulse/receiver.   The output of the pulse/receiver was connected through an 
A/D card (GAGE) to the PC for signal processing.  The transducer was moved 
automatically by a robotic system (MD-2, Arrick Robotics, Hurst, TX, USA). The 
total power delivered by the transducer was measured before the beginning of 
each experiment with an ultrasound power meter (Model UPM-DT-100N, Ohmic 
Instruments, Easton, MD, USA) shown in figure 10.1.  The error of the power 
measurement is approximately 2%.  The estimation of the acoustical field was 
based on the principles presented by Raum and O’Brien 1997 [164].  More 
details of the above system can be found in [165]. 
 
c. In Vitro Experiments 
The tissue under ablation was placed in a degassed water tank. The water tank 
was placed on top of the flat MRI coil. The tissue was placed on top of an 
absorbing material in order to eliminate reflections coming from the bottom of 
the plastic water tank. The transducer was placed on the arm of the 2-D 
positioning device and was immersed in the water tank, thus providing good 
acoustical coupling between tissue and transducer.  Any bubbles that may have 
collected under the face of the transducer face were removed in order to 
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eliminate any reflections.  In all experiments, the liver used, was extracted from 
freshly killed pigs.  The sample was cut down to a size of 60 mm x 60 mm with 
thickness of 40-50 mm.  Totally 18 samples were ablated, creating one large 
lesion in each liver.   
 
d. HIFU parameters 
The in situ spatial average intensity used for creating lesions was 2000 and 
2500 W/cm2 for 5s; an exposure that creates both thermal and cavitational 
lesions.  In order to create large lesions, a grid pattern of 4x4 overlapping 
lesions was used.  The spacing between successive transducer movements 
was 3mm, which creates overlapping lesions for the intensity and pulse duration 
used [165]. The delay between successive ultrasound firings was 10s.  
Although, the study by McDannold et al. 1999 [166], recommends a delay 
around 50-60 sec in order to avoid build up in front of the target, for this 
application and transducer geometry using 10 s delay eliminated most of the 
built up heating (the lesion length was extended by 2mm). 
 
If in a grid of let say 4x4 lesions of a specific exposure, one lesion was created 
under the mechanism of cavitation, then the probability of cavitation (POC) is 
1/16 or 6.25%. 
 
e. MRI analysis 
The MRI parameters used for the various pulse sequences are listed in table 
11.1.  The signal intensity was measured by placing a circular region of interest 
(ROI) of approximately 10mm in diameter.  The contrast to noise ratio (CNR) 
was obtained by dividing the signal intensity difference between the ROI in the 
lesion and in the ROI of normal liver tissue by the standard deviation of the 
noise in the ROI of normal liver tissue. 
f. Experimental Protocol 
The following protocol was used during all experiments: 
 
i. A freshly killed liver was used 1 hour after the sacrifice of the animal 
ii. The sample was degassed and then placed inside the container that 
contains degassed water 
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iii. The slave positioning device, transducer and water container that include 
the tissue sample were placed inside the MRI scanner 
iv. The signal generator, RF amplifier, master robotic system, and PC were 
placed outside the MRI room 
v. The sample was ablated using the parameters indicated earlier.  During 
the experiment the water bath, had the same temperature as the room 
temperature 
vi. The therapeutic protocol was evaluated by using various MRI pulse 
sequences 
vii. The sample was sliced and photos were taken using a digital camera. 
 
g. Results 
Figure 11.3 shows the POC as a function of in situ spatial average intensity for 
a 5s pulse duration in liver.  Note that by using intensity between 2000 and 
3500 W/cm2, it is possible to create both thermal and cavitational lesions. 
 
 
 
Figure 11.3: POC as a function of in situ spatial average intensity for 5s pulse 
duration in liver. 
 
Initially, the two traditional FSE techniques (T1-weighted, and T2-weighted) 
were evaluated.  T1-weighted FSE was explored by using different TR (100, 
200, 300, 400, 500, 700 and 1000 ms).  Figure 11.4A shows the CNR between 
lesion and liver plotted against TR.  All the parameters used are shown in table 
11.1 row 1.  T2-weighted FSE was explored by using seven different TE (10, 
15, 20 30, 40, 45, and 60 ms). Figure 11.4B shows the CNR between lesion 
and liver plotted against TE.  All the parameters used are shown in table 11.1 
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(row 2).  11.4C shows the CNR between lesion and liver plotted against TR 
using T1-weighte FSPGR.  All the parameters used are shown in table 11.1 
(row 3).   
 
 
 
  
 
 
Figure 11.4  A. CNR between lesion and liver plotted against TR using T1-
weighted FSE, B. CNR between lesion and liver plotted against 
TE using T2-weighted FSE, C. CNR between lesion and liver 
plotted against TR using T1-weighted FSPGR. 
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Figure 11.5A shows the MR image (in a plane perpendicular to the transducer 
beam) using T2-weighted FSE with TE=15 ms.  This large lesion was created 
using spatial average in situ intensity of 2500 W/cm2 for 5s.  By using this 
intensity, 4 out of the 16 lesions (POC=0.25) were created under the 
mechanism of cavitation.  Figure 11.5B shows a cavitation map, which shows in 
specific grid of single lesions (volume lesion or large lesion) having 4 lesions, 
which are created under the mechanism of cavitation.  A lesion was classified 
as cavitational if during the firing of the ultrasonic transducer, the frequency 
spectrum included subharmonic emissions.   
 
Figure 11.5C shows a typical frequency spectrum during the creation of a 
cavitational lesion.  The cavitational map was also verified using MRI imaging 
(figure 11.5A) and using gross examination.  With T2-weighted FSE the contrast 
of the cavitational lesion within the large thermal lesion is excellent.  The 
cavitational lesion appears as a scattered bright spot.   
 
Figure 11.6A shows the lesion in a plane parallel to the transducer beam using 
T2-weighted FSE. This large lesion was created using spatial in situ intensity of 
2500 W/cm2 for 5s. With this pulse sequence, it is possible to identify the lesion 
created under the mechanism of cavitation. Figure 11.6B shows the photograph 
after slicing. In this photograph, the void indicates a site influenced by the 
mechanism of cavitation (already confirm with harmonic emission and MRI). 
 
 
 
 
 
 
 
 
  
 
A 
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Figure 11.5:  A MR images (in a plane perpendicular to the transducer beam) 
of large lesion using T2-weighte FSE showing cavitational 
lesions, B cavitational map of the above large lesion, C typical 
frequency spectrum acquired during the occurrence of a 
cavitational lesion.   
       
 
 
 
 
 
 
 
 
    
   
 
Figure 11.6:  MR images (in a plane parallel to the transducer beam) of large 
lesion using A. T2-weigted FSE with TE=15ms. B. Photograph 
after slicing. 
0
20
40
60
80
0 1 2 3 4 5 6 7 8 9 10 11 12 13
S
p
ec
tr
al
 P
o
w
er
 (
m
W
) 
Frequency (MHz) 
T : thermal lesion
C : cavitational lesion
T T TC
TTTC
T
C
T
T
T T
T C
 
A B 
B 
C 
- 158 - 
 
h.  Discussion 
 
It was concluded so far by several studies (for example [5], [167], and [168]) 
that MR-guidance of ultrasound serves mainly 4 purposes:  
i. localisation of the focus,  
ii. imaging of the dynamic build-up of necrosis,  
iii. Imaging at the end of the treatment protocol, in order to evaluate the 
necrosis and possibly re-planned the treatment protocol in the event of 
incomplete coverage of the target (tumour for the case of oncology 
applications) and 
iv. Follow-up imaging, evaluating the effectiveness of HIFU ablation, 
several days after the treatment.  This research includes information that 
will be useful for cases i and iv.  
 
The results of this study indicate that: 
i. The contrast between lesion and normal liver tissue is acceptable when 
T1-weighted FSE is used.   
ii. Best contrast is observed for TR between 200 and 400 ms.  This was 
proved by evaluating the CNR between lesion and liver as a function of 
TR.  The difference in the signal of the lesion and liver is significant in 
this range.  The window that maximises contrast in liver is much smaller 
that the case of kidney [48].  MRI could detect the lesion 1-2 minutes 
after the ablation.  In the study by Chen [169], the lesions in the brain 
appeared in MRI in 15 minutes to 60 minutes using T2-weighted FSE.     
 
Similar evaluation was followed for T2-weighted FSE pulse sequence.  Best 
contrast can be achieved for TE up to 20 ms, with better contrast at lower TE, 
indicating that PD might be the best pulse sequence for the case of liver in vitro. 
Similar to what was seen in T1-weighted FSE, the window of TE that maximizes 
contrast is narrow in liver compared to kidney [48].  T2-weighted FSE was 
proven as the best pulse sequence that can detect cavitational activity.  This 
advantage is attributed to the significant difference in signal intensity between 
the water-filled air spaces and necrotic tissue.  Water-filled air spaces appear 
brighter than thermal lesions.  Therefore for therapeutic protocols created using 
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the cavitational mode, T2-weighted FSE maybe the optimum pulse sequence to 
be used.  
 
The T1-weighted FSPGR was investigated as a fast imaging pulse sequence. 
FSPGR is the most widely accepted fast pulse sequence, used by many 
researchers (for example [95], [167]). From this pulse sequence the parameter 
proton resonant frequency shift can be extracted, which allows relative small 
temperature elevation to be detected [95], [170].  The estimation of temperature 
can be used to identify the location of the focus using low intensity, which does 
not cause any irreversible damage to the tissue [95].  It can also be used to 
estimate the thermal dose during the application of ultrasound [95].  In this 
study it was found that with TR around 100 ms the CNR between lesion and 
liver is maximized. 
 
Mack et al. 2001 [171], and Morrison et al. 1998 [45] have shown that T1 and 
T2-weighted FSE and gradient-echo sequences can effectively monitor lesions 
created by laser-induced thermotherapy in patients with liver cancer.  Therefore 
we anticipate that the pulse sequences evaluated in this study will be successful 
also for treatments in vivo. In the in vivo case the CNR between the thermal 
lesion and normal liver tissue will be improved by using contrast-enhanced 
techniques (Aschoff et al. 2000 [172]). Because of the motion artifacts, other 
techniques should be evaluated (for example fast low-angle shot (FLASH)). 
Tsuda et al. 2003 [109] used T1-W and T2-W FSE to monitor lesion created in 
rabbit liver in vivo using radiofrequency ablation.  In their study they found that 
the contrast was optimised at TR of 500 ms, which is close to what was found in 
our study. 
 
Sibille et. al 1993 [39] reported incomplete coverage of implanted tumours with 
necrosis and therefore the importance of MR imaging is enhanced, because it 
provides feedback and therefore the treatment protocols can be redesigned so 
as to eliminate such problems. Follow-up of treatment in liver using MRI is very 
important since [95] showed that large areas of ultrasonically damaged tumour 
cells are identified one day after the treatment.   
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Preferential location of cavitation lesions is at interfaces between liver and the 
water-filled blood vessels (figure 11.6) an effect also seen by [34] and [173]. 
The threshold of 100 % cavitation in liver, which is about 3500 W/cm2, is similar 
to what was found in kidney [73].  This observation is in agreement with [34] 
who stated that whatever constitutes the nuclei for the cavitation events may be 
common to most soft tissues. The POC increases with intensity and above a 
certain threshold the POC is 1.  Significant POC (above 20%) is caused with 
intensity above 2500 W/cm2 at 5s. For the case of porcine liver in vitro this 
threshold of 100% cavitation is about 3500 W/cm2 at 5 s.  The trend of POC as 
a function of spatial in situ intensity is similar to what was found in the study of 
kidney ablation [73].  Also the length of a single lesion in liver at the intensity of 
2000 W/cm2 for 5s which is around 20 mm, is very close to the lesion measured 
in kidney [165].  This is not surprising since liver and kidney have similar 
absorption [174]. 
 
Finally, here a useful research tool is presented for evaluating cavitation, which 
we call cavitational map.  In the cavitational map, lesions are marked as thermal 
or cavitational.  A lesion was classified as cavitational if during the firing of the 
ultrasonic transducer, the frequency spectrum included subharmonic emissions.  
The cavitational map was also verified using MRI imaging and using gross 
examination.  This tool can be very useful for evaluating cavitation at different 
exposures (frequency, intensity and pulse duration) and at different locations 
(close to blood vessels, interfaces, tissue type).  At the moment we cannot think 
of any significant use of the cavitational map in the clinical setting, but it may be 
a very important research tool especially for cavitation studies. 
 
NAME 
 
TR (ms) TE 
(ms) 
Slice 
thickness 
(mm) 
Matrix FOV 
(cm) 
NEX BW 
(KHz) 
ETL Flip 
angle 
T1-weighted 
FSE 
100, 200, 
300, 400, 
500, 700, 
1000 
9.1 3  
(gap 0.3 
mm) 
256x256  16 1 31.25 8 - 
T2-weighted 
FSE 
 
2500 10, 15, 
20, 30, 
40, 45, 
60 
3 
(gap 0.3 
mm) 
256x256  16 1 31.25 8 - 
FSPGR 
T1-weighted 
50,100, 
150,300 
2.8 3  
(gap 0.3 
mm) 
256x256  16 1 62.50 -  
50
0
 
Table 11.1:  Parameters used for the various MRI pulse sequences. 
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11.2 Evaluation of fast spin echo MRI sequence for an 
MRI guided high intensity focused ultrasound 
system for in vivo rabbit liver ablation. 
 
Here, in this section the effectiveness of magnetic resonance imaging (MRI) to 
monitor thermal lesions created by High Intensity Focused Ultrasound (HIFU) in 
rabbit liver in vivo is investigated.  The MRI sequences of T1-weighted, and T2-
weighted fast spin echo (FSE) were evaluated.  The main goal in this research 
was to find the range of repetition time (TR) and range of echo time (TE) which 
maximizes the contrast to noise ratio (CNR).  An ultrasonic transducer operating 
at 2 MHz was used, which is navigated using the proposed positioning device 
version 1.  
 
11.2.1 Introduction 
 
Surgical resection is considered the therapy of choice for liver cancer.  
However, the percentage of patients who are good candidates for surgery is low 
[175].  Surgical resection is only feasible in 10–20% of the patients resulting to 
5-year survival rates in the region of 40% [175]. Moreover, the incidence of new 
metastases after resection is high, and the success rate after multiple 
resections is low [175]. Because of the above disadvantages of surgical 
resection the development of several less invasive local ablative therapies for 
liver tumours is imperative. These approaches have included percutaneous 
ethanol injection [176], cryotherapy [177], radiofrequency [108]-[112], 
microwave [115]-[117], [178], and laser ablation [101], [102].  These local 
therapies have produced survival rates similar to those with surgical resection in 
the treatment of metastases [179], but unfortunately high local recurrence rate 
is also reported [180].   
 
Therefore, thermal ablation methods could possibly become a main treatment 
option for liver cancer, especially if recurrence rate is minimized.  Another 
ablative method that could be used for liver cancer treatment is High Intensity 
Focused Ultrasound (HIFU). HIFU is the only non-invasive local therapy to be 
proposed to date. If HIFU is proven equivalent to surgical resection, this 
minimally invasive approach may be able to replace surgery as the treatment of 
choice.   
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Since the 90’s clinical work has been initiated for liver cancer.  Vallancien et al. 
[181] treated two patients with solitary liver metastases prior to surgical 
resection.  The team headed by Wu in 1999 reported a clinical study for treating 
68 patients with liver malignancies [182].  The same group reported a clinical 
study with 474 patients with Hepatocellular Carcinoma (HCC) treated using 
HIFU in combination with transarterial chemo-embolization [89].  HIFU ablation 
has also been used for palliation in 100 patients with advanced-stage liver 
cancer [183].  Following treatment, symptoms, such as pain and lethargy, were 
relieved in 87% of the patients.   
 
Without an imaging system that allows for online monitoring of the deposition of 
ultrasound energy or the creation of induced lesion, it is impossible to predict 
the precise location of the HIFU beam, to monitor the temperature changes, or 
to control the deposited thermal dose. In the past, these major constraints 
limited the development of HIFU as a non-invasive surgical technique.  In recent 
years, however, integration of HIFU with MRI, which allows high-sensitivity 
tumour detection and the ability to monitor temperature in real time, has 
increased the potentials of HIFU.  MRI-guided HIFU has generally been 
reserved for the treatment of uterine fibroids [184] and breast adenomas [185].  
However, it is very likely that this mode of treatment monitoring and delivery will 
have a role in the treatment of liver tumours. Recently, a non-randomised 
clinical trial is under way [186] to assess the safety and efficacy of the MRI 
guided HIFU system ExAblate 2000 (InSightec, Haifa, Israel) in the treatment of 
liver tumours.   It was reported that a small number of patients has been treated 
to date with promising results [186].   
 
The first attempt to monitor the effect of HIFU using MRI in liver was reported by 
Rowland et al. 1997 [162], who demonstrated that monitoring of thermal lesions 
in liver is feasible. The MRI appearance of lesions in liver created using HIFU 
was also studied by Jolesz et al. 2004 [187] and Kopelman et al. 2006 [188].  In 
this study the goal is to investigate the effectiveness of MRI to monitor 
therapeutic protocols of HIFU in rabbit liver in vivo. The two basic and most 
important MRI sequences of T1-weighted fast spin echo (FSE) and T2-weighted 
FSE are investigated.  The goal was to create large lesions and use MRI to 
discriminate between liver tissue and lesion.  With T1W FSE the signal intensity 
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vs. repetition time (TR) is evaluated and based on this analysis, the contrast to 
noise ratio (CNR) is estimated, in order to find the range of TR that produces 
maximum contrast.  Similarly for T2W FSE the range of echo time (TE) is found 
that maximizes the contrast.  A spherically focused transducer operating at 2 
MHz was used, which is navigated inside MRI using an MRI compatible robot. 
 
11.2.2 Methods 
a. HIFU/ MRI system 
The HIFU/MRI system is analysed and described in chapter 5.  Figure 5.1 
shows the block diagram of a typical HIFU/MRI system and figure 5.2 shows the 
setup of the actual devices of the HIFU/MRI system. 
b. HIFU system 
The HIFU system for this study consists of a signal generator (HP 33120A, 
Agilent technologies, Englewood, CO, USA), an RF amplifier (250 W, AR, 
Souderton, PA, USA), and the HIFU transducer (Etalon, Lebanon, IN, USA). 
The transducer operates at 2 MHz, has focal length of 10 cm and diameter of 5 
cm. The transducer is rigidly mounted on the MRI-compatible positioning device 
version 1. 
c. MRI Imaging 
The positioning device and the transducer were placed inside a MRI scanner 
(Signa 1.5 T, by General Electric, Fairfield, CT, USA).  A spinal coil (USA 
instruments, Cleveland, OH, USA) was used to acquire the MRI signal for all 
tissues. 
d. Positioning Device  
The positioning device is described in details in chapter 6.  The enclosure 
hosting the motor drivers shown in figures 9.2 and 9.3 is placed outside the MRI 
room since magnetic materials are involved.  The DC supply (24 V, 6 A) used to 
drive the Shinsei drivers is also placed outside of the MRI room. 
e. MRI compatible camera 
In order to monitor the condition of the animal or humans (future use), an MRI 
compatible camera (MRC Systems GmbH, Heidelberg, Germany) was mounted 
on the system.  The camera was interfaced by means of a video card. With the 
aid of the MRI compatible camera, the researcher can monitor the welfare of the 
animal. 
- 164 - 
11.2.3 In vivo experiments 
 
For the in vivo experiments, New Zealand adult rabbits were used weighting 
approximately 3.5-4 kg. Totally 7 rabbits were used in the experiments. The 
rabbits were anaesthetized using a mixture of 500 mg of ketamine (100 mg/mL, 
Aveco, Ford Dodge, IA), 160 mg of xylazine(20 mg/mL, Loyd Laboratories, 
Shenandoah, IA), and 20 mg of acepromazine (10 mg/mL, Aveco, Ford Dodge, 
IA) at a dose of 1 mL/kg.  The animal experiments protocol was approved by 
the national body in Cyprus responsible for animal studies (Ministry of 
Agriculture, Animal Services). 
 
a. HIFU parameters 
The in situ spatial average intensity was estimated based on the applied power 
and the half-power width of the beam of the transducer. The attenuation used 
was 4 Np/m-MHz.  The half-power length of the beam is 15.6mm and the half-
power width is 1.2 mm.  The details of the intensity estimation can be found in 
[48].  In order to create large lesions, a square grid pattern of 4x4 overlapping 
lesions was used.  The spacing between successive transducer movements 
was 2 mm, which creates overlapping lesions for the intensity and pulse 
duration used.  In all the exposures the ultrasound was turn on for 5s.  The in 
situ spatial average intensity used was 1000W/cm2. The delay between 
successive ultrasound firings was 10s. 
 
b. MRI processing 
The following parameters were used for T1-W FSE: TR was variable from 100-
1000 ms, TE=9 ms, slice thickness=3 mm (gap 0.3 mm), matrix=256x256, 
FOV=16cm, NEX=1, and ETL=8. For T2-W FSE: TR=2500 ms, TE was variable 
from 10 ms to 160 ms, slice thickness=3mm (gap 0.3 mm), matrix=256x256, 
FOV=16 cm, NEX=1, and ETL=8. 
 
The contrast to noise ratio (CNR) was obtained by dividing the signal intensity 
difference between the Region of Interest (ROI) in the lesion and in the ROI of 
normal liver tissue by the standard deviation of the noise in the ROI of normal 
liver tissue. The ROI was circular with diameter of 3 mm. 
- 165 - 
The tissue temperature change (T) has been estimated using the proton 
resonance frequency method given by the equation stated in Chung et al. 1996 
[189]: 
 
= *B0**T *TE,  
 
 
where is the temperature-dependent phase shift which is the phase acquired 
before and during temperature elevation and which accumulates during the 
echo time TE using fast spoiled gradient (FSPGR).  The other terms are  which 
is the gyromagnetic ratio of proton, 42.58MHz/T,  is the average proton 
resonance frequency coefficient, and B0 is the flux density of the static magnetic 
field.  The measured temperature elevation can be added to the base-line 
temperature to obtain the absolute temperature.  The average proton resonance 
frequency coefficient  for the frequency shift was taken to be -0.0105ppm/oC 
as determined by the method described by Vykhodtseva et al 2000 [191]. 
 
11.2.4 Results 
The goal in this study was to use T1W FSE using different TR (from 100 to 
1000 ms) and then evaluate the effect of TR on the CNR.  Figure 11.7 shows a 
large lesion in liver in vivo using T1-w FSE (TR=400 ms). This lesion was 
created using in situ spatial average intensity of 1000 W/cm2 for 5 s. Since the 
step size of this 4x4 lesion was 2mm, the size of this lesion is approximately 
8mm x 8mm. The MRI estimated maximum temperature in this lesion was 65 
oC. Since the estimated temperature is below 100 oC, the occurrence of boiling 
was excluded.  The thermal lesion appears bright and the contrast with liver 
tissue is excellent.   
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Figure 11.7: Large lesion in liver in vivo using T1-w FSE 
 
Figure 11.8 shows the photograph of the lesion of Figure 3 after the animal was 
sacrificed in a plane perpendicular to the transducer face. 
 
Figure 11.9 shows the CNR between lesion and liver plotted against TR for the 
MRI image of Figure 11.7.  The same trend of CNR was seen in all the 
remaining 6 rabbits. 
 
Also the maximum CNR between liver and lesion of the other 6 rabbits was also 
close to 25, and thus we are confident that this typical graph represents the 
behaviour of CNR vs. TR for rabbit liver ablation in vivo. The relaxation time T1 
of the lesion is 250ms, and relaxation time T1 of the liver is 600ms. The proton 
density of the lesion increases by 20 % compared to the host tissue. 
 
  
Figure 11.8: Photograph of the lesion shown in Figure 11.7 
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Figure 11.9: CNR vs TR 
 
Figure 11.10 shows the MRI image of the lesion of Figure 11.7 using T1W FSE 
demonstrating the excellent propagation deep in the liver (i.e. in plane parallel 
to the transducer beam axis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.10: MRI image of the lesion of Figure 11.7 using T1W FSE 
 
 
 
The second goal in this study was to explore T2W FSE using different TE (from 
10 to 140 ms) and then evaluate the effect of TE on the CNR.  Figure 11.11 
shows the MRI images of the same lesion as in Figure 11.7 using T2W FSE 
(TE=60 ms). 
 
Figure 11.12 shows the CNR between lesion and liver plotted against TE for the 
liver and lesion of the MRI image of Figure 11.11.  The relaxation time T2 of 
lesion is 35ms and the relaxation time T2 of the liver is 50ms.  The proton 
density of the lesion decreases by 5% compared to the host tissue. 
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Figure 11.11: MRI images of the same lesion as in Figure 11.7 using T2W 
FSE. 
 
 
 
 
 
Figure 11.12: CNR vs TE for the MRI image shown in 11.11 
 
 
 
11.2.5 Discussion 
In this paper the goal was to measure the CNR of FSE MRI sequences in 
detecting thermal lesions created by HIFU in rabbit liver in vivo.  Both T1-W 
FSE and T2-W FSE have been proven successfully for providing excellent 
contrast between liver and thermal lesion in rabbit in vivo. 
 
The CNR with T1W FSE is significantly higher than T2W FSE (25 with T1W 
compared to 14 with T2W).  With T1W FSE the range of TR under which CNR 
is high and ranges from 400 to 900 ms.  Obviously one should use TR of 400 
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ms in order to minimize the imaging time. Thus, the optimum TR to be used is 
400 ms.  The maximum contrast measured is approximately 25.  The window 
that maximises contrast in liver is much wider than the case of kidney [189]. 
The maximum CNR obtained for liver is the highest we measured after 17 years 
of experience in this field.  The relaxation time T1 of lesion (250 ms) is much 
lower than the T1 of the host tissue (liver) which is 600 ms.  The greater the 
difference, the greater the CNR.  However, one might not ignore the significant 
role that the value of proton density plays in the CNR. The proton density of the 
lesion is increased by 20%. 
 
The trend of CNR vs TR starts to increase then it becomes flat and then at high 
TRs it starts to decrease again. This trend is justified because at low TR, the 
difference in signal intensity between lesion and liver is low at the beginning and 
therefore CNR is lower.  At higher TR the signal intensity of lesion and tissue 
reaches their maxima and therefore the signal difference is lower and hence the 
CNR drops again. 
 
With T2W the range of TE that establishes maximum contrast is between 40 ms 
and 80 ms.  This range was estimated by assuming that a CNR value of 10 is 
acceptable.  Similar to what was seen in T1-weighted FSE, the window of TE 
that maximizes contrast is wider in liver compared to kidney [189].  Note that the 
maximum CNR value with T2W FSE is around 14 which is much lower than the 
value obtained with T1W FSE. The relaxation time T2 of lesion (35 ms) is lower 
than the T2 of the host tissue (liver) which is 50 ms. Therefore, in T2 W FSE the 
variation of signal intensity between lesion and liver is small (5%) and therefore 
the factor dominating the CNR in T2-W FSE is the T2 relaxation time. The trend 
of CNR vs TE starts to increase then it becomes flat and then at high TEs it 
starts to decrease again. The same explanation holds as in the case of T1-W 
FSE. 
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11.3 MRI monitoring of lesions created at temperature 
below the boiling point and of lesions created 
above the boiling point using High Intensity 
Focused ultrasound. 
 
This research evaluates lesions created at temperatures above the boiling point 
during HIFU exposures using MRI. The evaluation was performed in kidney, 
and liver.  
 
Kidney and liver were chosen for this study because there is currently a lot of 
on-going research either in animal models or in humans for both of these 
tissues.  In the area of kidney ablation with HIFU Watkin et al. 1997 [198] used 
a large animal model and proved the feasibility of this treatment method.  
Recently Roberts et al. 2006 [199] have performed ablations in the normal 
rabbit kidneys and they suggested that the mechanical effects of ultrasound, 
can be used to homogenize tissue. 
 
HIFU ablation of renal tumours in humans remains in the early stages of clinical 
trials. In the early 1990s, Vallancien et al. [200] reported the first clinical 
feasibility study in kidney using extracorporeal HIFU. Susani et al 1993 [201], 
Wu et al. 2003 [202] and Marberger et al. 2005 [203] conducted clinical trials in 
patients with renal tumours and proved that HIFU may have a place in the 
treatment of renal tumours. 
 
Hacker et al. 2006 [204] performed also ablation of 43 kidneys (porcine and 
human), using an experimental handheld extracorporeal technology. Finally 
Klingler et al. 2008 [205] use laparoscopic methods to treat kidney tumours.  
 
Small animal models [206]-[207] were used to establish the feasibility of HIFU to 
create lesions in liver tissue. The thresholds for liver tissue destruction at 
varying exposure parameters were established in the 70s and 80s [35]. 
 
Basic research in the area of liver continued during the 1990s; for example the 
histological effects of HIFU [208], the effects of blood perfusion on during liver 
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ablation [209], and the relationship between tissue depth and the required 
intensity levels [36]. 
 
Several tumour models have been used to predict the effects of HIFU on liver 
tumours in humans (for example [38], [210]) and to destroy VX2 liver tumours in 
rabbits [39], [40].  Hooded Sarcoma N (HSN) fibrosarcoma has been also used 
as a tumour model in rats with some success [211]. HIFU was also used for the 
treatment of metastatic melanoma in liver in a cat [212] and Wu et al. 2005 
[213] use HIFU in combination with TACE for the treatment of HCC.  
 
MRI was a great enhancement for the HIFU systems because the therapeutic 
protocols can be accurately guided.  Therefore the interest of using MRI as the 
diagnostic modality of guiding HIFU was increased.  This study focuses in the 
detection of lesions above boiling using MRI.  Several MRI sequences are 
investigated.  For high quality imaging, which can be used at the end of a 
therapeutic protocol or at some instances of the protocol, the fast spin echo 
(FSE) techniques T1, and T2-weighted are investigated in both tissues under 
investigation.  For fast imaging, the T1-weighted fast spoiled gradient (FSPGR) 
MRI sequence was used.  Fast imaging can be used to monitor the dynamic 
increase of tissue temperature during the application of an ultrasonic exposure.  
 
In order to prove whether a lesion is created at temperature below boiling or 
above, it is necessary to estimate the temperature at the focus.  The proton 
resonance frequency (PRF) shift has been proven to be best pulse sequence 
for estimating temperature, because with this sequence the temperature is less 
dependent on the physiological changes of tissue during high-temperature HIFU 
exposures [134]. The temperature dependence of the PRF shift was measured 
to be linear above 50 °C [134].  This linearity of the PRF shift above the tissue 
necrosis threshold allows the tissue temperature to be estimated during the 
therapeutic ultrasound exposures. 
 
The task with high quality imaging was to find an optimum technique that can 
discriminate thermal from boiling lesions. Discriminating between lesion and 
normal tissue involves two types of tissues. Discriminating between thermal and 
boiling lesions involves three types of layers (normal tissue, lesion and cavity).  
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Therefore the signal intensity vs. MR parameters needs to be evaluated for the 
above layers in order to optimise the contrast among tissue of interest, lesion 
and cavity.  The other main task was to monitor the temperature elevation using 
a fast MRI technique in order to observe the shape of the beam during HIFU 
exposures.  
 
The growth of vapour bubbles due to boiling occurs due to the temperature 
induced by HIFU.  Boiling is different from cavitation which occurs due to 
pressure oscillations induced by HIFU.  Vapour bubbles created by boiling can 
grow rapidly to a size of few millimetres (Khokhlova et. al. 2006 [214]). This 
growth can be explosive due to the super heating caused by HIFU. Therefore 
the cavities produced of few mms can be easily monitored by MRI. 
 
There are two reasons for studying the MRI appearance of boiling lesions that 
could be of importance: 
i. Since boiling provides enhanced heating, it could be possible for large 
tumours (for example giant fibroadenomas) to use this type of heating 
(especially in the centre of the tumour) in order to accelerate the ablation, 
ii. Since the rabbit model is used extensively by many researchers in MRI 
animal experiments, then it is very useful for them to know the 
appearance of boiling lesions. 
 
11.3.1 Materials and Methods 
a. HIFU/ MRI system  
 
The HIFU/MRI system is analysed and described in chapter 5.  Figure 5.1 
shows the block diagram of a typical HIFU/MRI system and figure 5.2 shows the 
setup of the actual devices of the HIFU/MRI system. 
b. HIFU system 
 
The HIFU system for this study consists of a signal generator (HP 33120A, 
Agilent technologies, Englewood, CO, USA), a RF amplifier (250 W, AR, 
Souderton, PA, USA), and a spherically shaped bowl transducer (Etalon, 
Lebanon, IN, USA).  The transducer used for the kidney and liver ablation 
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operates with frequency of 4 MHz. The transducer is rigidly mounted on the 
MRI-compatible positioning device version 1. 
 
c. MRI Imaging 
 
The positioning device and the transducer were placed inside a MRI scanner 
(Signa 1.5 T, by General Electric, Fairfield, CT, USA).  The spinal coil (USA 
instruments, Cleveland, OH, USA) was used to acquire the MRI signal for the 
case of kidney and liver. 
 
d. Temperature measurement 
 
Temperature was measured in few experiments in order to confirm that the 
temperature estimated using the PRF method was accurate enough. 
Temperature is measured using a data acquisition system (HP 34970A, Agilent 
technologies, Englewood, CO, USA).  Temperature is sensed using a 50-μm 
diameter T-type copper-costantan thermocouple (Physitemp Instruments, Inc. 
New Jersey, USA) which is MRI compatible.  The thermocouple is placed in the 
tissue by means of a catheter.  The thermocouple measures the temperature at 
the focus.  This is achieved by applying low-intensity (low enough not to cause 
tissue damage) and during the application of ultrasound the transducer is 
scanned accordingly in order to detect the maximum temperature. This 
establishes positioning of the thermocouple in the focus of the transducer. The 
temperature error of the thermocouple is in the order of 0.1 ºC. 
 
e. Cavitation detector 
 
From a scientific point of view it will be useful to separate lesions developed 
based on thermal and based on cavitation mechanisms.  In this system we use 
a passive MRI compatible cavitation detector (Etalon, Lebanon, IN, USA), which 
is placed perpendicularly to the beam of the HIFU transducer (method 
described in [215]).  Since the HIFU protocol is applied inside the magnet of an 
MRI scanner, the detector must be MRI compatible.  The diameter of the 
detector was 1 cm, its radius of curvature was 10 cm and operated between 1 
and 13 MHz (centre frequency is 7 MHz). The detector was mechanically 
coupled to the HIFU transducer.  The voltage from the detector was fed to an 
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analogue to digital (A/D) card (CS1250, A/D 12 bit, 50 MHz, from GAGE, 
Lachine, Canada).  The A/D card was synchronised to receive the signal when 
the HIFU transducer was activated.  The received signal was stored in a 
storage device of a PC.  The signal was then displayed using EXCEL (Microsoft 
Corporation, Redmond, WA USA) in order to visualize whether cavitation occurs 
or not. 
 
11.3.2 In vitro experiments 
 
The tissue was placed on top of an absorbing material in order to shield 
adjacent tissue form stray radiation from the bottom.   The transducer was 
placed on the arm of the positioning device and was immersed in the water 
tank, thus providing good acoustical coupling between tissue and transducer. 
Any bubbles that may have collected under the face of the transducer face were 
removed in order to eliminate any reflections.  In all experiments the tissues 
used (kidney and liver) were extracted from freshly killed lamb, and the 
experiment was conducted in the same day. Totally 22 kidneys and 8 liver were 
ablated for investigating various issues. 
 
11.3.3 In vivo experiments 
 
For the in vivo experiments, adult rabbits from Cyprus were used weighting 
approximately 3.5-4 kg. Totally 8 rabbits were used in the experiments. The 
rabbits were anaesthetized using a mixture of 500 mg of ketamine (100 mg/mL, 
Aveco, Ford Dodge, IA), 160 mg of xylazine (20 mg/mL, Loyd Laboratories, 
Shenandoah, IA), and 20 mg of acepromazine (10 mg/mL, Aveco, Ford Dodge, 
IA) at a dose of 1 mL/kg.  
 
The animal experiments protocol was approved by the national body in Cyprus 
responsible for animal studies (Ministry of Agriculture, Animal Services). 
a. HIFU parameters 
 
In order to create large lesions, a grid pattern of 3x3 or 4x4 overlapping lesions 
was used.  The spacing between successive transducer movements was 2 mm, 
which creates overlapping lesions for the intensity and pulse duration used. In 
all the exposure, unless stated otherwise the ultrasound was turn on for 5 s. 
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The delay between successive ultrasound firings was 10 s for the scanned 
ablation.  The intensity indicated through this paper is in situ spatial average 
intensity. 
b. MRI parameters 
 
The various MRI parameters used for the various pulse sequences are listed in 
table 11.2.  The Region of Interest (ROI) was circular with diameter of nearly 2 
mm. 
The temperature change (T) has been estimated using the equation stated in 
Chung et al. 1996 [189] and Ishihara et al. 1995 [190] which is as follows: 
 
 
=B0T* TE,  
 
 
Where is the temperature-dependent phase shift which is the phase 
acquired before and during temperature elevation and which accumulates 
during the echo time TE using the gradient-echo pulse sequence FSPGR.  The 
other terms are  which is the gyromagnetic ratio of proton, 42.58 MHz/T,  is 
the average proton resonance frequency coefficient and B0 is the flux density of 
the static magnetic field.  The measured temperature elevation can be added to 
the base-line temperature to obtain the absolute temperature.  The average 
temperature coefficient for the frequency shift was taken from the study of 
Vykhodtseva et al 2000 [191]. 
 
11.3.4 Results 
 
Figure 11.13 shows an MRI image of 4 lesions in vitro kidney (plane 
perpendicular to the beam) resulting from intensities ranging from 1000 to 2500 
W/cm2 using T1-weighted FSE (Figure 11.13A), T2-weighted FSE (Figure 
11.13B) and T1-weigthed FSPGR (Figure 11.13C) with pulse duration of 5s. 
The MRI parameters used are shown in table 1(row 1, 2 and 4). The MRI 
estimated maximum temperature at the focus was 55 ºC for the intensity of 
1000 W/cm2, 83 ºC for 1500 W/cm2, 105 oC for 2000 W/cm2 and 123 ºC for 
2500 W/cm2. The temperature measured using the thermocouple for the 1000 
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W/cm2 was 53 ºC, which is very close to the temperature estimated using the 
PRF method.     
 
 
 
 
 
 
 
 
 
 
        
 
 
Figure 11.13: MR images (in a plane perpendicular to the beam) of four lesions 
(intensities 1000, 1500, 2000 and 2500 W/cm2) in kidney in vitro 
using A. T1-weighted FSE, B. T2-weighted FSE, C. T1-weighted 
FSPGR. With intensities above 2000 W/cm2 the lesions exhibit 
boiling activity. The discrimination between boiling and non-
boiling lesion is best monitored using T2-W FSE 
 
 
Note that with T2-weighted FSE (Figure 11.13B) white spots (cavity) within the 
dark thermal lesion are seen for intensities higher than 2000 W/cm2. T1-W FSE 
and FSPGR show some indication of these cavities, but the resolution is weaker 
than T2-w FSE.  
 
Figure 11.14 shows MRI images (in a plane parallel to the transducer beam) of 
3 lesions in kidney in vitro at intensities of 1000, 2000 and 3000 W/cm2. Again 
T2-weighted FSE shows cavities (due to boiling) within the thermal lesion. T1-W 
FSE and T1-W FSPGR fail to provide good resolution in this axis.  
 
Having observed that T2-W FSE was probably a successful MRI sequence to 
detect boiling lesions, this pulse sequence was investigated further by 
evaluating the Contrast to Noise Ratio (CNR) vs. Echo Time (TE). 
 
Figure 11.15 shows the plot of CNR vs. TE for kidney tissue, lesion and cavity 
of the lesion of Figure 11.14B (intensity of 3000 W/cm2) demonstrating that 
good contrast between lesion and cavity is achieved using T2-weighted FSE 
between 20 and 50 ms. 
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Figure 11.16 shows a T2-weighted FSE image of 3 lesions in rabbit kidney in 
vivo using different intensities 
 
Table 11.2:  Parameters used for the various MRI pulse sequences 
 
 
The lesion created using 2500 W/cm2 appears to have a white spot (cavity). 
These temperatures are lower than the corresponding temperatures in vitro 
(Figure 11.14) for the same intensity due to the removal of heat due to blood 
flow or possibly due to reflection from various interfaces.   
 
                 
      
 
Figure 11.14: MR images (in a plane parallel to the beam) of 3 lesions in kidney 
in vitro using A. T1-weighted FSE, B. T2-weighted FSE, C. T1-
weighted FSPGR. With intensities above 2000 W/cm2 the lesions 
exhibit boiling activity. The discrimination between boiling and 
thermal lesion is best monitored using T2-W FSE. 
 
 
Figure 11.17A shows an MR image of a lesion acquired using T1-weighted 
FSPGR (for MRI parameters see table 11.2, row 4).  Figure 11.17B shows the 
photograph of the kidney showing cavity within the large thermal lesion.  
 
Note that this large lesion was created using a matrix of 4x4 single lesions with 
intensity of 1500 W/cm2.  Out of these 16 lesions, one lesion was created 
possibly due to the mechanism of cavitation, which results to tissue evaporation 
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or boiling. The estimated temperature during the creation of this lesion was 120 
oC, whereas the temperature for the rest of the lesions (non-boiling) varied from 
80 to 85 oC. 
 
 
 
Figure 11.15: CNR vs. TE for the lesion, kidney and cavity for the lesion of    
Figure 11.18B with intensity of 3000 W/cm2 
 
 
 
 
Figure 11.16: MRI image using T2-weighted FSE of 3 lesions in rabbit kidney in 
vivo at different intensities (1000, 2000, and 2500 W/cm2) for a 5 
s pulse.  The lesion with intensity of 2500 W/cm2 is affected by 
tissue boiling 
 
 
This bubbly lesion exhibits low-signal lesion (dark spot) and lies inside the large 
lesion (white spot within the kidney tissue). At the location of the boiling lesion, 
the passive cavitation detector confirmed the occurrence of cavitation since 
broadband emission was detected (see figure 11.17C which shows the 
frequency spectrum of the HIFU transducer). Although with this intensity bubbly 
lesions should not be produced, the high temperature estimated for this one 
lesion, should be attributed to cavitation. Cavitation was possibly initiated by 
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bubbles that are trapped in the in vitro tissue due to the absence of blood in the 
vasculature. 
 
Figure 11.18 demonstrates the temperature increase in vitro kidney using HIFU 
and MRI monitoring. The MRI images were acquired using the dynamic 
sequence T1-weighted FSPGR.  Each image was acquired in 5s.  In image 
11.18a ultrasound was OFF.  In the next 5 images the applied spatial average 
intensity was 1000 W/cm2 (for 25 s), and in the last 2 images ultrasound is 
turned OFF.  Due to the heating a dark spot is observed (see arrows). The 
estimated maximum temperature was 55 ºC. 
 
 
 
                   
     
    
 
 
 
 
      
 
 
Figure 11.17: A. MR image (in a plane perpendicular to the beam) of large 
lesion in kidney in vitro using T1-weighted FSPGR (TR=50 ms), 
showing one cavitation lesion. B. Photograph of the kidney 
showing the cavitation lesion within the large thermal lesion, C. 
Frequency spectrum of the HIFU transducer exhibiting cavitation 
activity 
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Figure 11.19 shows the corresponding temperature increase using T1-weighted 
FSPGR influenced by boiling.  In figure 11.19A ultrasound was OFF.  In the 
next 5 images the applied spatial average intensity was 3500 W/cm2 (for 25 s). 
Note that compared to figure 11.17 where the focal beam is circular, the focal 
beam in this figure is distorted, which is attributed to the occurrence of boiling 
confirmed also by the temperature of 112 ºC measured.  
  
 a     b 
  
 c     d 
  
 e     f  
  
 g     h  
 
Figure 11.18: Temperature evolution in vitro kidney using T1-weighted FSPGR 
(thermal mechanism).  Each image was acquired in 5s. a. 
Ultrasound is OFF b.-f. applied spatial average intensity: 1000 
W/cm2 (for 25s), g.-h. ultrasound is OFF 
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Figure 11.20 shows MRI image of lesion in liver. The image was acquired using 
Proton density. The lesion was created using low intensity (1000 W/cm2) for 
long time (30s). These ultrasonic parameters produce temperature elevation 
which is above the boiling point (120 ºC). Thus, the evaporation of tissue 
causes a cavity that follows the shape of the beam.  
 
  
  a    b 
  
  c    d  
  
  e    f 
 
Figure 11.19: Temperature elevation in vitro kidney using T1-weighted FSPGR 
(boiling). a. Ultrasound is OFF b.-f. applied spatial average 
intensity: 3500 W/cm2 (for 25s) 
 
 
 
 
Figure 11.20: MR image using proton density of lesion in liver created under 
the influence of boiling. The lesion was created using low 
intensity (1000 W/cm2) for long time (30 s) 
10 mm 
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The methodology applied for kidney which evaluates T1-W FSE, T2-W FSE and 
FSPGR (Figure 11.13 and 11.15) was also applied for liver. It was found that for 
liver the best pulse sequence to evaluate boiling lesions was T2-w FSE with 
minimum TE (i.e. proton density). Table 11.3 summarizes the recommended 
MRI sequence according to our experience for monitoring boiling lesions. 
 
Tissue type Contrast between lesion below boiling 
and tissue 
Contrast between lesion below boiling, 
tissue, and lesion above boiling 
Kidney T1-W FSE, T2-W FSE T2-W FSE 
Liver T1-W FSE, T2-W FSE T2-W FSE 
Table 11.3: Recommended pulse sequences for discriminating between a) 
normal and thermal lesions and b) normal tissue, lesions created 
with temperature below boiling and lesions created with 
temperature above boiling  
 
11.3.5 Discussion 
 
So far it was concluded by several studies (for example Quesson et al. 2000 
[167], Salomir et al. 2000 [216], McDannold et al. 2000 [168] that MRI-guidance 
of HIFU serves mainly 4 purposes:  
i. localisation of the focus,  
ii. imaging of the temperature elevation, 
iii. imaging at the end of the treatment protocol, in order to evaluate the 
necrosis and possibly re-planning the treatment protocol in the event of 
incomplete coverage of the target and  
iv. follow-up imaging, evaluating the effectiveness of HIFU ablation, 
several days after the treatment.   
 
This study enhances the role of MRI guidance in HIFU because it provides 
techniques to discriminate between non-boiling and boiling lesions.  
 
In kidney the best MRI sequence to detect boiling lesions was T2-W FSE. T2-W 
FSE was evaluated further by plotting the CNR vs. TE for the three regions of 
interest (kidney, lesion and cavity).  It was concluded that between TE’s of 20 
and 50 ms, the signal difference, and hence the contrast between the three 
regions of interest (kidney, lesion and cavity) is maximum (Figure 11.15).  
According to figure 11.15, the cavity, which appears inside the lesion, has 
stronger signal and decays slower.  
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T1-weighted FSE and T1-weighted FSPGR do not consistently show boiling 
lesions in kidney, and even when cavities are visible the contrast is not very 
good.   
In liver T2-W FSE with low TE (i.e. Proton density) is recommended as an MRI 
sequence to detect non-boiling lesions and boiling lesions.  
 
Boiling bubbles scatter and reflect ultrasound. These reflections result in 
shielding the HIFU focus and thus increased prefocal heating is observed. 
Therefore boiling bubbles, similar to cavitation bubbles, result to distortion of the 
lesion from a cigar shape into a tadpole shape (Figure 11.14). In addition to this 
the growth of the lesion is shifted towards the transducer. This phenomenon 
which is attributed to bubbles, either due to ultrasound-induced cavitation or to 
boiling has been observed also in the study by ter Haar [217], and by Chavier et 
al 2000 [72].  For the scanned lesions the focus is not shifted towards the 
transducer, because while boiling begins in a very short time in both single and 
scanned lesions, it cannot distort the lesion for scanned exposures because the 
focus of the transducer moves away from the boiling site. This speculation is 
also supported in the paper by Khokhlova [214] 
 
This study also showed by means of MRI images that focal beam is distorted 
during the occurrence of boiling. Initially low intensity was used (1000 W/cm2) 
and the temperature elevation was monitored using T1-weigthed FSPGR. The 
shortest acquisition time that we could achieve with our system was 5s.  
Modifying any MRI parameter to decrease the time resulted to poor contrast or 
low signal to noise ratio (SNR). If we had achieved faster acquisitions (less than 
5s), then it would have possible to see more drastic changes.  A decrease in the 
signal (black spot) demonstrated the increase in the temperature (also observed 
by Hynynen at al 1995 [14].  The shape of the black spot was circular. The 
black spot increased gradually with increased temperature, and the shape 
remains circular at all times (Figure 11.18).  When the intensity was increased 
to 3500 W/cm2, the shape of the black spot was irregular indicating that boiling 
occurred (Figure 11.19). 
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12 Conclusion and future enhancements 
 
HIFU seems to be the most promising technology in non-invasive procedures in 
medicine.  A technology evolved in the 1950s by the Fry brothers, Francis and 
William.  Back then, fry brothers had introduced the first HIFU system as a non-
invasive procedure in medicine.  The first application of this system was the 
treatment of neurologic disorders like Parkinson’s disease.  However this 
methodology remained unutilized due to the lack of necessary imaging 
technology devices.  The road towards a major breakthrough innovation opened 
wide four decades later by Jolesz and Jakab and Ronald Watkins at the GE 
Corporate R&D lab.  Jolesz and Jakab provided a solution for visualization of 
this non-invasive procedure.  They demonstrated that an ultrasonic transducer 
can be used inside a MRI scanner.   That was the beginning of a new era in 
medicine and non-invasive procedures.  Since then more and more researchers 
joined forces and today two decades after the Jolesz, Jakab successful and 
revolutionary idea, physicians provided with an enhanced tool which it appears 
to be applicable for unlimited medical processes.  HIFU started as a scalpel 
ablating any applicable target.  Applications include ablating tumours of the 
brain, breast, uterine fibroids, prostate, liver, kidney and pancreas or even treat 
cardiac arrhythmia.  Meanwhile, researchers are currently study applications of 
lower energy HIFU for drug delivery, trigger system to restore function like 
stimulating nerves, ischemic stroke by removing blood clod or thrombus, revive 
heart operation or even trigger the immune system.  Moreover, clinical trials 
some of which they have receive an FDA approval and/or CE marking, proved 
that HIFU can be applied for neurological disorders including neuropathic pain, 
Parkinson’s  disease and essential tremor.    
    
The innovation of HIFU has brought many benefits to medicine for both the 
physicians and the patients.  The most important benefit is the effect on the 
patient.  Since HIFU procedures are non-invasive the patients can walk out of 
the surgery room without passing through the intensive care unit (ICU) or by 
minimizing the number of days in the ICU.  This implies that patient have to 
undergo much less pain, the recovery period is minimized and patients are back 
to normal life at no time, the cost of the operations is also reduced since the 
patients to not need to recover in the ICU and the psychological effects on the 
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patients are also minimized.  Furthermore, the treatment can stop any time 
during the process if the patient feels pain or uncomfortable, something that 
cannot be done with classical surgery and the treatment can be repeated any 
number of times if necessary without any effect on the patient.  Last but not 
least, the physicians perform the operation using a mouse and therefore, these 
procedures are becoming much like an electronic game. On the other hand 
HIFU is not applicable to all organs, on the lungs for example where there is air, 
HIFU cannot be applied since ultrasound does not propagate through the air.  
Although, MRI is the only modality available today for monitoring and receiving 
feedback on where the focal spot is and on what damage has been achieved on 
the targeted tissue, there must be a major improvement on MRI scanners in 
order to be able to truck moving organs in real time and keep the focal spot on 
target all the time.  Another weaknesses of this technology is that it cannot take 
place in normal surgery room since it involves the MRI and this adds to the cost 
of the operation 
Convinced that HIFU is an optimistic and beneficial alternative to traditional 
surgery the aim of this research concentrates on the treatment of tumours of the 
abdominal organs liver, kidney, and pancreas, as well as thyroid tumours.  
Moreover, this study focuses on the design and development of an MR 
compatible robot which will operate in the gantry of an MRI scanner and guide 
the HIFU transducer which will ablate the tumours under study.  Also, the MR 
compatible robot will have the ability to be used in experiments on animals. 
To achieve the main goal of this study three versions of positioning devices 
were designed, developed and evaluated.  The first version of positioning 
device proved to be suitable for the guidance of the HIFU transducer in the 
gantry of an MR scanner.  In addition, this first version of positioning device is 
simple, small to operate in the gantry of the MR, lightweight (approximately 6 
Kg) and therefore, portable, and can be used in virtually any clinical MRI 
scanner since it can be sited on the scanner's table.  Moreover, this positioning 
device is flexible since it can be easily reduced or increased in size.  This can 
be adjusted easily by varying the lengths of the rods, sheets and belts.  All the 
other components remain fixed in size. Thus, easily any size of positioning 
device can be designed.  This positioning device includes a flexible coupling 
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system, and thus it can be used in all the anatomies considered in this study 
(brain, liver, kidney, pancreas and thyroid). 
The positioning device proved to be functional and discrete and large lesions 
were created successfully with reproducible results.  Finally, the results also 
show that the quality of MRI imaging is not affected by the presence of the HIFU 
system.  
However, this positioning device is driven with the timing belts and hence there 
is a possibility for these timing belts to loosen and as a result this will lessen 
robot’s accuracy and stability.  Another weakness of this robot is that it cannot 
be reproduced precisely.  These weaknesses brought the idea for the design 
and development of the second version of positioning device.  
The second version of positioning device since it was based on the experience 
gained from the first version, inherited all the benefits of the first version and in 
addition the weaknesses were resolved.  The timing belts were replaced with 
racks and pinions and as a result both stability and accuracy of the robot were 
enhanced.  Furthermore, the second robot was designed on CAD software and 
manufactured by the 3D printer and gave the robot smother edges more 
accurate design and made the robot reproducible. A major enhancement in the 
second version is that it was designed to be as flexible as possible.  All the 
parts of this robot are detachable and this contributed to the portability but even 
more important any part of the robot can be replaced with no effect on the rest 
of the parts of the robot.  Also, different transducer holders designed for 
different applications and different transducers can be attached on the robot.  
Furthermore, this robot can be easily modified and attached on the top of the 
MRI’s gantry providing top-to-bottom access to patients.  In addition to the 
benefit inherited from version one, this robot is durable robust, and reliable.  
The flexibility added to this robot made the robot applicable for several organs 
such as liver, kidneys, pancreas and thyroid and also for experiments on 
animals.   
The disadvantage of this second version of positioning device is that at this 
moment it is not feasible to attach it on the top of the gantry of the MR scanner.  
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Therefore, at present will only be used for experiments in vitro tissues and gel 
phantom or on animals.  
The third version of positioning device inherited all of the characteristic 
advantages of the previous versions.  Moreover, this positioning device is 
principally influenced by and therefore replaces the first version.   
The third version of positioning device can be used for brain tumours as shown 
in figure 8.19 with the horizontal HIFU transducer holder.  Furthermore the 
water container holder shown in figure 8.12.B, is suitable for in vitro targets 
placed inside or underneath the water tank (kidney, liver, turkey fillet, porcine 
muscle etc.) by attaching the appropriate vertical HIFU transducer holder and 
also for in vivo targets  (small animals like rabbits and rats). 
The software developed to guide the robot outside the MRI room is user friendly 
and enriched with useful features that can be used by the physician during or 
after the procedure.  The user interface proved to be reliable, stable and 
accurate.  The software is flexible and adaptable and therefore, it can be easily 
updated and modified to fulfil any future requirements.   
Evaluation procedures show that the presence of the positioning device in the 
gantry of the MRI does not affect the quality of MRI imaging.  Therefore, all 
three versions of positioning devices are proved to be MR compatible.  In 
addition discrete and large lesions were created successfully with reproducible 
results. 
The quality of the images captured from the MR compatible camera was not 
affected by the strong magnetic field of the MR. However, the MRI image 
slightly affected by the presence of the MRI compatible camera. 
In this study several experiments were conducted to evaluate the HIFU/MRI 
system and the effectiveness of MRI to monitor therapeutic protocols of HIFU. 
Detection of large lesions using MRI and the best contrast between different 
tissues and lesions using different MRI sequences were evaluated. The range 
of repetition time (TR) and range of echo time (TE) which maximizes the 
contrast to noise ratio (CNR) was also investigated and evaluated.  MRI was 
also utilized to monitor lesions created at temperature below the boiling point 
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and lesions created at temperature above the boiling point using HIFU in freshly 
excised tissues and in vivo rabbit kidney. T2-weighted fast spin echo (FSE) was 
proven to be an excellent MRI sequence that can detect lesions with 
temperature above the boiling point in kidney. This advantage is attributed to 
the significant difference in signal intensity between the cavity and the thermal 
lesion.  Moreover, in liver the MRI sequence of Proton Density to detect lesions 
above boiling proved to be a suitable choice.  
 
Finally the MRI compatible positioning devices developed with resolution for all 
three axes of 0.1 mm will offer a valuable multi-tool for the physicians for a 
variety of applications.  The user will be able to control and monitor the process 
through a user friendly interface.  Furthermore, this HIFU system can be setup 
at no time and also accepts different HIFU transducer holders of different 
length, height, and pointing direction or angle as well as HIFU transducers from 
different manufacturers or with different focal length and therefore different 
diameter that can be used for almost every accessible organ in the body.  
 
12.1 Future enhancements 
 
The plans for this study are to be able in the near future to acquire an approval 
for clinical trials. The following steps are to be followed in order to optain 
approval for clinical trials: 
i. Obtain CE marking for the HIFU system. 
ii. Apply for clinical trials through the Cyprus Medical device agency. This is 
the national body for approving clinical trials when a medical device is 
involved. The Cyprus Medical device agency will consult the Cyprus 
Bioethic committee and if all the necessary information is submitted 
satisfactorily, an approval will be given for conducting clinical trials. 
Additionally, the directives below will be considered: 
i. Directive 2001/20/EEC of the European Parliament and of the Council of 
4th April 2001 on the approximation of the laws, regulations and 
administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on 
medicinal products for human use. 
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http://europa.eu.int/eur-lex/pri/en/oj/dat/2001/l_121/l_12120010501en00340044.pdf 
ii. Guidelines as suggested by the European Science foundation, in 
European science foundation policy briefing May 2001, on Controlled 
clinical trials.  
www.esf.org/publication/90/ESPB13.pdf. 
 
Although, the encoders of the motor drivers were utilized to return the location 
of the motor at any time this location may not directly reflect the actual position 
of the transducer.  Therefor a localization system has to be employed in order to 
get in real time the actual position of the transducer.  This can be achieved by 
engaging three optical sensors acting like beacons to detect the position of the 
transducer and send it back to the system.  This will be used as a real time 
feedback to evaluate and correct the process. 
 
Furthermore, the flexible design of the positioning devices will easily allow 
modifications to target and ablate other organs accessible by HIFU and not 
consider here such as prostate, uterine fibroids, breast, brain and more.  Also, it 
may be employed in treating other diseases like Parkinson’s, ischemic stroke, 
drug delivery, reviving heart operation and many more.  
 
Also, the software can be enhanced by automating the process further.  
Engaging in the software image processing will enable the physician to use the 
mouse to cover the area of the tumour, lineate three dimensional the tumour 
and hence the software will develop a three dimensional treatment plan.  The 
treatment plan should be editable enabling the physician to add or remove 
tissue in the treatment plan. However, this implies a closer collaboration with 
the MRI manufacturer. 
 
Moreover, the database of patient treatments should be expanded to keep more 
data about the patients and their treatments as well as for the physician which 
can be utilised to derive useful conclusions for medicine through statistics. 
 
The valuable thermometry property of the MRI should also being embedded in 
the software and this will give the necessary for a non-invasive procedure, 
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feedback which will help to visualize the effect (damage) of the ultrasound to the 
targeted tissue and prevent damage to healthy tissues.  
 
Through the evaluation the lack of rotational motion was appreciated so that the 
transducer does not only manoeuvre in the XYZ dimensions, but also in an 
angular direction, thus ablating tissues through the appropriate angle.  
 
The results through the evaluation are very optimistic and with the future 
enhancements described here the positioning devices developed will drive this 
research to clinical trials for treating brain, kidney, liver, pancreas, and thyroid 
tumours.  
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13.1.2 Conference papers 
 
 
1. C. Damianou, N. Milonas, V. HadjiSavas, A. Couppis, D. Iosif, K. Ioannides, 
‘Thermal ablation system using High Intensity Focused Ultrasound (HIFU) 
and guided by MRI’ CARS 2008 Computer Assisted Radiology and Surgery, 
June 25 -  28, Barcelona, Spain ,2008. 
 
2. C. Damianou, K. Ioannides, V. HadjiSavas, N. Milonas, A. Couppis, D. Iosif, 
M. Komodromos F. Vrionides, ‘Thermal ablation system using high intensity 
focused ultrasound (HIFU) and guided by MRI’ , International Society of 
Therapeutic Ultrasound, Minneapolis, 10-13 September, 2008. 
 
3. C.Damianou, K. Ioannides, V. HadjiSavas, N. Milonas, A. Couppis, D. Iosif, 
M. Komodromos, F. Vrionides, ‘High intensity focused ultrasound (HIFU) 
system guided by MRI’. 12th World Congress of the World Federation for 
Ultrasound in Medicine and Biology, 30 August – 3 September 2009, 
Sydney Convention & Exhibition Centre, Sydney, Australia. 
 
4. C.Damianou, N. Milonas, V. HadjiSavas, A. Couppis, D. Iosif, K. Ioannides,  
Evaluation of the contrast between tissues in rabbit in vivo and thermal 
lesions produced by HIFU using fast spin echo MRI sequences in liver, 
kidney, heart, brain and pancreas. International Society of Therapeutic 
Ultrasound, Aux En Provence, France, 23-26 September, 2009. 
 
5. C. Damianou, K. Ioannides, N. Mylonas, V. HadjiSavvas, A. Couppis, D. 
Iosif ‘Liver ablation using a high intensity focused ultrasound system and 
MRI guidance’, 9th International Conference on Information Technology and 
Applications in Biomedicine, November 5-7, 2009, Larnaca, Cyprus. 
 
6. V. HadjiSavvas, C. Damianou, K. Ioannides, N. Mylonas, , A. Couppis, P. 
Kyriakou, D. Iosif, , T. Hadji Charambous, G. Parea, ‘Penetration of high 
intensity focused ultrasound in vitro and in vivo rabbit brain using MR 
imaging. ’, 9th International Conference on Information Technology and 
Applications in Biomedicine, November 5-7, 2009, Larnaca, Cyprus. 
 
7. N. Mylonas, V. Hadjisavvas, C. Damianou, An MR compatible positioning 
device for treating brain cancer and stroke using high intensity focused 
ultrasound (HIFU) under MRI guidance, 10th meeting of the International 
Society of Therapeutic Ultrasound, ISTU10, Tokyo, Japan, June 9-12, 2010. 
 
8. A. Couppis, K. Ioannides,  N. Mylonas,  D. Iosif, P. Kyriakou,C.Lafon, F. 
Chavrier J. Chapelon, M. Komodromos, C. Damianou, Evaluation of an MRI 
guided planar rectangular high intensity focused ultrasound transducer for 
thermal ablation of cardiac tissue, 10th meeting of the International Society of 
Theraputic Ultrasound, ISTU10, Tokyo, Japan, June 9-12, 2010. 
 
9. N. Mylonas, C. Damianou MR-guided focused ultrasound robot for 
performing experiments on large animals, 10th  meeting of the International 
Society of Theraputic Ultrasound, ISTU10, Tokyo, Japan, June 9-12, 2010.
- 193 - 
13.2 Animal Experiments Issues 
FUC has been approved by the Ministry of agriculture of Cyprus to conduct 
experiments with animals.  The Cyprus's authority has revised the regulations 
regarding animal experiments in 2000 as part of the harmonisation process.  
The revised regulations follow exactly the EU directives 86/609/EEC (Directive 
title: "On the approximation of laws, regulations and administrative provisions of 
the Member States regarding the protection of animals used for experimental 
and other scientific purposes").  In order to obtain the approval to perform 
animal experiments we have responded to the following issues: 
 
a. Authorised persons. 
Experiments will be performed solely by a veterinarian who is a competent 
persons authorized with the provisions of national legislation. Persons who 
carry out experiments or take part in them and persons who take care of 
animals used for experiments, have appropriate education and training. 
 
b. Investigator responsibilities.                    
The task leader involved in animal experiments is responsible for the standard 
of animal care and use by all other persons involved in the experiment. It will be 
ensured that the extent of supervision is compatible with the level of 
competence of each person and the responsibilities they are given. 
 
c. Previous Work 
We will investigate others studies performed earlier in the brain in order to 
reduce the number of animals used. 
 
d. Pain and distress 
If animals develop signs of severe pain or distress despite the precautions 
outlined above, they will have the pain or distress alleviated promptly or will be 
killed humanely and without delay.  If in doubt, we will always seek the 
veterinarian’s opinion before continuing an experiment. 
Unexpected deaths occurring during a project will be properly investigated by 
the veterinarian to determine the cause and initiate remedial action. If the 
deaths are due to manipulations, these will cease. The national authority will be 
notified and the project protocol resubmitted with appropriate modification. 
 
e. Signs of pain or distress 
We are familiar with the normal behavior of the animal species chosen, the 
signs of pain or distress specific to that species, and will monitor the animals for 
these signs. Animals will be monitored during the experiment appropriately for 
clinical signs of acute pain or distress. These may include one or more of the 
following: a. Abnormal stance or movements, b. Abnormal sounds, c. Altered 
cardiovascular and/or respiratory function, d. Vomiting and abnormal defecation 
or urination. 
 
f. Animals species 
We will use New Zealand rabbits.  
 
g. Repeated use of animals in experiments 
Since each animal is sacrificed after the experiment then the issue of using the 
same animal does not exist. 
h. Anaesthesia 
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The animals will be totally anesthetized.  The anesthesia protocol is as follows: 
142 mg (1.42 mL) of xylazine is mixed into a 1000 mg vial of Ketamine (10 mL).  
Each animal receives 1 mL of this cocktail per 10 lbs via an intramuscular 
injection.  The doses administered after that is half the initial dose every 30-40 
min.  The anesthesia will be monitored by measuring the heart rate and 
respiration and by visual inspection 
 
i. Euthanasia 
The chosen Euthanasia will produce rapid loss of consciousness without pain 
until death occurs.  The animals will be euthanised using 1 ml per 10 lbs of 
Bethanasia-D special. The route of euthanasia is IV.  Following the administration 
of this drug, a scalpel will be used to create a bilateral pneumothorax. 
 
j. Pre-operative Planning 
Surgical success can be improved by careful attention to the following: 
a. The use of healthy, disease-free animals will ensure more reliable research 
data. We will consult a veterinarian to assist in obtaining such animals.  
b. Surgical time will be reduced by practice on cadavers. This will familiarize us 
with anatomical landmarks, streamline the experimental surgical procedures 
and thereby reduce the quantity of anesthetic required. This will promote animal 
well being.  
 
k. Post-operative care 
Not applicable for this type of experiments because the animals will be 
euthanized at the end of the experiment. 
              
l. Supplying establishments 
Since at FUC there are no other researchers doing experiments with animals, 
we will pick up animals from supplying establishments.  The supplying 
establishment is approved by the national authority.  
 
m. User establishments 
Our establishments are registered with and approved by the national authority.  
Arrangements are made to have installations and equipment suited to the 
species of animals used and the performance of the experiments conducted 
there. The design, construction and method of functioning is such as to ensure 
that the experiments are performed as effectively as possible, with the object of 
obtaining consistent results with the minimum number of animals and the 
minimum degree of pain, suffering, and distress harm. 
 
n. Report of results 
We will keep records of all animals used and produce them whenever required 
to do so by the authority. In particular, these records will show the number and 
species of all animals acquired, from whom they were acquired and the date of 
their arrival. Such records will be kept for a minimum of three years and shall be 
submitted to the authority upon request. 
 
o. Animal protocols 
Ablate tissue using high intensity ultrasound.  The maximum temperature in the 
brain will never exceed 3 oC.  The experiments will demonstrate the ability of the 
ultrasonic source to dissolve clots in the brain.  Power levels and pulse duration 
that optimize the treatment will be derived   
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13.2.1 Licenses from Ministry of Agriculture, animal services 
 
a. Lab license for experiments on rabbits 
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b. Approval of the Ministry of Agriculture, animal services for experiments 
on rabbits 
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13.3 Cancer Statistics 
 
13.3.1 Liver cancer Statistics 
It is estimated that 22,620 men and women (16,410 men and 6,210 women) will 
be diagnosed with and 18,160 men and women will die of cancer of the liver 
and intrahepatic bile duct in 2009.   
The following information is based on National Cancer Institute’s (NCI) 
Surveillance Epidemiology and End Results (SEER) Cancer Statistics Review.  
Incidence & Mortality with liver cancer 
 
SEER Incidence with liver cancer  
From 2002-2006, the median age at diagnosis for cancer of the liver and 
intrahepatic bile duct was 64 years of age. Approximately 1.1% was diagnosed 
under age 20; 1.0% between 20 and 34; 3.7% between 35 and 44; 20.3% 
between 45 and 54; 24.6% between 55 and 64; 23.5% between 65 and 74; 
19.8% between 75 and 84; and 5.9% 85+ years of age. 
The age-adjusted incidence rate was 6.6 per 100,000 men and women per 
year. These rates are based on cases diagnosed in 2002-2006 from 17 SEER 
geographic areas. 
Incidence Rates by Race 
Race/Ethnicity Male Female 
All Races 10.2 per 100,000 men 3.6 per 100,000 women 
White 8.6 per 100,000 men 3.0 per 100,000 women 
Black 13.4 per 100,000 men 4.2 per 100,000 women 
Asian/Pacific Islander  21.4 per 100,000 men 8.3 per 100,000 women 
American Indian/Alaska Native  13.6 per 100,000 men 6.6 per 100,000 women 
Hispanic  15.2 per 100,000 men 5.9 per 100,000 women 
Table 13.1: Incidence rates by race of cancer of the liver and intrahepatic bile duct (NCI) [51]. 
 
 
US Mortality with liver cancer 
From 2002-2006, the median age at death for cancer of the liver and 
intrahepatic bile duct was 70 years of age. Approximately 0.3% died under age 
20; 0.7% between 20 and 34; 2.5% between 35 and 44; 15.0% between 45 and 
54; 20.5% between 55 and 64; 24.1% between 65 and 74; 26.2% between 75 
and 84; and 10.7% 85+ years of age. 
- 198 - 
The age-adjusted death rate was 5.1 per 100,000 men and women per year. 
These rates are based on patients who died in 2002-2006 in the US. 
 
Death Rates by Race 
Race/Ethnicity Male Female 
All Races  7.5 per 100,000 men 3.2 per 100,000 women 
White 6.8 per 100,000 men 2.9 per 100,000 women 
Black 10.8 per 100,000 men 3.9 per 100,000 women 
Asian/Pacific Islander  15.0 per 100,000 men 6.6 per 100,000 women 
American Indian/Alaska Native  10.3 per 100,000 men 6.5 per 100,000 women 
Hispanic  11.3 per 100,000 men 5.1 per 100,000 women 
Table 13.2: Death rates by race of cancer for the liver and intrahepatic bile duct (NCI) [51]. 
 
 
 
13.3.2 Kidney cancer statistics 
The following information was taken from National Cancer Institute (NCI) [51]. 
It is estimated that 57,760 men and women (35,430 men and 22,330 women) 
will be diagnosed with and 12,980 men and women will die of cancer of the 
kidney and renal pelvis in 2009 
The following information is based on NCI’s SEER Cancer Statistics Review. 
 
Incidence & Mortality with kidney cancer (SEER) 
 
 
SEER Incidence with kidney cancer  
From 2002-2006, the median age at diagnosis for cancer of the kidney and 
renal pelvis was 64 years of age.  Approximately 1.3% was diagnosed under 
age 20; 1.5% between 20 and 34; 6.1% between 35 and 44; 16.4% between 45 
and 54; 24.6% between 55 and 64; 24.3% between 65 and 74; 20.0% between 
75 and 84; and 5.7% 85+ years of age. 
The age-adjusted incidence rate was 13.6 per 100,000 men and women per 
year. These rates are based on cases diagnosed in 2002-2006 from 17 SEER 
geographic areas. 
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Incidence Rates by Race 
Race/Ethnicity Male Female 
All Races 18.6 per 100,000 men 9.5 per 100,000 women 
White 19.2 per 100,000 men 9.9 per 100,000 women 
Black 21.3 per 100,000 men 10.3 per 100,000 women 
Asian/Pacific Islander  9.6 per 100,000 men 4.8 per 100,000 women 
American Indian/Alaska Native  21.7 per 100,000 men 14.1 per 100,000 women 
Hispanic 17.6 per 100,000 men 9.6 per 100,000 women 
Table 13.3: Incidence rates by race of cancer for the kidney and renal pelvis in 2009 (NCI) [51]. 
 
 
US Mortality with kidney cancer 
From 2002-2006, the median age at death for cancer of the kidney and renal 
pelvis was 71 years of age. Approximately 0.5% died under age 20; 0.5% 
between 20 and 34; 2.4% between 35 and 44; 10.2% between 45 and 54; 
20.0% between 55 and 64; 25.4% between 65 and 74; 27.9% between 75 and 
84; and 13.2% 85+ years of age. 
The age-adjusted death rate was 4.1 per 100,000 men and women per year. 
These rates are based on patients who died in 2002-2006 in the US. 
 
Death Rates by Race 
Race/Ethnicity Male Female 
All Races  6.0 per 100,000 men 2.7 per 100,000 women 
White 6.1 per 100,000 men 2.8 per 100,000 women 
Black 6.0 per 100,000 men 2.7 per 100,000 women 
Asian/Pacific Islander  2.4 per 100,000 men 1.2 per 100,000 women 
American Indian/Alaska Native  9.0 per 100,000 men 4.2 per 100,000 women 
Hispanic  5.2 per 100,000 men 2.4 per 100,000 women 
Table 13.4: Death rates by race of cancer for kidney and renal pelvis in 2009 (NCI) [51]. 
 
 
13.3.3 Pancreatic cancer statistics 
The following information was taken from National Cancer Institute (NCI) [51]. 
It is estimated that 42,470 men and women (21,050 men and 21,420 women) 
will be diagnosed with and 35,240 men and women will die of cancer of the 
pancreas in 2009 
The following information is based on NCI’s SEER Cancer Statistics Review.  
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Incidence & Mortality with pancreatic cancer  
 
SEER Incidence with pancreatic cancer  
From 2002-2006, the median age at diagnosis for cancer of the pancreas was 
72 years of age. Approximately 0.0% was diagnosed under age 20; 0.4% 
between 20 and 34; 2.4% between 35 and 44; 9.6% between 45 and 54; 19.2% 
between 55 and 64; 26.1% between 65 and 74; 29.4% between 75 and 84; and 
12.8% 85+ years of age. 
The age-adjusted incidence rate was 11.7 per 100,000 men and women per 
year. These rates are based on cases diagnosed in 2002-2006 from 17 SEER 
geographic areas. 
Incidence Rates by Race 
Race/Ethnicity Male Female 
All Races 13.1 per 100,000 men 10.4 per 100,000 women 
White 13.1 per 100,000 men 10.2 per 100,000 women 
Black 16.6 per 100,000 men 14.6 per 100,000 women 
Asian/Pacific Islander  10.1 per 100,000 men 8.2 per 100,000 women 
American Indian/Alaska Native  10.2 per 100,000 men 9.3 per 100,000 women 
Hispanic  11.1 per 100,000 men 10.2 per 100,000 women 
Table 13.5:  Incident rates by race of pancreatic cancer 2009 (NCI) [50]. 
 
 
US Mortality with pancreatic cancer 
From 2002-2006, the median age at death for cancer of the pancreas was 73 
years of age. Approximately 0.0% died under age 20; 0.2% between 20 and 34; 
1.7% between 35 and 44; 8.2% between 45 and 54; 17.9% between 55 and 64; 
25.9% between 65 and 74; 31.1% between 75 and 84; and 14.9% 85+ years of 
age. 
The age-adjusted death rate was 10.7 per 100,000 men and women per year. 
These rates are based on patients who died in 2002-2006 in the US. 
Death Rates by Race 
Race/Ethnicity Male Female 
All Races  12.3 per 100,000 men 9.3 per 100,000 women 
White 12.2 per 100,000 men 9.1 per 100,000 women 
Black 15.4 per 100,000 men 12.4 per 100,000 women 
Asian/Pacific Islander  8.1 per 100,000 men 7.0 per 100,000 women 
American Indian/Alaska Native  9.1 per 100,000 men 7.8 per 100,000 women 
Hispanic  9.1 per 100,000 men 7.5 per 100,000 women 
Table 13.6:  Death rates by race of pancreatic cancer 2009 (NCI) [51]. 
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13.3.4 Thyroid cancer statistics 
It is estimated that 56,460 men and women (13,250 men and 43,210 women) 
will be diagnosed with and 1,780 men and women will die of cancer of the 
thyroid in 2012. 
The following information is based on NCI’s SEER Cancer Statistics Review.  
Incidence & Mortality with thyroid cancer 
 
SEER Incidence with thyroid cancer  
From 2005-2009, the median age at diagnosis for cancer of the thyroid was 50 
years of age.  Approximately 1.8% was diagnosed under age 20; 15.5% 
between 20 and 34; 20.4% between 35 and 44; 24.3% between 45 and 54; 
19.0% between 55 and 64; 11.7% between 65 and 74; 5.9% between 75 and 
84; and 1.4% 85+ years of age. 
The age-adjusted incidence rate was 11.6 per 100,000 men and women per 
year. These rates are based on cases diagnosed in 2005-2009 from 18 SEER 
geographic areas. 
Incidence Rates by Race 
Race/Ethnicity Male Female 
All Races 5.9 per 100,000 men 17.3 per 100,000 women 
White 6.2 per 100,000 men 18.3 per 100,000 women 
Black 3.3 per 100,000 men 10.1 per 100,000 women 
Asian/Pacific Islander  5.3 per 100,000 men 17.7 per 100,000 women 
American Indian/Alaska Native 3.2 per 100,000 men 10.9 per 100,000 women 
Hispanic 4.2 per 100,000 men 16.0 per 100,000 women 
Table 13.7:  Incident rates by race of thyroid cancer 2009 (NCI) [50]. 
 
US Mortality with thyroid cancer 
From 2005-2009, the median age at death for cancer of the thyroid was 73 
years of age.  Approximately 0.1% died under age 20; 0.8% between 20 and 
34; 2.2% between 35 and 44; 8.3% between 45 and 54; 16.9% between 55 and 
64; 24.7% between 65 and 74; 29.8% between 75 and 84; and 17.3% 85+ 
years of age. 
The age-adjusted death rate was 0.5 per 100,000 men and women per year. 
These rates are based on patients who died in 2005-2009 in the US. 
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Death Rates by Race 
Race/Ethnicity Male Female 
All Races  0.5 per 100,000 men 0.5 per 100,000 women 
White 0.5 per 100,000 men 0.5 per 100,000 women 
Black 0.4 per 100,000 men 0.6 per 100,000 women 
Asian/Pacific Islander  0.5 per 100,000 men 0.8 per 100,000 women 
Hispanic  0.5 per 100,000 men 0.6 per 100,000 women 
Table 13.8:  Death rates by race of thyroid cancer 2009 (NCI) [51]. 
 
 
Lifetime Risk  
Based on rates from 2007-2009, 1.03% of men and women born today will be 
diagnosed with cancer of the thyroid at some time during their lifetime. This 
number can also be expressed as 1 in 97 men and women will be diagnosed 
with cancer of the thyroid during their lifetime. These statistics are called the 
lifetime risk of developing cancer.  Sometimes it is more useful to look at the 
probability of developing cancer of the thyroid between two age groups.  For 
example, 0.24% of men will develop cancer of the thyroid between their 50th 
and 70th birthdays compared to 0.60% for women.  
13.3.5 Brain and other nervous system 
It is estimated that 22,910 men and women (12,630 men and 10,280 women) 
will be diagnosed with and 13,700 men and women will die of cancer of the 
brain and other nervous system in 2012. 
The following information is based on NCI’s SEER Cancer Statistics Review  
Brain and Other Nervous System Section  
Incidence & Mortality with brain cancer and other nervous 
system 
 
SEER Incidence with brain and other nervous system. 
From 2005-2009, the median age at diagnosis for cancer of the brain and other 
nervous system was 57 years of age3 Approximately 13.0% were diagnosed 
under age 20; 8.8% between 20 and 34; 9.2% between 35 and 44; 14.8% 
between 45 and 54; 19.0% between 55 and 64; 16.7% between 65 and 74; 
13.8% between 75 and 84; and 4.7% 85+ years of age. 
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The age-adjusted incidence rate was 6.5 per 100,000 men and women per 
year. These rates are based on cases diagnosed in 2005-2009 from 18 SEER 
geographic areas. 
 
Incidence Rates by Race 
Race/Ethnicity Male Female 
All Races 7.7 per 100,000 men 5.4 per 100,000 women 
White 8.4 per 100,000 men 5.9 per 100,000 women 
Black 4.7 per 100,000 men 3.6 per 100,000 women 
Asian/Pacific Islander  4.1 per 100,000 men 3.1 per 100,000 women 
American Indian/Alaska Native 3.9 per 100,000 men 3.8 per 100,000 women 
Hispanic 5.9 per 100,000 men 4.7 per 100,000 women 
Table 13.9:  Incident rates by race of brain and nervous system 2009 (NCI) [50]. 
 
US Mortality  
From 2005-2009, the median age at death for cancer of the brain and other 
nervous system was 64 years of age. Approximately 3.9% died under age 20; 
3.7% between 20 and 34; 6.5% between 35 and 44; 14.6% between 45 and 54; 
22.5% between 55 and 64; 22.5% between 65 and 74; 19.4% between 75 and 
84; and 6.9% 85+ years of age.The age-adjusted death rate was 4.3 per 
100,000 men and women per year. These rates are based on patients who died 
in 2005-2009 in the US. 
Trends in Rates  
Trends in rates can be described in many ways. Information for trends over a 
fixed period of time, for example 1996-2009, can be evaluated by the annual 
percentage change (APC). The average annual percent change over several 
years. The APC is used to measure trends or the change in rates over time. For 
information on how this is calculated, go to Trend Algortihms in the SEER*Stat 
Help system. The calculation involves fitting a straight line to the natural 
logarithm of the data when it is displayed by calendar year. (See Fast Stats for 
trends over fixed time intervals) . If there is a negative sign before the number, 
the trend is a decrease; otherwise it is an increase. If there is an asterisk after 
the APC then the trend was significant, that is, one believes that it is beyond 
chance, i.e. 95% sure, that the increase or decrease is real over the period 
1996-2009.  
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 A statistical model for characterizing cancer trends which uses statistical 
criteria to determine how many times and when the trends in incidence or 
mortality rates have changed. The results of joinpoint are given as calendar 
year ranges, and the annual percent change (APC) in the rates over each 
period can be used over a long period of time to evaluate when changes in the 
trend have occurred along with the APC which shows how much the trend has 
changed between each of the joinpoints.  
 
13.3.6 World Health Organization: International Agency for 
research on Cancer; World statistics for liver, pancreas, 
kidney and thyroid cancer. 
Lung cancer is the most common cancer worldwide, accounting for 1.2 million 
new cases annually; followed by cancer of the breast, just over 1 million cases; 
colorectal, 940,000; stomach, 870,000; liver, 560,000; cervical, 470,000; 
esophageal, 410,000; head and neck, 390,000; bladder, 330,000; malignant 
non-Hodgkin lymphomas, 290,000; leukemia, 250,000; prostate and testicular, 
250,000; pancreatic, 216,000; ovarian, 190,000; kidney, 190,000; endometrial, 
188,000; nervous system, 175,000; melanoma, 133,000; thyroid, 123,000; 
pharynx, 65,000; and Hodgkin disease, 62,000 cases. 
The three leading cancer killers are different than the three most common 
forms, with lung cancer responsible for 17.8 per cent of all cancer deaths, 
stomach, 10.4 per cent and liver, 8.8 per cent [55].   
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Liver 
Cancer  
Incidence Mortality 5-year prevalence 
Number (%) ASR 
(W) 
Number (%) ASR 
(W) 
Number (%) Prop. 
Men 523432 7.9 16.0 478134 11.3 14.5 433207 3.2 17.6 
Women 226312 3.7 6.0 217592 6.5 5.7 180006 1.2 7.3 
Both sexes 749744 5.9 10.8 695726 9.2 9.9 613213 2.1 12.5 
          
All cancers excl. 
non-melanoma 
skin cancer 
(men) 
6617844 100.0 202.8 4219626 100.0 127.9 13514868 100.0 550.6 
All cancers excl. 
non-melanoma 
skin cancer 
(women) 
6044710 100.0 164.4 3345176 100.0 87.2 15288300 100.0 620.8 
All cancers excl. 
non-melanoma 
skin cancer 
(both sexes) 
12662554 100.0 180.8 7564802 100.0 105.6 28803166 100.0 585.8 
Incidence and mortality data for all ages. 5-year prevalence for adult population only. 
ASR (W) and proportions per 100,000. 
   
Table 13.10:  Estimated incidence, mortality and 5-year prevalence: Liver Cancer [55] 
 
Pancreatic 
Cancer  
Incidence Mortality 5-year prevalence 
Number (%) ASR 
(W) 
Number (%) ASR 
(W) 
Number (%) Prop. 
Men 144859 2.2 4.4 138377 3.3 4.2 91997 0.7 3.8 
Women 133825 2.2 3.3 128292 3.8 3.1 80495 0.5 3.3 
Both sexes 278684 2.2 3.9 266669 3.5 3.7 172492 0.6 3.5 
          
All cancers excl. 
non-melanoma 
skin cancer 
(men) 
6617844 100.0 202.8 4219626 100.0 127.9 13514868 100.0 550.6 
All cancers excl. 
non-melanoma 
skin cancer 
(women) 
6044710 100.0 164.4 3345176 100.0 87.2 15288300 100.0 620.8 
All cancers excl. 
non-melanoma 
skin cancer 
(both sexes) 
12662554 100.0 180.8 7564802 100.0 105.6 28803166 100.0 585.8 
Incidence and mortality data for all ages. 5-year prevalence for adult population only. 
ASR (W) and proportions per 100,000. 
   
Table 13.11:  Estimated incidence, mortality and 5-year prevalence: Pancreatic Cancer [55] 
 
 
Kidney 
Cancer  
Incidence Mortality 5-year prevalence 
Number (%) ASR 
(W) 
Number (%) ASR 
(W) 
Number (%) Prop. 
Men 169155 2.6 5.2 72019 1.7 2.2 466631 3.5 19.0 
Women 104363 1.7 2.8 44349 1.3 1.1 277559 1.8 11.3 
Both sexes 273518 2.2 4.0 116368 1.5 1.6 744190 2.6 15.1 
          
All cancers excl. 
non-melanoma 
skin cancer 
(men) 
6617844 100.0 202.8 4219626 100.0 127.9 13514868 100.0 550.6 
All cancers excl. 
non-melanoma 
skin cancer 
(women) 
6044710 100.0 164.4 3345176 100.0 87.2 15288300 100.0 620.8 
All cancers excl. 
non-melanoma 
skin cancer 
(both sexes) 
12662554 100.0 180.8 7564802 100.0 105.6 28803166 100.0 585.8 
Incidence and mortality data for all ages. 5-year prevalence for adult population only. 
ASR (W) and proportions per 100,000. 
   
Table 13.12:  Estimated incidence, mortality and 5-year prevalence: Kidney Cancer [55]. 
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Thyroid 
Cancer  
Incidence Mortality 5-year prevalence 
Number (%) ASR 
(W) 
Number (%) ASR 
(W) 
Number (%) Prop. 
Men 49211 0.7 1.5 11206 0.3 0.3 195097 1.4 7.9 
Women 163968 2.7 4.7 24177 0.7 0.6 667377 4.4 27.1 
Both sexes 213179 1.7 3.1 35383 0.5 0.5 862474 3.0 17.5 
          
All cancers excl. 
non-melanoma 
skin cancer 
(men) 
6617844 100.0 202.8 4219626 100.0 127.9 13514868 100.0 550.6 
All cancers excl. 
non-melanoma 
skin cancer 
(women) 
6044710 100.0 164.4 3345176 100.0 87.2 15288300 100.0 620.8 
All cancers excl. 
non-melanoma 
skin cancer 
(both sexes) 
12662554 100.0 180.8 7564802 100.0 105.6 28803166 100.0 585.8 
Incidence and mortality data for all ages. 5-year prevalence for adult population only. 
ASR (W) and proportions per 100,000. 
   
Table 13.13:  Estimated incidence, mortality and 5-year prevalence: Thyroid Cancer [55]. 
 
Brain and 
nervous 
system 
Cancer  
Incidence Mortality 5-year prevalence 
Number (%) ASR 
(W) 
Number (%) ASR 
(W) 
Number (%) Prop. 
Men 126815 1.9 3.8 97251 2.3 2.9 171827 1.3 7.0 
Women 111098 1.8 3.1 77629 2.3 2.2 145212 0.9 5.9 
Both sexes 237913 1.9 3.5 174880 2.3 2.5 317039 1.1 6.4 
          
All cancers excl. 
non-melanoma 
skin cancer 
(men) 
6617844 100.0 202.8 4219626 100.0 127.9 13514868 100.0 550.6 
All cancers excl. 
non-melanoma 
skin cancer 
(women) 
6044710 100.0 164.4 3345176 100.0 87.2 15288300 100.0 620.8 
All cancers excl. 
non-melanoma 
skin cancer 
(both sexes) 
12662554 100.0 180.8 7564802 100.0 105.6 28803166 100.0 585.8 
Incidence and mortality data for all ages. 5-year prevalence for adult population only. 
ASR (W) and proportions per 100,000. 
   
Table 13.14:  Estimated incidence, mortality and 5-year prevalence: Brain and nervous system 
Cancer [55]. 
 
Summary statistics (2008) 
WORLD Male Female Both sexes 
Population (thousands) 3414566 3358715 6773281 
Number of new cancer cases (thousands) 6617.8 6044.7 12662.6 
Age-standardised rate (W) 202.8 164.4 180.8 
Risk of getting cancer before age 75 (%) 21.1 16.5 18.6 
Number of cancer deaths (thousands) 4219.6 3345.2 7564.8 
Age-standardised rate (W) 127.9 87.2 105.6 
Risk of dying from cancer before age 75 (%) 13.4 9.1 11.1 
5-year prevalent cases, adult population (thousands) 13514.9 15288.3 28803.2 
Proportion (per 100,000) 550.6 620.8 585.8 
5 most frequent cancers (ranking defined by total 
number of cases) 
   
 Lung Breast Lung 
 Prostate Colorectum Breast 
 Colorectum Cervix uteri Colorectum 
 Stomach Lung Stomach 
 Liver Stomach Prostate 
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Methods of estimation (summary) 
Incidence: Population weighted average of the area-specific country rates applied to the 
2008 area population.  
Mortality: Population weighted average of the area-specific country rates applied to the 
2008 area population.  
Prevalence: Sum of area-specific prevalent cases  
 
Glossary 
Age-standardised rate (W): 
A rate is the number of new cases or deaths per 100 000 persons per year. An age-
standardised rate is the rate that a population would have if it had a standard age structure. 
Standardization is necessary when comparing several populations that differ with respect to 
age because age has a powerful influence on the risk of cancer.  
Risk of getting or dying from the disease before age 75 (%): 
The probability or risk of individuals getting/dying from cancer. It is expressed as the 
number of new born children (out of 100) who would be expected to develop/die from 
cancer before the age of 75 if they had cancer rates (in the absence of other causes of 
death).  
 
Table 13.15:  Summary cancer statistics [55] 
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13.4 Software Coding 
The code below is written using MATLAB (The Mathworks Inc., Natick, MA) and 
is the code for reading the temperature at the focal point of the HIFU 
Transducer. 
 
function varargout = Interface_09_25_08(varargin) 
%29/01/09 
%INTERFACE_09_25_08 M-file for Interface_09_25_08.fig 
%      INTERFACE_09_25_08, by itself, creates a new INTERFACE_09_25_08 
or raises the existing 
%      singleton*. 
% 
%      H = INTERFACE_09_25_08 returns the handle to a new 
INTERFACE_09_25_08 or the handle to 
%      the existing singleton*. 
% 
%      INTERFACE_09_25_08('CALLBACK',hObject,eventData,handles,...) 
calls the local 
%      function named CALLBACK in INTERFACE_09_25_08.M with the given 
input arguments. 
% 
%      INTERFACE_09_25_08('Property','Value',...) creates a new 
INTERFACE_09_25_08 or raises the 
%      existing singleton*.  Starting from the left, property value 
pairs are 
%      applied to the GUI before Interface_09_25_08_OpeningFunction 
gets called.  An 
%      unrecognized property name or invalid value makes property 
application 
%      stop.  All inputs are passed to Interface_09_25_08_OpeningFcn 
via varargin. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows 
only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
  
% Edit the above text to modify the response to help 
Interface_09_25_08 
  
% Last Modified by GUIDE v2.5 30-Sep-2008 15:45:23 
  
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @Interface_09_25_08_OpeningFcn, 
... 
                   'gui_OutputFcn',  @Interface_09_25_08_OutputFcn, 
... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 
    gui_State.gui_Callback = str2func(varargin{1}); 
end 
  
if nargout 
    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
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else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
  
daqregister('c:MATLAB7\toolbox\daq\daq\private\mwnidaq.dll') 
% --- Executes just before Interface_09_25_08 is made visible. 
function Interface_09_25_08_OpeningFcn(hObject, eventdata, handles, 
varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to Interface_09_25_08 (see 
VARARGIN) 
  
% Choose default command line output for Interface_09_25_08 
handles.output = hObject; 
  
% Update handles structure 
guidata(hObject, handles); 
  
% UIWAIT makes Interface_09_25_08 wait for user response (see 
UIRESUME) 
% uiwait(handles.figure1); 
  
  
% --- Outputs from this function are returned to the command line. 
function varargout = Interface_09_25_08_OutputFcn(hObject, eventdata, 
handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Get default command line output from handles structure 
varargout{1} = handles.output; 
  
  
% --- Executes on button press in Btnstart. 
function Btnstart_Callback(hObject, eventdata, handles) 
% hObject    handle to Btnstart (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
%tcount = intmin; 
for tcount = 0:1:1000 
  t = timer('TimerFcn', 'stat=false; 
disp(''Timer!'')','StartDelay',0.01);   
  start(t) 
  wait(t) 
  disp(tcount); 
  set(handles.txttime, 'string',num2str(tcount/100)); 
end 
%stat=true; 
%while(stat==true)   
   
  %txttime.string = tcount; 
  %set(handles.txttime, 'string',int2str(tcount)); 
 % tcount =tcount +1 
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  %if (tcount == 20000) 
  % stat=false 
      %stop(t); 
 % end     
    
   
   %disp('.'); 
%end %END WHILE 
  
function txttime_Callback(hObject, eventdata, handles) 
% hObject    handle to txttime (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of txttime as text 
%        str2double(get(hObject,'String')) returns contents of txttime 
as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function txttime_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to txttime (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
  
% --- Executes on button press in txtExit. 
function txtExit_Callback(hObject, eventdata, handles) 
% hObject    handle to txtExit (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
close 
  
  
  
% --- Executes on button press in BtnStop. 
function BtnStop_Callback(hObject, eventdata, handles) 
% hObject    handle to BtnStop (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
 stop(t) 
  
  
  
function txttemper_Callback(hObject, eventdata, handles) 
% hObject    handle to txttemper (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of txttemper as text 
- 211 - 
%        str2double(get(hObject,'String')) returns contents of 
txttemper as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function txttemper_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to txttemper (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
  
% --- Executes on button press in btnTemper. 
function btnTemper_Callback(hObject, eventdata, handles) 
% hObject    handle to btnTemper (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
%TFileName = '' 
%while TfileName == '' 
TFileName = get(handles.txttempfile , 'string' ); 
%end % WHILE 
  
%filename = txttempfile.String 
fid = fopen(TFileName, 'wt');  
%Open file <lblfilename>, the mode wt is to open a text file for 
writing 
  
TempRead = 1; 
% Keep on measuring the temperature as lon as tempRead is true. 
TempRead 
% will become false if the stop reading button is pressed 
  
ai=analoginput('nidaq','dev2') 
%Create analog input object 
%ai = analoginput('adaptor') 
%ai = analoginput('adaptor',ID) 
%Arguments'adaptor'The hardware driver adaptor name. The supported 
adaptors are advantech, hpe1432, keithley, mcc, nidaq, and winsound. 
%ID The hardware device identifier. ID is optional 
  
chans = addchannel(ai,1) 
% Add hardware channels to analog input or analog output object 
  
  
tic  
%tic starts the clock toc is the ellasped time since tic was initiated 
TSamplesCount = 0; 
while TempRead == 1 
    % Keep on measuring the temperature as lon as tempRead is true. 
TempRead 
 TSamplesCount = TSamplesCount + 1; 
start(ai); 
inter = 100; 
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data = getdata(ai,inter)  
stop(ai); 
%data is an array which in this case will get 100 values of temerature 
in 
%1/10 of a second 
  
Sumtemp = 0; 
%The for loop below will calculate the average temperature of 100 
readings 
for dcount = 1:1:inter 
  Sumtemp = Sumtemp + data(dcount); 
   
% 1000 samples per second - the average of 100 inter, samlple in 1/10 
of a second is calculated  
end % FOR 
%fprintf(fid, '%10.4f\n', data(dcount)* 1000); 
% Write each temperature reading in to the file   
 % 1mV per 1 degree celcius 
AvgTemp = 1000*(Sumtemp / inter); 
toc; 
t= toc; 
fprintf(fid, '%4.0f\t %10.4f\t %10.4f\n',TSamplesCount, AvgTemp, t); 
%write the average of inter readings into the file 
%disp(AvgTemp); 
  
set(handles.txttemper, 'string',num2str(AvgTemp)); 
set(handles.txttime, 'string',num2str(t)); 
%Display tcount/100 on the txttime on GUI  
  
end  %WHILE 
  
fclose(fid) 
% --- Executes on button press in txtStopTempRead. 
function txtStopTempRead_Callback(hObject, eventdata, handles) 
% hObject    handle to txtStopTempRead (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
TempRead = 0 
  
  
  
function txttempfile_Callback(hObject, eventdata, handles) 
% hObject    handle to txttempfile (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of txttempfile as text 
%        str2double(get(hObject,'String')) returns contents of 
txttempfile as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function txttempfile_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to txttempfile (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
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if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
The code below is written using MATLAB (The Mathworks Inc., Natick, MA) and 
is the code for that provides the graphical user interface for the end user and 
drives the motors of the robot. Other features added to this user interface are 
explained in chapter 9. 
function varargout = sonomri_main_page(varargin) 
% SONOMRI_MAIN_PAGE_NEW M-file for sonomri_main_page.fig 
%      SONOMRI_MAIN_PAGE_NEW, by itself, creates a new 
SONOMRI_MAIN_PAGE or raises the existing 
%      singleton*. 
% 
%      H = SONOMRI_MAIN_PAGE returns the handle to a new 
SONOMRI_MAIN_PAGE or the handle to 
%      the existing singleton*. 
% 
%      SONOMRI_MAIN_PAGE('CALLBACK',hObject,eventData,handles,...) 
calls the local 
%      function named CALLBACK in SONOMRI_MAIN_PAGE.M with the given 
input arguments. 
% 
%      SONOMRI_MAIN_PAGE('Property','Value',...) creates a new 
SONOMRI_MAIN_PAGE or raises the 
%      existing singleton*.  Starting from the left, property value 
pairs are 
%      applied to the GUI before sonomri_main_page_OpeningFunction 
gets called.  An 
%      unrecognized property name or invalid value makes property 
application 
%      stop.  All inputs are passed to 
sonomri_main_page_new_OpeningFcn via varargin. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows 
only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
  
  
% Copyright 2002-2003 The MathWorks, Inc. 
  
% Edit the above text to modify the response to help sonomri_main_page 
  
% Last Modified by GUIDE v2.5 31-May-2007 10:40:50 
  
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @sonomri_main_page_OpeningFcn, 
... 
                   'gui_OutputFcn',  @sonomri_main_page_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 
    gui_State.gui_Callback = str2func(varargin{1}); 
end 
- 214 - 
  
if nargout 
    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
  
  
% --- Executes just before sonomri_main_page is made visible. 
  
function sonomri_main_page_OpeningFcn(hObject, eventdata, handles, 
varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to sonomri_main_page_new (see 
VARARGIN) 
  
% The statemnt below is needed to register the NI DAQ drivers. It is 
done 
% only once. 
  
  
  
  
% Choose default command line output for sonomri_main_page_new 
handles.output = hObject; 
  
% Update handles structure 
guidata(hObject, handles); 
  
  
initial_dir='C:\matlab7\dicom'; 
load_listbox(initial_dir,handles) 
  
% UIWAIT makes sonomri_main_page_new wait for user response (see 
UIRESUME) 
% uiwait(handles.figure1); 
  
  
% --- Outputs from this function are returned to the command line. 
  
function varargout = sonomri_main_page_OutputFcn(hObject, eventdata, 
handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Get default command line output from handles structure 
varargout{1} = handles.output; 
  
  
% --- Executes on selection change in power. 
function power_Callback(hObject, eventdata, handles) 
% hObject    handle to power (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
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% Hints: contents = get(hObject,'String') returns power contents as 
cell array 
%        contents{get(hObject,'Value')} returns selected item from 
power 
  
  
volt=str2double(get(hObject,'String'))  %reads voltage frpm command 
line. 
                              
handles.voltage=volt    %Stores V(1) to handle structure which is 
accesible in all 
% objects 
  
guidata(hObject,handles)  % Saves new structure of handles 
  
  
% --- Executes during object creation, after setting all properties. 
function power_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to power (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: popupmenu controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
% --- Executes on selection change in frequency. 
function frequency_Callback(hObject, eventdata, handles) 
% hObject    handle to frequency (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: contents = get(hObject,'String') returns frequency contents 
as cell array 
%        contents{get(hObject,'Value')} returns selected item from 
frequency 
  
freq=str2double(get(hObject,'String'));  %reads frequency 
                                    
  
handles.frequency=freq;    %Stores V(1) to handle structure which is 
accesible in all 
% objects 
  
guidata(hObject,handles);  
  
  
% --- Executes during object creation, after setting all properties. 
function frequency_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to frequency (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
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% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: popupmenu controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
% --- Executes on button press in powerON. 
  
function powerON_Callback(hObject, eventdata, handles) 
% hObject    handle to powerON (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% s = serial('COM1');           % Creates a serial port interface 
%fopen(s);                     % Opens the serial port. 
  
f=handles.frequency;          % Calls the frequency handle 
f=f*1000000;                   % Converts MHz to HZ. 
  
fstring=int2str(f); % Converts integer to string 
fstringnew=['frequency ',fstring];      % Concatanates frequency and 
frequency 
                                        % value in the format required 
by Agilent generator. 
  
%fprintf(s,fstringnew); % Sent frequency to generator. 
  
v=handles.voltage;                   % Calls handle voltage which is 
in mV. 
v=int2str(v); 
  
Vstring=['VOLTage ',v,'E-3'];        % Concatanates voltage and 
voltage  
                                    % value in the format required by 
Agilent generator. 
%fprintf(s,Vstring); % Sent voltage to generator. 
  
  
timing(handles.timeON,handles)  % Duration that power is ON. 
  
  
%fclose(s); 
%delete(s); 
%clear s; 
  
  
% --- Executes on button press in PowerOFF. 
function PowerOFF_Callback(hObject, eventdata, handles) 
% hObject    handle to PowerOFF (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
%Global s 
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%s = serial('COM1'); 
%fopen(s); 
  
v=55;    % Sent a low-voltage (ie power OFF). 
Vstring=int2str(v); % Converts integer to string 
Vstringnew=['VOLTage ',Vstring,'E-3']; % Concatanates voltage and 
voltage  
% value in the format required by Agilent generator. 
  
%fprintf(s,Vstringnew); % Sent voltage to generator. 
  
timing(handles.timeOFF,handles) 
  
%fclose(s); 
%delete(s); 
%clear s; 
  
  
function duration_Callback(hObject, eventdata, handles) 
% hObject    handle to duration (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of duration as text 
%        str2double(get(hObject,'String')) returns contents of 
duration as a double 
  
  
% Duration ultrasound is ON. 
handles.timeON=str2double(get(hObject,'String'))  
guidata(hObject,handles);  
  
  
% --- Executes during object creation, after setting all properties. 
function duration_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to duration (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
  
function xaxisdist_Callback(hObject, eventdata, handles) 
% This function read x distance from an edit box. 
% hObject    handle to xaxisdist (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of xaxisdist as text 
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%        str2double(get(hObject,'String')) returns contents of 
xaxisdist as a double 
  
  
xdist=str2double(get(hObject,'String'));  %reads x distance to be 
moved 
                                    
  
handles.xdistance=xdist;    %Stores x distance to handle structure 
which is accesible in all 
% objects 
  
guidata(hObject,handles);  
  
  
% --- Executes during object creation, after setting all properties. 
function xaxisdist_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to xaxisdist (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
function yaxisdist_Callback(hObject, eventdata, handles) 
% This function read y distance from an edit box. 
% hObject    handle to yaxisdist (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of yaxisdist as text 
%        str2double(get(hObject,'String')) returns contents of 
yaxisdist as a double 
  
ydist=str2double(get(hObject,'String'));  %reads z distance to be 
moved 
                                    
  
handles.ydistance=ydist;    %Stores y distance to handle structure 
which is accesible in all 
% objects 
  
guidata(hObject,handles);  
  
  
  
% --- Executes during object creation, after setting all properties. 
function yaxisdist_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to yaxisdist (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
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% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
  
function zaxisdist_Callback(hObject, eventdata, handles) 
% This function read z distance from an edit box. 
% hObject    handle to zaxisdist (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of zaxisdist as text 
%        str2double(get(hObject,'String')) returns contents of 
zaxisdist as a double 
  
  
zdist=str2double(get(hObject,'String'));  %reads z distance to be 
moved 
                                    
  
handles.zdistance=zdist    %Stores z distance to handle structure 
which is accesible in all 
% objects 
  
guidata(hObject,handles);  
  
  
  
% --- Executes during object creation, after setting all properties. 
function zaxisdist_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to zaxisdist (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
% --- Executes on button press in xmove. 
  
function xmoveforward_Callback(hObject, eventdata, handles) 
% hObject    handle to xmove (see GCBO) 
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% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
nx=handles.xdistance; 
nx=16000000*nx; 
  
%Creates a Digital output object 
%dio=digitalio('nidaq',1);    PCI 6602 
dio=digitalio('nidaq','dev2')% USB 6251 
  
% Creates output lines for port 0, line 0 (CW)  
% terminal of the Shinsei driver.  
addline(dio,0:7,0,'out'); 
  
% CW is initially set to logical high and since the ground is logigal 
low 
% (zero) the motor does not move yet. 
boarddata=logical([1 1 1 1 1 1 1 1]); 
  
% Sends the above logical word to output port. 
putvalue(dio,boarddata); 
  
% The motor goes locical zero and since the Ground terminal of the 
Shinsei driver is 
% connected to ground, the motor starts to move. 
boarddata(3)=0; 
putvalue(dio,boarddata); 
  
% Loop that establishes motion in the X forward axis. 
for n = 1:nx 
end 
  
  
% To stop the motor you need to set the CW or CCW terminal to high 
  
boarddata(3)=1;          % High  
  
% Puts the terminal CW or CCW to logical high and thus motor stops 
putvalue(dio,boarddata); 
  
% When you no longer need dio, you should remove it from 
% memory and from the MATLAB workspace. 
delete(dio) 
clear dio 
  
handles.x=handles.x+handles.xdistance; 
guidata(hObject,handles);  
  
%Sends the x position to the position display (text box) 
set(handles.xposition,'String',handles.x) 
  
  
% --- Executes on button press in xmovereverse. 
function xmovereverse_Callback(hObject, eventdata, handles) 
% hObject    handle to xmovereverse (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
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nx=handles.xdistance; 
nx=16000000*nx; 
  
%Creates a Digital output object 
%dio=digitalio('nidaq',1);    PCI 6602 
dio=digitalio('nidaq','dev2')% USB 6251 
  
% Creates output lines for port 0, line 0 (CCW)  
% terminal of the Shinsei driver.  
addline(dio,0:7,0,'out'); 
  
% CCW is initially set to logical high and since the ground is logigal 
low 
% (zero) the motor does not move yet. 
boarddata=logical([1 1 1 1 1 1 1 1]); 
  
% Sends the above logical word to output port. 
putvalue(dio,boarddata); 
  
% The motor goes locical zero and since the Ground terminal of the 
Shinsei driver is 
% connected to ground, the motor starts to move. 
boarddata(4)=0; 
putvalue(dio,boarddata); 
  
% Loop that establishes motion in the X reverse axis. 
for n = 1:nx 
end 
  
  
% To stop the motor you need to set the CW or CCW terminal to high 
  
boarddata(4)=1;          % High  
  
% Puts the terminal CW or CCW to logical high and thus motor stops 
putvalue(dio,boarddata); 
  
% When you no longer need dio, you should remove it from 
% memory and from the MATLAB workspace. 
delete(dio) 
clear dio 
  
handles.x=handles.x-handles.xdistance; 
guidata(hObject,handles);  
  
  
%Sends the x position to the position display (text box) 
set(handles.xposition,'String',handles.x) 
  
  
% --- Executes on button press in ymoveleft. 
function ymoveleft_Callback(hObject, eventdata, handles) 
% hObject    handle to ymove (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
ny=handles.ydistance; 
ny=9000000*ny; 
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%Creates a Digital output object 
%dio=digitalio('nidaq',1);    PCI 6602 
dio=digitalio('nidaq','dev2')% USB 6251 
  
% Creates output lines for port 0, line 0 (CW)  
% terminal of the Shinsei driver.  
addline(dio,0:7,0,'out'); 
  
% CW is initially set to logical high and since the ground is logigal 
low 
% (zero) the motor does not move yet. 
boarddata=logical([1 1 1 1 1 1 1 1]); 
  
% Sends the above logical word to output port. 
putvalue(dio,boarddata); 
  
% The motor goes locical zero and since the Ground terminal of the 
Shinsei driver is 
% connected to ground, the motor starts to move. 
boarddata(1)=0; 
putvalue(dio,boarddata); 
  
% Loop that establishes motion in the Y left axis. 
for n = 1:ny 
end 
  
  
% To stop the motor you need to set the CW or CCW terminal to high 
  
boarddata(1)=1;          % High  
  
% Puts the terminal CW or CCW to logical high and thus motor stops 
putvalue(dio,boarddata); 
  
% When you no longer need dio, you should remove it from 
% memory and from the MATLAB workspace. 
delete(dio) 
clear dio 
  
  
handles.y=handles.y+handles.ydistance; 
guidata(hObject,handles); 
  
%Sends the y position to the position display (text box) 
set(handles.yposition,'String',handles.y) 
set(handles.historylist,'String','yleft') 
  
  
% --- Executes on button press in ymoveright. 
function ymoveright_Callback(hObject, eventdata, handles) 
% hObject    handle to ymoveright (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
ny=handles.ydistance; 
ny=9000000*ny; 
  
%Creates a Digital output object 
%dio=digitalio('nidaq',1);    PCI 6602 
dio=digitalio('nidaq','dev2')% USB 6251 
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% Creates output lines for port 0, line 0 (CCW)  
% terminal of the Shinsei driver.  
addline(dio,0:7,0,'out'); 
  
% CCW is initially set to logical high and since the ground is logigal 
low 
% (zero) the motor does not move yet. 
boarddata=logical([1 1 1 1 1 1 1 1]); 
  
% Sends the above logical word to output port. 
putvalue(dio,boarddata); 
  
% The motor goes locical zero and since the Ground terminal of the 
Shinsei driver is 
% connected to ground, the motor starts to move. 
boarddata(2)=0; 
putvalue(dio,boarddata); 
  
% Loop that establishes motion in the Y right axis. 
for n = 1:ny 
end 
  
  
% To stop the motor you need to set the CW or CCW terminal to high 
  
boarddata(2)=1;          % High  
  
% Puts the terminal CW or CCW to logical high and thus motor stops 
putvalue(dio,boarddata); 
  
% When you no longer need dio, you should remove it from 
% memory and from the MATLAB workspace. 
delete(dio) 
clear dio 
  
handles.y=handles.y-handles.ydistance; 
guidata(hObject,handles);  
  
%Sends the y position to the position display (text box) 
set(handles.yposition,'String',handles.y) 
set(handles.historylist,'String','yright') 
  
  
% --- Executes on button press in zmoveup. 
function zmoveup_Callback(hObject, eventdata, handles) 
% hObject    handle to zmove (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
nz=handles.zdistance; 
nz=4000000*nz; 
  
%Creates a Digital output object 
%dio=digitalio('nidaq',1);    PCI 6602 
dio=digitalio('nidaq','dev2')% USB 6251 
  
% Creates output lines for port 0, line 0 (CCW)  
% terminal of the Shinsei driver.  
addline(dio,0:7,0,'out'); 
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% CW is initially set to logical high and since the ground is logigal 
low 
% (zero) the motor does not move yet. 
boarddata=logical([1 1 1 1 1 1 1 1]); 
  
% Sends the above logical word to output port. 
putvalue(dio,boarddata); 
  
% The motor goes locical zero and since the Ground terminal of the 
Shinsei driver is 
% connected to ground, the motor starts to move. 
boarddata(5)=0; 
putvalue(dio,boarddata); 
  
% Loop that establishes motion in the Z up axis. 
for n = 1:nz 
end 
  
  
% To stop the motor you need to set the CW or CCW terminal to high 
  
boarddata(5)=1;          % High  
  
% Puts the terminal CW or CCW to logical high and thus motor stops 
putvalue(dio,boarddata); 
  
% When you no longer need dio, you should remove it from 
% memory and from the MATLAB workspace. 
delete(dio) 
clear dio 
  
handles.z=handles.z+handles.zdistance; 
  
%Sends the z position to the position display (text box) 
set(handles.zposition,'String',handles.z) 
guidata(hObject,handles);  
  
% --- Executes on button press in zmovedown. 
function zmovedown_Callback(hObject, eventdata, handles) 
% hObject    handle to zmovedown (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
nz=handles.zdistance; 
nz=4000000*nz; 
  
%Creates a Digital output object 
%dio=digitalio('nidaq',1);    PCI 6602 
dio=digitalio('nidaq','dev2')% USB 6251 
  
% Creates output lines for port 0, line 0 (CCW)  
% terminal of the Shinsei driver.  
addline(dio,0:7,0,'out'); 
  
% CCW is initially set to logical high and since the ground is logigal 
low 
% (zero) the motor does not move yet. 
boarddata=logical([1 1 1 1 1 1 1 1]); 
  
- 225 - 
% Sends the above logical word to output port. 
putvalue(dio,boarddata); 
  
% The motor goes locical zero and since the Ground terminal of the 
Shinsei driver is 
% connected to ground, the motor starts to move. 
boarddata(6)=0; 
putvalue(dio,boarddata); 
  
% Loop that establishes motion in the Z down axis. 
for n = 1:nz 
end 
  
  
% To stop the motor you need to set the CW or CCW terminal to high 
  
boarddata(6)=1;          % High  
  
% Puts the terminal CW or CCW to logical high and thus motor stops 
putvalue(dio,boarddata); 
  
% When you no longer need dio, you should remove it from 
% memory and from the MATLAB workspace. 
delete(dio) 
clear dio 
  
handles.z=handles.z-handles.zdistance 
  
%Sends the z position to the position display (text box) 
set(handles.zposition,'String',handles.z) 
guidata(hObject,handles);  
  
  
function edit10_Callback(hObject, eventdata, handles) 
% hObject    handle to edit10 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of edit10 as text 
%        str2double(get(hObject,'String')) returns contents of edit10 
as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function edit10_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to edit10 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
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function edit11_Callback(hObject, eventdata, handles) 
% hObject    handle to edit11 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of edit11 as text 
%        str2double(get(hObject,'String')) returns contents of edit11 
as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function edit11_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to edit11 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
  
function nxgrid_Callback(hObject, eventdata, handles) 
% hObject    handle to nxgrid (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of nxgrid as text 
%        str2double(get(hObject,'String')) returns contents of nxgrid 
as a double 
  
  
handles.nxgrid=str2double(get(hObject,'String'));  
guidata(hObject,handles);  
  
  
  
% --- Executes during object creation, after setting all properties. 
function nxgrid_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to nxgrid (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
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end 
  
  
  
function nygrid_Callback(hObject, eventdata, handles) 
% hObject    handle to nygrid (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of nygrid as text 
%        str2double(get(hObject,'String')) returns contents of nygrid 
as a double 
  
handles.nygrid=str2double(get(hObject,'String'));  
guidata(hObject,handles);  
  
  
% --- Executes during object creation, after setting all properties. 
function nygrid_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to nygrid (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
function nxstep_Callback(hObject, eventdata, handles) 
% hObject    handle to nxstep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of nxstep as text 
%        str2double(get(hObject,'String')) returns contents of nxstep 
as a double 
  
handles.xstep=str2double(get(hObject,'String'));  
guidata(hObject,handles);  
  
% --- Executes during object creation, after setting all properties. 
function nxstep_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to nxstep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
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set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
  
function nystep_Callback(hObject, eventdata, handles) 
% hObject    handle to nystep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of nystep as text 
%        str2double(get(hObject,'String')) returns contents of nystep 
as a double 
  
  
handles.ystep=str2double(get(hObject,'String'));  
guidata(hObject,handles);  
  
  
% --- Executes during object creation, after setting all properties. 
function nystep_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to nystep (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
% --- Executes on button press in startGrid. 
function startGrid_Callback(hObject, eventdata, handles) 
% hObject    handle to startGrid (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
 handles.ydistance=handles.ystep; 
 handles.xdistance=handles.xstep; 
 %guidata(hObject,handles);  
  
for i=1:handles.nxgrid 
      r=rem(i,2); 
       
    for j=1:handles.nygrid 
     
       if r == 0  
     ymoveleft_Callback(hObject, eventdata, handles) 
        powerON_Callback(hObject, eventdata, handles) 
        PowerOFF_Callback(hObject, eventdata, handles)  
        %elseif r == 0  
       else 
     ymoveright_Callback(hObject, eventdata, handles) 
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        powerON_Callback(hObject, eventdata, handles) 
        PowerOFF_Callback(hObject, eventdata, handles)         
       
       end   
         
    end   
     xmoveforward_Callback(hObject, eventdata, handles) 
      powerON_Callback(hObject, eventdata, handles) 
      PowerOFF_Callback(hObject, eventdata, handles)   
         
end     
     
  
% --- Executes on button press in loadmri. 
function loadmri_Callback(hObject, eventdata, handles) 
% hObject    handle to loadmri (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% File must be in the current directory or you may specify directory. 
  
% info = dicominfo('IM000000')  % Displays dicom contents 
cd c:\MATLAB7   % Directory where the Dicom file is stored. 
%scrsz = get(0,'ScreenSize'); 
%figure('Position',[10 scrsz(4)/2 scrsz(3)/2 scrsz(4)/2]) 
figure('position', [450,180,300,150])%left, bottom, width, height 
I = dicomread('IM000000');   % Reads image data 
image (I);   %displays image in colour map 
colormap(gray);  %  Converts to gray scale 
  
  
  
% --- Outputs from this function are returned to the command line. 
function varargout = lbox2_OutputFcn(hObject, eventdata, handles) 
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Get default command line output from handles structure 
varargout{1} = handles.output; 
  
% ------------------------------------------------------------ 
% Callback for list box - open .fig with guide, otherwise use open 
% ------------------------------------------------------------ 
function varargout = listbox1_Callback(h, eventdata, handles) 
% hObject    handle to listbox1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: contents = get(hObject,'String') returns listbox1 contents as 
cell array 
%        contents{get(hObject,'Value')} returns selected item from 
listbox1 
  
%figure('position', [450,180,300,150])%left, bottom, width, height 
  
get(handles.figure1,'SelectionType'); 
  
%Compares two strings. If the strings are the same it returns 
% a one, otherwise zero. 
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% If you double click an item in the listbox you get an open stringn 
% for selection type, and therefore strcmp results to logical one. 
if strcmp(get(handles.figure1,'SelectionType'),'open'); 
     
% If you select for examle third item in the list you get a value of 
3. 
    index_selected = get(handles.listbox1,'Value'); 
     
    % Read all strings from the list. 
    file_list = get(handles.listbox1,'String'); 
     
    % Selection of 3 rd string in the list. 
    filename = file_list{index_selected}; 
    if  handles.is_dir(handles.sorted_index(index_selected)); 
         
      %If item selected is a directory then go one level down this 
direcrory   
        cd (filename) 
         
       
        load_listbox(pwd,handles) 
     
    %Load items of this directory     
    file_list = get(handles.listbox1,'String'); 
     
    %Get number of total files in the directory 
    nimage=length(file_list); 
     
    % Display all images 
        for k=3:nimage 
            j=k-2;     
            I{k} = dicomread(file_list{k});   % Reads image data 
            image (I{k});   %displays image in colour map 
            colormap(gray);  %  Converts to gray scale 
            F(j) = getframe;  % Gets frames of the figure 
            end 
  
            %movie(F) 
          
  
     end 
end 
  
  
% ------------------------------------------------------------ 
% Read the current directory and sort the names, and displays 
% files in the listbox. 
% ------------------------------------------------------------ 
function load_listbox(dir_path,handles) 
  
%Move to the selected directory 
cd (dir_path); 
  
%Gets name, date, bytes and isdir of the current directory. 
% perharps date is usefull for date sorting. 
dir_struct = dir(dir_path); 
  
% Sorts name, First dot, then two dots, then numbers and then 
% alphavetically. 
[sorted_names,sorted_index] = sortrows({dir_struct.name}'); 
- 231 - 
% Stores file names in handles. 
handles.file_names = sorted_names; 
  
%If directory stores a 1, if a file it strores a 0. 
handles.is_dir = [dir_struct.isdir]; 
  
% Stores index in handle 
handles.sorted_index = [sorted_index]; 
  
%Saves handles data 
guidata(handles.figure1,handles) 
  
%Puts file names in the listbox 
set(handles.listbox1,'String',handles.file_names,... 
    'Value',1) 
  
% Outputs the curent directory to the text 
%Pwd prints or displays working directory 
set(handles.text1,'String',pwd) 
  
  
% --- Executes during object creation, after setting all properties. 
function listbox1_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to listbox1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: listbox controls usually have a white background, change 
%       'usewhitebg' to 0 to use default.  See ISPC and COMPUTER. 
  
usewhitebg = 1; 
if usewhitebg 
    set(hObject,'BackgroundColor','white'); 
else 
   
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
% --- Executes on button press in zeroxyz. 
function zeroxyz_Callback(hObject, eventdata, handles) 
% hObject    handle to zeroxyz (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
%Zeros x,y,z  
handles.x=0; 
handles.y=0; 
handles.z=0; 
  
%Sends the x or y or z position (zero) to the position display (3 
texts 
%boxes) 
set(handles.xposition,'String',handles.x) 
set(handles.yposition,'String',handles.y) 
set(handles.zposition,'String',handles.z) 
  
guidata(hObject,handles);  
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function xposition_Callback(hObject, eventdata, handles) 
% hObject    handle to xposition (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of xposition as text 
%        str2double(get(hObject,'String')) returns contents of 
xposition as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function xposition_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to xposition (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
 
function yposition_Callback(hObject, eventdata, handles) 
% hObject    handle to yposition (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of yposition as text 
%        str2double(get(hObject,'String')) returns contents of 
yposition as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function yposition_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to yposition (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
  
function zposition_Callback(hObject, eventdata, handles) 
% hObject    handle to zposition (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
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% Hints: get(hObject,'String') returns contents of zposition as text 
%        str2double(get(hObject,'String')) returns contents of 
zposition as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function zposition_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to zposition (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
function timing(periodON,handles) 
  
c=fix(clock);           %Reads time based on PC clock(integer format) 
tinit=c(4)*3600+c(5)*60+c(6);             % Sixth element is time in 
seconds 
  
t=c(4)*3600+c(5)*60+c(6);                 % Current time 
while t-tinit<periodON  % If difference between current time and  
                        %initial time is less than timeON then  
                        % increase time 
c=fix(clock);           % Get new time within the WHILE loop 
t=c(4)*3600+c(5)*60+c(6);                 % Get seconds. 
end 
  
  
% --- Executes on selection change in historylist. 
function historylist_Callback(hObject, eventdata, handles) 
% hObject    handle to historylist (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: contents = get(hObject,'String') returns historylist contents 
as cell array 
%        contents{get(hObject,'Value')} returns selected item from 
historylist 
  
  
% --- Executes during object creation, after setting all properties. 
function historylist_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to historylist (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: listbox controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
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    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
function delay_Callback(hObject, eventdata, handles) 
% hObject    handle to delay (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of delay as text 
%        str2double(get(hObject,'String')) returns contents of delay 
as a double 
  
  
handles.timeOFF=str2double(get(hObject,'String'))  
guidata(hObject,handles);  
  
% --- Executes during object creation, after setting all properties. 
function delay_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to delay (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
% -------------------------------------------------------------------- 
function enter_patient_data_Callback(hObject, eventdata, handles) 
% hObject    handle to enter_patient_data (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
open ('save_patient_data.fig') 
  
% -------------------------------------------------------------------- 
function retrieve_patient_data_Callback(hObject, eventdata, handles) 
% hObject    handle to retrieve_patient_data (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
open ('retrieve.fig') 
  
% --- Executes on button press in exit_button. 
function exit_button_Callback(hObject, eventdata, handles) 
% hObject    handle to exit_button (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
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% handles    structure with handles and user data (see GUIDATA) 
  
  
%close all; 
  
exit 
  
%delete(gcbf); 
  
 
% --- Executes on button press in startcamera. 
function startcamera_Callback(hObject, eventdata, handles) 
% hObject    handle to startcamera (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
IMAQMEM(50000000000); 
vid = videoinput('winvideo',1); 
  
handles.camera=vid; 
guidata(hObject,handles);  
  
set(handles.camera,'TriggerRepeat',Inf); 
%set(vid,'FramesPerTrigger',8000); 
start(handles.camera); 
preview(handles.camera); 
  
  
% --- Executes on button press in stopcamera. 
function stopcamera_Callback(hObject, eventdata, handles) 
% hObject    handle to stopcamera (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
flushdata(handles.camera); 
delete(handles.camera) 
clear handles.camera 
  
  
% --- Executes on button press in savecamera. 
function savecamera_Callback(hObject, eventdata, handles) 
% hObject    handle to savecamera (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
  
   
function edit20_Callback(hObject, eventdata, handles) 
% hObject    handle to edit20 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of edit20 as text 
%        str2double(get(hObject,'String')) returns contents of edit20 
as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function edit20_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to edit20 (see GCBO) 
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% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
  
  
function edit21_Callback(hObject, eventdata, handles) 
% hObject    handle to edit21 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of edit21 as text 
%        str2double(get(hObject,'String')) returns contents of edit21 
as a double 
  
  
% --- Executes during object creation, after setting all properties. 
function edit21_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to edit21 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc 
    set(hObject,'BackgroundColor','white'); 
else 
    
set(hObject,'BackgroundColor',get(0,'defaultUicontrolBackgroundColor')
); 
end 
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